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From association to function: elucidating the role of G Protein Signaling 




Rheumatoid arthritis (RA) is an autoimmune disease that is estimated to affect 
1% of Americans. RA causes significant morbidity as a result of autoimmune stimuli 
inducing pro-inflammatory leukocyte recruitment to the joint. Despite the large effect on 
quality of life and significant research into RA pathophysiology, there is still much that is 
not known about the etiology of RA. Although effective treatment options do exist for RA, 
many of them carry significant risks of compliance-limiting adverse effects, high costs, 
and a subset of patients do not respond to treatment. This work attempts to respond to 
the limitations of current therapeutics by characterizing GPSM3 as a potential genetic 
marker and pharmaceutical target for RA through genetic and ex vivo modeling. 
 Based on data from compelling genome-wide association studies (GWAS), and 
supporting evidence from knockout mouse inflammatory arthritis models, we 
hypothesize that the G protein signaling modulator-3 (GPSM3) gene and protein play a 
significant role in the pathogenesis of RA. Current literature has identified two single-
nucleotide polymorphisms (SNPs) in humans, rs204989 and rs204991, associated with 
protection from multiple autoimmune diseases including RA. We show that qRT-PCR 
analyses of whole blood-isolated RNA from volunteers homozygous for the GPSM3 
SNPs show a decrease in GPSM3 transcript abundance compared to volunteers without 
the minor SNP alleles. Results from reporter gene studies support rs204989 as the 
causal SNP in decreasing GPSM3 promoter activity. In cell line models of neutrophil and 
monocyte physiology, GPSM3 deficiency results in disrupted migration patterns toward 
LTB4 and MCP-1, respectively. We hypothesize the minor allele of rs204989 represents 
a genetic factor contributing to the pathogenesis of RA, acting by decreasing GPSM3 
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1.1 – Rheumatoid arthritis clinical introduction 
 
1.1.1 – Background 
 
 
Rheumatoid arthritis (RA) is a chronic, autoimmune polyarthritis that, if left untreated, 
leads to deformity, chronic pain, and disability for patients through a process of synovial 
inflammation, synovial cell proliferation with angiogenesis, and joint destruction. Clinically, RA is 
characterized by chronic inflammation of the synovial tissue of multiple joints, and may manifest 
in severe joint deformity2. Additional extra-articular disease co-morbidities, such as vascular 
disease from unchecked inflammation, further lead to increased mortality3–5. Improved 
understanding of immune system-mediated RA pathogenesis has led to new biologic treatments 
that target selective elements of the RA inflammatory response; however, there are still patients 
who are non-responders or experience adverse effects limiting their treatment6,7. This is likely a 
result of disease variability between the pathology of RA in different patients, characterized by 
differences in the frequency and severity of inflammation, duration of inflammation, and 
frequency of inflammatory bouts. This variability can be characterized by defining three 
subclasses of RA: monocyclic, polycyclic, and progressive RA. A minority of patients present 
with monocyclic RA, where a single inflammatory episode occurs and then remission follows. 
Polycyclic RA is defined as patients presenting with a continuously fluctuating level of disease 
activity, while progressive RA will continue to increase in severity and does not resolve2.  
 
1.1.2 – Treatment Options 
 
1.1.2a – Non-steroidal anti-inflammatory drugs (NSAIDs):  
 
NSAIDs are typically used to treat mild to moderate rheumatoid arthritis as a first-line therapy. 
The anti-inflammatory capabilities of non-selective NSAIDs are due to their antagonism of 
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cyclooxygenase preventing the conversion of arachidonic acids to prostaglandins. The primary 
effect of NSAIDs is likely due to inhibition of cyclooxygenase-2. Conversely, cyclooxygenase-1 
is involved in platelet aggregation, gastric protection, and renal regulation. Therefore, inhibition 
of cyclooxygenase-1 in non-selective NSAIDs results in many of the reported adverse effects. 
Selective NSAIDs have been developed with selectivity for cyclooxygenase-2, and have similar 
effects to non-selective NSAIDs with lower risks of adverse effects with prolonged use 
(reviewed in 8). Drugs of this class have protective benefits over placebo in patients with RA, 
and show improvements in pain and stiffness scores9. At clinical dosages, NSAIDs do not 
reduce acute-phase proteins in the serum or inhibit progression of radiographic joint damage8.  
 
1.1.2b – Non-biologic disease-modifying antirheumatic drugs (DMARDs): 
 
Methotrexate (MTX): MTX is currently the first-line therapy for RA. The classical mechanism of 
action of MTX in malignancies is the competitive inhibition of the enzyme dihydrofolate 
reductase, responsible for the reduction of folic acid to metabolically active forms10. However, in 
the treatment of RA the weekly low-dose treatment is approximately three orders of magnitude 
lower than the weekly dosing in oncology11, and supplementation of MTX treatment with 
metabolically active folates apparently does not disrupt the anti-inflammatory properties of 
MTX12. Despite the approval of MTX by the FDA, researchers have yet to fully elucidate its 
mechanism of action for low-dose RA therapy. Some proposed hypotheses for this action 
include the release of anti-inflammatory adenosine13,14, growth arrest, and impaired adhesion15. 
Although most patients respond well to low dose MTX treatment, a number of adverse effects 





Azathioprine: Azathioprine is a purine synthesis inhibitor, disrupting the functions of 
amidophosphoribosyltransferase17. The adverse effects of azathioprine are similar to those seen 
in MTX treatment18. 
  
Leflunomide: Leflunomide is a pyrimidine synthesis inhibitor, disrupting the functions of 
dihydroorotate dehydrogenase19. The adverse effects of Leflunomide are similar to those seen 
in MTX treatment, with the addition of hepatotoxicity, and a higher risk of diarrhea. Additionally 
Leflunomide is contraindicated during pregnancy, and inhibits the activity of  the metabolically 
relavent proteins cytochrome P4502C8 and organic anion transporter 320. 
 
Hydroxychloroquine: Hydroxychloroquine treatment results in a decrease in a number of 
proinflammatory cytokines including interleukin-1β (IL-1β), IL-6, and tumor necrosis factor alpha 
(TNFα). This effect is the result of a poorly understood mechanism of action that may include 
inhibition of toll-like receptors21 and alkalization of intracellular vacuoles (disrupting pH sensitive 
enzymes and antigen processing)22. 
 
Sulfasalazine: The mechanism of action of sulfasalazine is poorly understood in the context of 
RA. Both sulfasalazine and its metabolite are poorly absorbed in the bloodstream23. 
Sulfasalazine has been shown to function in isolated colon epithelial and T-lymphocyte 
immortalized cell lines through inhibition of IκB kinases. By inhibiting IκB kinases, sulfasalazine 
indirectly disrupts proinflammatory Nuclear Factor κB activity24,25. Although sulfasalazine 
treatment is generally well tolerated, immunosuppression and megaloblastic anemia can be side 




1.1.2c – Biologics 
 
TNFα Inhibitors (TNFi): TNFi are a drug class that functions by inhibition of TNFα, and result in 
marked decreases in inflammatory markers27. There are currently five TNFi approved for 
treatment of RA. These are divided into four subcategories: humanized mouse monoclonal 
antibodies (infliximab), fully human monoclonal antibodies (adalimumab and golimumab), a 
recombinant soluble TNFα receptor-IgG Fc region fusion protein (etanercept), and polyethylene 
glycolated humanized Fab fragment (certolizumab)28. Phase III clinical trials with each of the five 
TNFi resulted in more than half of patients experiencing a reduction in American College of 
Rheumatology (ACR) scores of ≥20% (ARC20) versus placebo, except golimumab 
monotherapy (44%)29–32. In head-to-head comparisons between TNFi and MTX, meta-analytic 
data show that when administered as a monotherapy, TNFi and MTX are equally efficacious in 
reaching ACR20 criteria; however, when TNFi are administered in combination with MTX, TNFi 
elicit a significant improvement in ACR20 over MTX alone33. Noted TNFi side effects include 
increased risk of serious infections34,35, and of lymphomas36, due in part to the systemic 
immunomodulatory role of TNFα37–39. Additionally, the immunogenicity of TNFi can lead to 
increased adverse reactions and treatment failure in patients40. 
 
T cell co-stimulatory signal inhibitor – abatacept: Abatacept is a fusion protein composed of the 
Fc region of immunoglobulin G (IgG) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-
4). In order for T-cells to become activated by antigen presenting cells, they require interaction 
of the major histocompatibility complex with T-cell receptor and a co-stimulatory interaction 
between CD80 or CD86 and CD2841. Conversely interaction between abatacept and CD80/86 
inhibits the required co-stimulatory signal and results in decreased activity of T-cells41. In head-
to-head comparisons of co-administration of MTX with adalimumab or abatacept, the efficacies 
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of these two treatments were not statistically different, although abatacept-treated patients did 
report fewer adverse effects and a greater number completed the 12-month treatment42. 
 
Anti-CD20 antibody – rituximab: Rituximab is a monoclonal antibody targeting CD20, a cell 
membrane-localized phosphoprotein expressed on B-cells but not plasma cells. Rituximab-
CD20 binding results in B-cell cytotoxicity via antibody- and complement-dependent 
mechanisms43. Another effect seems to be the inhibition of anti-apoptotic signaling pathways, 
further reducing circulating B-cells44. These mechanisms are believed to reduce the production 
of B-cell-derived autoantibodies. In a meta-analysis of rituximab monotherapy, it was shown to 
have similar efficacy to other non-TNFi biologics with 51% of patients meeting ACR20 criteria45. 
 
Interleukin 1 (IL-1) inhibitor – anakinra: Anakinra is a recombinant form of the endogenous 
human IL-1-receptor antagonist. Anakinra functions by binding to and inhibiting IL-1, which acts 
as a proinflammatory cytokine in RA. In brief, IL-1 has several functions related to RA 
pathogenesis including stimulating bone resorption46, cartilage degradation, and leukocyte 
activation47. A phase III trial of MTX non-responders reported mild improvements in percent of 
patients receiving anakinra and MTX meeting ACR20 criteria compared to MTX monotherapy 
(38% vs. 22%)48. The most frequently reported serious side effect in anakinra therapy is severe 
infectious episodes, when compared to placebo49, however head-to-head comparisons are 
needed to assess if this is more severe than in TNFi therapy.  
 
IL-6 receptor inhibitor – tocilizumab: Tocilizumab is a humanized monoclonal antibody targeting 
the IL-6 receptor, thus disrupting its signaling. Activation of the IL-6 receptor in RA promotes the 
pro-inflammatory differentiation of Th17 cells (with Transforming Growth Factor-β), the 
production of acute phase proteins50, osteoclast differentiation51, and matrix metalloproteinase 
production (with IL-1)52. ACR20 responses in combination with MTX were reported at 61%53, 
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and tocilizumab treatment is uniquely effective at decreasing degradation of joint tissue as 
well54,55. Treatment with tocilizumab has been shown to increase the risk of infection56 and 
immunogenicity57, without the risk of malignancies over placebo56. 
 
1.1.2d – Glucocorticosteroids (GC): 
Glucocorticosteroids: GC exerts multiple anti-inflammatory effects relevant to the 
pathophysiology of RA. One of the effects is to inhibit NFκB-induced transcription of 
proinflammatory genes, such as cyclooxygenase-2, IL-1β58, IL-659, IL-1760, and TNFα61. GC 
treatment is most effective prior to onset of tissue damage in early stages of RA (i.e., 1-2 years 
post onset), when in combination with a DMARD, GC significantly reduced radiographic bone 
erosion62. The primary limitation of GC treatment is off-target effects in the adrenal gland (e.g., 
adrenal hypertrophy), cardiovascular system (e.g., dyslipidemia), kidney (e.g., sodium 
retention), and nervous system (e.g., glucocorticoid-induced psychoses) (reviewed in 63) 
 
1.1.3 Treatment Approach 
 
The most common treatment approach for RA follows “treat-to-target” recommendations, 
which were initially proposed in 201064, and are now recommended by the American College of 
Rheumatology (ACR)65. In summary, the overarching principles of “treat-to-target” 
recommendations are to maintain either remission or low disease activity by careful monitoring 
of disease activity and modifying treatments as deemed necessary by the rheumatologist and 
patient64. The ACR has since adapted this principle into their guidelines for the treatment of RA 
(Fig. 1.2). 
Under the ACR 2015 guidelines, the primary goal for patients presenting with early RA is 
disease remission, with disease activity monitored every 1-3 months. If over-the-counter non-
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steroidal anti-inflammatory drugs do not control disease activity, patients are typically prescribed 
a non-biologic DMARD monotherapy. Of the classical non-biologic DMARDs, methotrexate 
(MTX) is recommended (purine synthesis inhibitor). Other non-biologic DMARDs available to 
rheumatologists include azathioprine, leflunomide, sulfasalazine, and hydroxychloroquine. The 
goal of this treatment is to enter disease remission. If patients continue to present with high 
disease activity following this initial treatment, then combination therapy can be prescribed. 
Combination therapy involves the addition of another non-biologic DMARD, a TNFi, or a non-
TNF biologic DMARD at the patient and rheumatologist’s discretion. In the event that remission 
cannot be attained, the ACR 2015 guidelines recommends an alternative goal of attaining low 
disease activity (Fig. 1.1)65. Once the patient’s disease activity meets the criteria for either 
remission or continued low disease activity, the treatment goal becomes the maintenance of the 
lowest possible disease severity. Typically disease activity will be monitored every 3-6 months, 
and treatments will be adapted as required (Fig. 1.1)64,65. 
 
1.1.4 Rheumatoid arthritis risk factors 
 
The mechanism of RA pathogenesis remains elusive, although it is hypothesized that it 
is a result of both genetic and environmental factors2. A non-inclusive list of RA risk factors 
includes age, sex, smoking, physical activity level, and genetics. It is generally accepted that 
onset of RA is most frequently seen in patients greater than 60-years old, with the incidence 
rate in women 2-3 times greater than what is seen in men. Smoking is one of the greatest 
modifiable risk factors with a reported risk ratio between 1.3-2.42.  
The genetic risk factors for RA may have an even more important role in RA 
pathogenesis, as indicated by a concordance rate 4.3 times greater among monozygotic twins 
relative to dizygotic twins66. Another study in twins confirms this report, estimating genetic 
factors contribute 60% of the risk of developing RA67. The introduction of genetic references, 
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like the human genome and HapMap projects, has led to significant advances in technologies 
such as genome-wide association studies (GWAS). These technologies have contributed 
greatly to the understanding of the genetic risk factors involved in RA; however, much of the 
complex genetic contributions to RA pathogenesis have yet to be elucidated. An example of the 
complexity of this disease is reflected in the results from one of the largest GWAS meta-
analyses performed to date. This study analyzed 22 different RA GWAS studies with a total of 
>10 million single nucleotide polymorphisms (SNPs) in >100,000 volunteers, and identified 101 
risk alleles that were conserved across multiethnic individuals of Asian and European 
ancestries68. Another database reports 123 risk alleles that have been confirmed in multiple 
independent GWAS69. Among the identified risk alleles, some of the most significantly 
associated with RA include haploblocks of HLA-DRB170–72, PADI473, PTPN2274, TNFAIP375, 
TRAF1/C576, REL77, and CCR678 (reviewed in ref.72). Despite the advances in GWAS, 
conclusions from these studies are strictly limited to disease association. To validate many of 
these findings, much more research needs to be performed to better understand the 
physiological consequences of many identified genetic variants.  
 
1.2 Neutrophils in Rheumatoid Arthritis 
 
This work is currently being edited for submission as a review publication in: Arthritis and 
Rheumatism 
 
1.2.1 Introduction to Neutrophils 
 
Neutrophils represent a terminally differentiated leukocyte population derived from 
myeloid progenitor cells, which also give rise to monocytes, basophils, and eosinophils. In 
humans, neutrophils are the most common circulating leukocyte in peripheral blood (40-60%)41. 
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These cells have multiple granules containing preformed inflammatory mediators and 
antimicrobial substances that are tightly regulated to ensure they are not inappropriately 
released. In healthy individuals, neutrophils exist in a resting state where they require additional 
signals to prime and subsequently release these compounds. Neutrophils require a three-step 
process to release pre-formed granules: (1) priming, (2) migration, and (3) activation. Priming of 
resting neutrophils is mediated by pathogen-associated molecular patterns (PAMPs; e.g., 
lipopolysaccharides)79 and cytokines (e.g., TNF-α, GM-CSF, IL-8, and IFN-γ)80–82. Primed 
neutrophils rapidly mobilize intracellular granules, containing pre-formed receptors, to the 
plasma membrane, and priming agents also affect transcription of many genes to alter 
neutrophil function and increase lifespan (discussed in detail later). Primed neutrophils can then 
migrate to the site of inflammation via chemotaxis and are the first leukocytes to arrive in 
inflamed or injured tissues83. Once within the inflamed tissue, neutrophils are activated by auto-
reactive immunoglobulin complexes, cytokines, and complement, inducing the release of 
granule contents (Table 1.1; reviewed in ref. 84).  
 
Once within the inflamed tissues, additional granules containing oxidant-producing 
enzymes and proinflammatory compounds are released into the extracellular space and 
contribute significantly to tissue damage in chronic disease processes like RA (Table 1.2)85,86. 
This non-specific release of cytotoxic mediators is amplified as activated neutrophils continue to 
release cytokines that induce further neutrophil and pro-inflammatory leukocyte recruitment in a 
positive feedback loop. This positive feedback recruitment must therefore be prevented prior to 
any repair of tissues and resolution of the inflammatory response. In healthy individuals the 
acute stage of inflammation is followed by the recruitment of anti-inflammatory macrophages 
that inhibit neutrophil migration to tissues and removes apoptotic and necrotic cells via 
phagocytosis. These macrophages then continue to secrete anti-inflammatory cytokines 




This review will focus on neutrophil physiology as it pertains the pathophysiology of RA, 
covering the recruitment to inflamed synovial tissues, the common presence of neutrophil-
derived anti-granulocyte and anti-citrullinated protein antibodies in RA patients87, the disruption 
of induced arthritic inflammation in transgenic mouse models88, and the ability of neutrophils to 
affect other leukocytes.  
 
1.2.2 Recruitment of neutrophils to synovial tissues and fluid 
 
 In RA, sterile tissue damage or autoantibody complexes can disrupt tissue homeostasis 
resulting in the production of damage-associated molecular pattern molecules (DAMPs) that can 
be recognized by resident antigen-presenting cells (e.g., macrophages, dendritic cells) or 
resident stromal cells89,90. The activated resident cells then release a number of pro-
inflammatory mediators including IL-1β, TNF-α, lipid mediators (e.g., leukotriene B4), and 
chemokines. This process results in recruitment of circulating neutrophils into the synovial 
tissues, thereby initiating the tissue inflammation that is a hallmark of RA91. 
 
 The cascade of events by which neutrophils are recruited toward pro-inflammatory 
mediators includes (1) adhesion to vascular endothelial cells, (2) transendothelial migration, and 
(3) migration through tissue along chemokine gradients. (1) Neutrophil adhesion to vascular 
endothelial cells is a complex process, which can be further subdivided into (a) vascular 
neutrophil activation, (b) rolling adhesion, and (c) tight adhesion. (a) The activation of circulating 
neutrophils results in preferential association with vascular endothelial cells. Induction of this 
activation state is not completely characterized, but it may be the result of elevated serum 
TNFα, IL-1, chemoattractants (e.g., formylated peptides, C5a), or anti-neutrophil autoantibodies 
(e.g., ANCA, ACPA) 80,92. (b) Neutrophil rolling adhesion is a process mediated predominantly 
	
	 12	
through TNFα- and IL-1-activated93 endothelial cell E- and P-selectin interaction with neutrophil 
adhesion molecules (e.g., P-selectin glycoprotein ligand-1 [PSGL-1], cluster of differentiation 44 
[CD44], and E-selectin ligand 1 [ESL1])94. These weak interactions result in neutrophil “rolling” 
in the post-capillary venules at shear stress between 1-10 dynes per cm2 (95), and the process is 
mediated by sequential weak binding and vascular shear stress-mediated release of 
complementary binding molecules. While neutrophils are rolling across the vascular 
endothelium, they are “sampling” chemokines and cytokines from the underlying tissue that are 
transported and bound to the apical/vascular surface of endothelial cells by negatively-charged 
glycoaminoglycans96. Chemokine receptors on “rolling” neutrophils recognize endothelial-bound 
chemokines, resulting in a conformational change of β-integrins increasing their affinity and 
promoting (c) firm adhesion of neutrophils to activated endothelial cells proximal to the site of 
inflammation97,98. This activation of β1- (e.g., VLA-4) and β2-integrins (e.g., LFA-1, MAC1) occurs 
via intracellular signaling networks – believed to be mediated through the actions of G protein βγ 
subunits99,100. Once activated, firmly adhered neutrophils can begin the process of 
transendothelial migration (reviewed in ref. 94).  
 (2) Neutrophil transendothelial migration occurs following adhesion; however, 
neutrophils do not frequently transmigrate at the site of initial adhesion. Often neutrophils extend 
pseudopods and appear to ‘probe’ the vascular endothelial cells without moving from the initial 
anchor point. Under in vivo flow conditions, neutrophils then proceed to slowly migrate along the 
endothelial cells, in a MAC-1-dependent process101, perpendicular to forces of shear stress102. 
This migration pattern likely increases the odds of a neutrophil recognizing a ‘transmigration 
point’, because neutrophils are moving across endothelial cell axis that is elongated by vascular 
shear stress and therefore encounter more endothelial junctions103. To leave the vasculature, 
neutrophils must first cross the endothelial cell layer through paracellular (i.e., between cells) or 
transcellular (i.e., through cells). Because paracellular migration presents the fewest barriers to 
migration and occurs more rapidly, neutrophils preferentially use this pathway101,104,105. 
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Transcellular migration is observed, but is less efficient and more time consuming104. The 
paracellular route typically occurs at endothelial tricellular junctions, where junctional proteins 
are at the lowest density105,106. Transmigration involves the interaction of a number of neutrophil 
surface molecules (e.g., LFA-1, MAC-1, VLA-4, CD99, PECAM1) with endothelial surface 
molecules (e.g., ICAMs, VCAM1, CD99, junctional adhesion molecules) (reviewed in 92). 
 
(3) Following adhesion and transmigration, neutrophils must next migrate through a 
number of barriers, including the vascular basement membrane, vascular pericytes, and tissue 
matrix. Neutrophils preferentially migrate where the extracellular matrix is least dense107, then 
are induced by chemoattractants108 within the basement membrane to release matrix 
metalloproteinases (e.g., MMP-9) and proteases (e.g., elastase, collagenase; table 1.4)109. 
These enzymes make the basement membrane more porous and allow neutrophils to migrate 
toward the vascular pericytes, which are less densely packed in regions with porous basement 
membranes, thus are readily circumnavigated110. Migration through additional tissue 
extracellular matrix is less dependent on enzymes to degrade matrix, due to the decreased 
density of matrix polymers. Migration through additional extracellular matrix is primarily 
mediated by chemokine gradients92. The final barrier to entry of neutrophils into the synovial 
tissues in early RA is a poorly vascularized layer of cartilage. This process is not well 
characterized, but is likely a result of the actions of neutrophil collagenase, elastase, and MMP9 
(Table 1.2). There is less of a necessity to migrate through cartilage late in the RA inflammatory 
response, because of the formation of a neovascularized pannus, formed by synoviocyte 
hyperplasia, within the synovial tissues111. The additional blood vessels within the synovial 
tissues likely increase leukocyte recruitment by decreasing the distance and barriers to 
migration.  
In RA, the process of neutrophil migration through these barriers to the site of 
inflammation is mediated by a number of chemoattractant gradients. Chou et al. highlights the 
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complexity of neutrophil recruitment by hypothesizing that a temporal cascade of leukotriene B4 
(i.e., LTB4 or 5,12-diHETE), IL-1β, then CXCR2 agonists (e.g., CXCL1/GROα, CXCL2/GROβ, 
CXCL8/IL-8)112 and complement orchestrates leukocyte recruitment in RA112–114, a hypothesis 
that is widely accepted by others in the field86,115,116. Initially, lipid mediators like LTB4, a highly 
potent chemoattractant for neutrophils, are produced at a low concentration by activated 
resident leukocytes. The low concentration of LTB4 induces in a mild recruitment of circulating 
neutrophils, which are activated in synovial tissue, leading to the release of additional LTB4, 
thus establishing a positive feedback loop and markedly increasing the number of neutrophils 
recruited. One study has shown this positive feedback on neutrophil-derived LTB4 results in 
concentrations as high as 400 ng/ml (1.2 µM) in synovial fluid samples of a cohort of 
seropositive RA patients during inflammatory bouts117. The role of LTB4 in rheumatoid arthritis-
like inflammation is apparent in leukotriene B4 receptor 1 (Ltb4r1 or Blt1)-deficient mice that 
exhibit a profound lack of detectable inflammation in both serum-transfer (K/BxN)112 and 
collagen-induced (CIA)118,119 models of inflammatory arthritis. Similar protection from models of 
arthritis are also afforded to mice deficient in enzymes involved in LTB4 synthesis, including 5-
lipoxygenase activating protein (Flap)120, 5-lipoxygenase (Alox5)121, and leukotriene A4 
hydrolase (Lta4h)121; protection was also reported in mouse models utilizing pharmaceutical 
inhibitors of many of these enzymes122–124. Of note, inhibition of LTB4 receptor with the orally-
active competitive antagonist, BIIL 284, did not significantly improve ACR20 scores in a 3 month 
clinical trial performed in patients with RA125. Although not reported in the literature, an 
additional LTB4 receptor inhibitor (CP-195,543 126; clinicaltrials.gov) also failed in clinical trials 
due to a poor tolerability profile. These results from human trials are discrepant from positive 
effects seen in mouse models, but may be a result of a elevated concentrations of LTB4 
outcompeting the antagonist or the confounding requirement that patients cease their 
therapeutic regimens prior to these studies. An alternative approach to inhibit LTB4 signaling 
may be to target an enzyme involved in LTB4 synthesis, which had been attempted in clinical 
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trials with a soluble phospholipase a2 inhibitor, LY333013, but was speculated to be hampered 
by poor uptake into synovial fluid and tissues127. An additional LTB4 synthetic enzyme to target 
may be LTA4 hydrolase, which would decrease levels of LTB4 secreted and prevent the 
inflammatory response in RA. Despite the inconclusive human clinical trial data, the previous 
mouse model studies and the elevated LTB4 levels detected in human synovial fluid suggest a 
role for LTB4 as an obligate mediator of early recruitment of neutrophils. 
 
Following LTB4-induced recruitment, additional chemoattractant signals are important in 
the continued recruitment of neutrophils. Recruited LTB4R1-positive neutrophils are then 
stimulated to release IL-1β in response to the increased synovial concentration of DAMPs (e.g., 
antibody complexes, purine metabolites, hyaluronan monomers, nucleic acids, interferons), and 
consequently, autocrine IL-1β signaling upregulates neutrophil synthesis and secretion of 
proinflammatory mediators, including LTB4, CCR1 agonists, and IL-8112,128. The clinical 
importance of IL-1β in arthritis is highlighted by the utility of Anakinara, an FDA-approved 
therapeutic synthesized from human recombinant interleukin 1 receptor antagonist (IL-1Ra)49. 
Of note, mouse strains deficient in IL-1β production (i.e., pro-Il1b-deficient and caspase-1-
deficient) are not protected from K/BxN serum transfer-induced acute paw swelling; however, 
these mice are protected from cartilage damage, proteoglycan depletion, and cell influx to 
synovial tissue in Streptococcal cell wall-induced chronic arthritis129. However, the role of IL-1β 
is highlighted by the exogenous administration of recombinant IL-1β to Ltb4r1-deficent mice 
restoring K/BxN serum transfer-induced acute arthritis, presumably via by-passing the 
requirement for LTB4-signaling to initiate this IL-1β production112. Therefore, it may be that the 
innate immune-driven models of acute arthritis may be capable of inducing inflammation 
primarily through lipid mediators (e.g., LTB4), but prolonged recruitment and activation of 
leukocytes is driven through IL-1β signaling.  
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In the pathophysiology of rheumatoid arthritis, recruitment of additional lymphocytes is 
required, and is believed to be partially mediated by IL-1β inducing the release of neutrophil 
extracellular traps (NETs)130. NETs have been shown to contain various targets for lymphocyte-
derived autoantibodies, including neutrophil cytoplasmic and histone proteins that have been 
citrullinated by enzymes like protein arginine deaminase 4 (PADI4). Anti-citrullinated protein 
antibodies (ACPA) and anti-neutrophil cytoplasmic antigen (ANCA) are hallmark RA 
autoantibodies that target these entities released from NETs131–133. Additionally, NET release 
from neutrophils releases a number of lymphocyte activating components (described in detail 
later). Although the complete mechanism of IL-1β in acute and chronic arthritis requires 
additional study; however, at least part of the role for IL-1β is the formation of NETs, which in 
turn release auto-antigens necessary for the chronic inflammatory state of RA.   
 
IL-1β also stimulates the release of resident leukocyte-derived CXCR2 agonists, 
including CXCL1 (GRO-α), CXCL2 (GRO-β), and CXCL8 (IL-8), all of which amplify the 
recruitment of neutrophils to continue the inflammatory response within synovial tissues112. In 
Cxcr2-deficient mice K/BxN serum-induced inflammatory arthritis does not appear to be different 
from the wild-type mice over the first 5 days. After that time, there is significant decrease in 
ankle swelling in the Cxcr2-deficient mice134; furthermore, mice treated with a synovial injection 
of a dominant-negative form of CXCL8 also exhibited only partial decreases in nociception in a 
methylated bovine serum albumin-induced model of inflammatory arthritis135. These data may 
reflect the temporal relationship of CXCR2 ligand signaling to the inflammatory process, i.e., 
primarily involved in late phase inflammation in RA113. Therefore, the CXCR2-deficient and -
blocked models of disease may develop early LTB4- and IL-1β-dependent inflammation but be 
protected from prolonged inflammation that is not reliably demonstrated in acute inflammatory 
arthritis models112,134. IL-1β may also increase recruitment of monocytes/macrophages, given 
that treatment of human monocyte-derived macrophages with IL-1β induces production of CCL2 
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(MCP-1)136 as well as endothelial cell CX3CL1 (fractalkine) expression137, both of which are 
monocyte/macrophage chemoattractants138–140. The influence of CCL2-induced monocyte 
recruitment may however be a minor component of arthritic inflammation. This notion is 
supported by the lack of protection in Ccr2-deficient mice and moderate protection in Cx3cr1-
deficient mice in K/BxN serum-induced inflammatory arthritis134, as well as blockade of CCR2 
and CCR5 failing to inhibit primary human monocyte recruitment in vitro or offer therapeutic 
benefits in clinical trials141. 
 
Beyond the LTB4/IL1β/CXCR2 axis, recruitment of neutrophils to synovial tissues in RA 
also occurs as an indirect result of autoimmune antibodies (e.g., ANCA, ACPA) or acute phase 
proteins (e.g., C-reactive protein) that activate the complement cascade, and additionally 
produce anaphlyatoxins like complement component 5a (C5a)142,143. The role of C5a in RA 
pathophysiology is supported by C5ar-deficient mice exhibiting protection from K/BxN serum 
transfer arthritis114, while C5a144 and C5a receptor145 antagonism by monoclonal antibodies 
protects wild type mice from collagen-induced arthritis models. Furthermore, mutations in the 
human C5 gene, which enhance the rate of proteolysis of the inert C5 protein into the 
anaphylatoxin C5a146, are risk alleles for RA76,147. These and other findings have led Novo 
Nordisk to develop a therapeutic C5a receptor inhibitor, which is currently in clinical trials145. 
However, it has yet to be fully elucidated how C5a signaling is incorporated into the proposed 
temporal chemokine cascade.  
 
In summary, these aforementioned data support the sequential recruitment of 
neutrophils and other leukocytes through the sequential functions of LTB4, IL-1β, CXCR2, and 
complement, which emphasizes the importance of each in the pathogenesis of RA. Lack of RA 
protective phenotypes detected in Ccr1-9, Cxcr3, and Cxcr5-deficient mouse strains further 
support a central role for this LTB4/IL-1β/CXCR2 chemokine axis in the development of 
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inflammatory arthritis134. However, there has been recent mild success in clinical trials of the 
CCR1 antagonist CCX354-C148. In this study, relative to placebo, patients naïve to traditional 
biologic medications saw an improved ACR20 response (≥20% improvement in 3 of 5 disease-
relevant criteria; placebo - 26% vs. CCX354-C - 62%) and a trend toward improvement of 
ACR50 response (≥50% improvement in 3 of 5 disease-relevant criteria; 15% vs. 35%) following 
placebo or CCX354-C treatment, respectively148. The greatest mRNA expression of CCR1 is 
seen in both neutrophils and monocytes, important innate immune cells in RA pathogenesis149, 
and therefore may support the additional complexity of human rheumatoid arthritis versus 
mouse models thereof.  
 
Furthermore, the LTB4/IL-1β/CXCR2 model may not completely explain neutrophil 
chemotaxis, as no mouse models of arthritis completely replicate human rheumatoid arthritis. It 
is also noteworthy that differences in physiology exist between human and mouse neutrophils. 
For example neutrophils only represent 10-25% of circulating leukocytes in mice150 compared to 
the 40-80% that human neutrophils represent41. Additionally, protein expression of the CXCR2 
sister receptor, CXCR1 – that shares many agonists with CXCR2, is absent in mouse 
neutrophils150; moreover, production of some cytokines including IL-6116 and IL-10151 is shown in 
mouse neutrophils, but in human neutrophils remains controversial. Furthermore, different 
models of inflammatory arthritis in mice may disproportionately represent certain arms of the 
immune response. For example, acute models of arthritis include K/BxN serum transfer and 
collagen antibody-induced arthritis (CAIA) that primarily model the innate immune response to 
autoantibody deposition. Chronic models of arthritis include as collagen-induced arthritis (CIA) 
and Streptococcal cell wall-induced arthritis (SCW), that involve both the innate and adaptive 
immune responses to develop autoantibodies. Stating these differences is not meant to suggest 
that the mouse models are non-translatable to the features of human RA, but rather these and 
other differences must be taken into account when interpreting mouse data. Therefore, although 
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a fair amount is known in human RA pathogenesis as a result of clinical studies, the need for 
additional clinical trials, in vitro, and genomic studies cannot be understated. 
 
1.2.3 Neutrophil degranulation  
 
Upon migration into the synovial tissues, cytokine-primed neutrophils can recognize both 
soluble and tissue-deposited antibodies (e.g., ACPA) via one of 3 highly expressed receptors 
(FcγRI, FcγRII, and FcγRIIIb), and activation of these receptors on primed neutrophils can 
initiate degranulation. Disruption of the normal physiology of each of these receptors may be 
involved in RA pathogenesis. (1) FcγRI (CD64) is a high-affinity receptor for IgG antibodies. 
FcγRI is not expressed at the cell surface in unprimed neutrophils from healthy individuals, but 
is expressed in neutrophils isolated from the synovial fluid of RA patients. The expression of this 
high-affinity antibody receptor may increase the sensitivity of RA neutrophils to antibody 
complexes resulting in increased degranulation152.  (2) FcγRII (CD32) is a low-affinity 
constitutively expressed receptor that exists in two isoforms, the activating FcγRIIa153 and 
inhibitory FcγIIb154 receptor. The importance of the balance between these isoforms is illustrated 
by the nearly doubled rate of radiologic joint damage in RA patients homozygous for the loss of 
function non-synonymous 695T>C polymorphism in the FcγRIIb gene154. Further evidence of 
the importance of the balanced expression of these two isoforms is represented by infliximab 
(TNFi) treatment, which induces a shift in expression favoring the inhibitory isoform and may 
contribute to some of its therapeutic benefits in RA153. Finally, (3) FcγRIIIb (CD16) is a low 
affinity receptor shown to play a role in reactive oxygen species production155. This receptor is of 
particular interest as an RA therapeutic target, because individuals completely deficient in 
FcγRIIIb transcript do not have impairment in bacterial phagocytosis156, but exhibit a functional 
deficit in antibody complex-mediated cytokine release154. Therefore, therapeutic inhibition of 
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FcγRIIIb may prevent leukocyte recruitment via disruption of reactive oxygen generation and 
cytokine release, but not affect host defense responses to bacteria. 
 
 Following activation by immune complexes, neutrophils then degranulate and produce 
reactive oxygen species O2-, OH-, and H2O2 (via NADPH oxidase) and HOCl (via 
myeloperoxidase). Normal resting neutrophils have little capacity to produce reactive oxygen 
species, because (1) the NADPH oxidase enzyme is multimeric and assembled at the plasma 
membrane during priming157 and (2) myeloperoxidase is contained within azurophilic granules 
and inactive without NADPH oxidase production of its substrate H2O2158. Following neutrophil 
activation in RA, NADPH oxidase enzyme is assembled and produces substrates for 
myeloperoxidase, resulting in the oxidative burst that increases oxidative stress in the synovial 
tissues. Increases in reactive oxygen species have been partially implicated in the pathogenesis 
of RA159, and RA patients display increased NADPH oxidase activity compared to controls160,161. 
The effects of reactive oxygen species in RA are likely mediated through a number of processes 
that result in synovial cell and tissue damage. Synovial cell damage follows oxidation of cell 
components and activation of NFκB transcription, both of which results in the transcription of 
proinflammatory genes (e.g., COX-2, PLA2, IL-1β, TNFα) and propagate the inflammatory 
response162. Reactive oxygen species also induce tissue damage directly through of catalysis of 
cartilage proteoglycans by HOCl and H2O2 85,163, and HOCl can promote cartilage degradation 
by activation neutrophil collagenase and gelatinase163.  
The oxidative burst also occurs concurrent to neutrophil degranulation, which positively 
correlates with severity of synovial tissue inflammation and damage in RA patients164. Neutrophil 
degranulation results in release of preformed granule enzymes that degrade structural 
components of the synovial tissues (Table 1.2). When neutrophils are activated these granule 
components are released into the synovial fluid, while autoantibodies deposited on synovial 
tissues result in release of granule components directly on tissues in a process known as 
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frustrated phagocytosis81,86 (Fig. 1.3). The neutrophil granule proteases, metalloproteases, 
catabolic enzymes, and reactive oxygen species act in concert to degrade high-molecular 
weight components of cartilage85,161,165. Elastase166, collagenase166, matrix metalloprotease 
9167,168, and gelatinase168 are all present within neutrophil granules (Table 1.2), and have all 
been shown to degrade the cartilage matrix. The activity of these enzymes results in the direct 
tissue damage of arthritic synovial tissues, a hallmark of RA histopathology. 
In summary, the role for antibody complex-induced activation and degranulation of 
neutrophils has been revealed by in vitro experiments in which co-culture of cell-free synovial 
fluid from RA patients with primary circulating neutrophils resulted in a significant increase in 
NADPH oxidase activity over those treated with synovial fluid from patients with other joint 
arthropathies. In the same study, depletion of synovial fluid antibodies resulted in a marked 
decrease in NADPH oxidase activity169, and blockade of neutrophil FcγRIIIb and FcγRIIa 
disrupted reactive oxygen species formation in response to soluble and insoluble antibody 
complexes, respectively155. These observations support the role of RA autoantibody complexes 
in the production of neutrophil reactive oxygen species and degranulation (Table 1.1 and 1.2) 
leading to the hallmark non-specific tissue damage that ensues86.  
 
1.2.4 Neutrophil extracellular traps in rheumatoid arthritis 
 
 Formation of neutrophil extracellular traps (NETs), first described by Brinkmann et al.170, 
represents a unique form of neutrophil cell death distinct from apoptosis and necrosis 
(reviewed171) that may be involved in the pathophysiology of RA. Correlative evidence shows 
neutrophils isolated from RA patients more readily undergo the formation of NETs than 
neutrophils isolated from patients with other forms of arthritis132. NET release results from the 
deimination of histone arginine to citrulline by PADI4 and degradation of the nuclear 
envelope172. Chromatin, in association with multiple anti-microbial granule components such as 
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myeloperoxidase, elastase173, and LL37131,174, is then released into the extracellular space175. 
The excessive release of citrullinated chromatin and numerous citrullinated antigens present in 
NETs, including elastase, cathepsin G, proteinase 3, α-defensins, and LL37131,176,177 act as 
potential autoantigens; therefore, NETs have been proposed to be a primary source of 
citrullinated peptides that can induce formation of ANCA autoantibodies132. The importance of 
this process in the development of inflammatory arthritis is demonstrated by protection from 
collagen-induced arthritis inflammation via therapeutic inhibition of a citrullinating enzyme 
present within NETs, PADI4178. Together these findings support a role for NET formation in RA 
pathogenesis by presenting potential autoantibody targets during the conversion of acute 
inflammation into an adaptive humoral immune response that is the hallmark of autoimmune 
RA. Further explanation of the development of autoantibodies specific for NET-released 
antigens is reviewed in depth by Darrah & Andrade179, and the role of NETs in autoimmunity is 
reviewed in depth by Dwivedi & Radic180. 
 
1.2.5 Neutrophil modulation of immune cells 
 
Innate immune cells are a subset of leukocytes classically described by their ability to 
respond to generic molecular patterns (e.g., DAMPs and PAMPs) immediately but innate 
immune cells are incapable of inducing long-term immunity for the host, like adaptive immune 
cells can. Classically, neutrophils, basophils, eosinophils, macrophages, dendritic cells (DCs), 
natural killer (NK) cells, and mast cells comprise the innate immune cell class of leukocytes41. 
Innate immune cells, like neutrophils, help to establish the chronic inflammatory response in RA 
and activate the adaptive immune response. Neutrophils are typically the initial leukocytes 
recruited, and therefore affect recruitment and activation of additional cells including 




Neutrophil-macrophage interaction: Macrophages are a subset of leukocytes derived 
from circulating monocytes or from tissue macrophage mitosis. Their canonical function is to 
recognize and phagocytize moieties that are considered dangerous, then present antigen to 
lymphocytes to induce an adaptive immune response41.  Neutrophils and macrophages share 
several common functions (e.g., phagocytosis, production of reactive oxygen species, cytokine 
production), possibly due to their common origin from myeloid progenitor cells; however, unlike 
short-lived neutrophils, macrophages have a lifespan on the scale of months and reside within 
tissues41. While resident synovial macrophages induce the recruitment of neutrophils, 
neutrophils in turn recruit additional circulating monocytes through the release of chemokines 
like CCL2 (MCP-1), CCL3 (MIP-1α), and CCL4 (MIP-1β)136,137,182. Neutrophils then release a 
number of cytokines that affect macrophage responses to inflammation. For example, activated 
neutrophils82 can produce interferon-γ183,184, which promotes polarization of monocytes toward 
proinflammatory M1 macrophage physiology185,186. In RA the activation of macrophages can 
induce pathogenic generation of reactive oxygen species, cytokines, and activation of 
lymphocytes of the adaptive immune response41,187. 
 
 Beyond the production of cytokines, neutrophils can also affect macrophages through 
the release of myeloperoxidase188, which can directly damage synovial tissues and, in the 
context of alveolar inflammation, interacts with the macrophage mannose receptor to increase 
reactive oxygen species, TNF-α, and IL-1β production189. TNF-α and IL-1β at sites of 
inflammation increase survival of recruited neutrophils, potentially prolonging and exacerbating 
inflammation190. Further work suggests Mpo-deficient (myeloperoxidase-deficient) mice are 
protected from the inflammatory phenotypes seen in collagen-induced arthritis, although it is 
difficult to determine if these effects are the result of a reduction of direct tissue damage or a 
reduction of myeloperoxidase activation of macrophages191. In the rheumatic arthritic joint, this 
interaction between neutrophils and macrophages may both augment tissue damage via 
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release of proinflammatory mediators (e.g., cytokines, reactive oxygen) and further recruit 
additional leukocyte subsets, thereby affecting RA pathophysiology. 
 
Neutrophil and dendritic cell (DC) interaction: DCs are another antigen-presenting cell 
type that functions to process antigens, migrate to proximal lymph nodes, and present antigens 
to lymphocytes to induce adaptive immune responses. Once activated by antigens, in this case 
RA-related autoantigens, DCs migrate through the lymphatic system. This process allows 
transport of antigen from distal sites of inflammation to lymphoid organs, which contain 
lymphocytes required for the establishment of adaptive immune responses41. Neutrophils are 
seen to co-localize with DCs when cultured together192, and their interaction is able to activate 
DCs naïve to antigen, which in turn elicits lymphocyte activation193. Neutrophils also produce a 
number of chemokines capable of recruiting mature DCs to sites of inflammation, the most well 
characterized being CCL21194 (see Table 1.3; neutrophil cytokine production). This capacity to 
recruit DCs suggests that initial neutrophil recruitment to inflammation zones may result in 
recruitment of local tissue DCs allowing their collection of antigens for presentation to adaptive 
immune cells. If this is the case, neutrophils would play an integral role in the conversion of an 
acute synovial inflammatory response to a chronic pathology like RA. 
Activated neutrophils also release granules and NETs containing a number of alarmins 
(e.g., HMGB1, α-defensins, LL-37) that are capable of affecting DC migration and maturation. 
HMGB1-DNA complexes are one example of a neutrophil-derived alarmin that influences both 
migration and activation of DCs via the TLR9 receptor195; this process results in the activation of 
a cytotoxic TH1 response196. Additionally, neutrophil granule-derived α-defensins (Human 
Neutrophil Peptide-1 and -2) are capable of recruiting immature DCs toward sites of 
inflammation197, and a cathelicidin, LL-37, from neutrophil granules is observed at a higher 
concentration in RA synovial fluid compared to healthy controls. LL-37-targeted autoantibodies 
have also been detected in rat models of arthritis198. Additionally, in the presence of DNA, LL-37 
	
	 25	
acts via a TLR7- and TLR8-dependent manner in DC maturation, and expression of lymphocyte 
co-stimulatory membrane proteins131,174,199. Thus, LL-37 may be a target of pathogenic 
autoantibodies in RA, and neutrophil-derived alarmins influence the function of DCs in RA 
inflammation. 
Beyond cytokine signaling, the physical interaction of neutrophils and DCs also plays a 
role in RA pathophysiology. Under inflammatory conditions, neutrophil cell surface expressed 
Mac-1 (CD11b/CD18) interacts with DC cell-surface expressed DC-SIGN resulting in (1) 
activation of DCs and (2) presentation of antigens to DCs192. The activation of DCs in a 
neutrophil-DC complex will result in DC expression of lymphocyte co-stimulatory molecules 
(e.g., CD80, CD86, CD40, and HLA-DR192,193), that are required for activation of lymphocytes, 
and therefore an adaptive immune response. Another neutrophil cell surface molecule, CECAM-
1 (CD66a), is also capable of interacting with DC-SIGN, resulting in a delay of neutrophil 
apoptosis and a prolonged inflammatory response152. In summary, an important role exists for 
neutrophil and DC interactions in the progression of RA. 
 
Neutrophil activation of adaptive immune response: The adaptive immune response is 
defined by the activation and responses of B- and T-lymphocytes, a specialized subset of 
leukocytes capable of recognizing specific antigenic signals. In contrast to the innate immune 
response discussed until this point, the adaptive immune response requires 1-2 weeks to be 
fully activated, recognizes highly specific antigens (not non-specific molecular patterns), and 
can generate a memory response for rapid mobilization during subsequent antigenic 
challenges41. Activated neutrophils can affect the adaptive immune response by promoting the 
migration of both B- and T-lymphocytes (Table 1.3). However, the canonical role for neutrophils 
in adaptive immunity is indirect via the activation of antigen-presenting cells (e.g., macrophages 
and DCs). This activation induces expression of co-stimulatory molecules that are capable of 
activating antigen specific lymphocytes.  
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Neutrophils are also capable of expressing MHC class II molecules and thereby directly 
activating lymphocytes. In vitro, synovial fluid neutrophil activation by GM-CSF and IFN-γ has 
been shown to induce cell surface expression of MHC class II with low expression of co-
stimulatory molecules CD80 or CD86200. Furthermore, in vitro treatment of peripheral 
neutrophils with GM-CSF, IL-4, and TNF-α increases cell surface protein localization of MHC 
class II molecules (e.g., HLA-DR and HLA-DQ), CD80, and CD86201. Primary synovial fluid 
neutrophils from RA patients exhibit a similar expression profile and are capable of activating 
primary T-lymphocytes in co-culture202,203. The activation of CD4+ T helper 2 (Th2) cells can 
promote antibody production, which can result in the production of additional autoantibodies. In 
summary, the MHC class II and co-stimulatory molecule expression by neutrophils appears to 
be context-dependent and present within RA inflammatory attacks. The extent of MHC class II 
presentation may also be a factor in individual susceptibility to various autoimmune diseases. 
Therefore, activated RA synovial neutrophils and recruited T-lymphocytes probably interact 
cooperatively to propagate antibody production and inflammation in RA.  
 
1.2.6 Resolution of neutrophil recruitment 
 
Resolution of a normal inflammatory response, within the synovial tissues, is a highly 
regulated process that protects the host from prolonged inflammation and prevents the 
establishment of a chronic inflammatory response. A chronic disease, like RA, is the result of a 
decreased ability to stop the acute inflammatory response. An integral cell type involved in RA 
pathophysiology is neutrophils, thus prolonged lifespan of RA neutrophils and disrupted egress 
from inflamed tissues may lead to chronic inflammatory responses. Many recruited neutrophils 
enter apoptosis following a normal inflammatory response, and then are cleared from the 
tissues by anti-inflammatory macrophages. Apoptosis in healthy peripheral blood neutrophils 
typically results in a short lifespan, with a half-life of between 18 and 90 hours as shown by in 
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vivo labeling studies204, and cultured neutrophils from RA patients exhibited a delay of apoptosis 
between 6-22 hours compared to healthy controls205. The lifespan of neutrophils increases 
significantly in the pro-inflammatory RA synovial tissues, where changes in dissolved oxygen 
and pH significantly delay apoptosis and resolution of inflammation206,207. There are also 
populations of neutrophils in RA that avoid apoptosis and return to the vasculature by reverse 
transmigration. As many as 2% of peripheral blood neutrophils from RA patients may have 
undergone reverse transmigration, in contrast this population make up only 0.25% of peripheral 
blood neutrophils are seen in healthy donors208. The implications of this process are not known, 
but it could be a protective mechanism to decrease the neutrophil load in synovial tissues, or a 
pathogenic mechanism that establishes a systemic state of inflammation. Although the process 
of neutrophil apoptosis versus reverse migration is not completely characterized, some 
hypotheses for the delay in neutrophil apoptosis include disrupted lipid mediator class 
switching209,210, elevated serum and synovial fluid concentration of GM-CSF in RA 
patients207,211,212,  elevated synovial fluid lactoferrin concentrations213, and hypoxic conditions 
within the inflamed synovial tissue206. Regardless of the cause, it appears there is a significant 
role of the anti-apoptotic protein myeloid cell leukemia sequence 1 (Mcl-1) in neutrophil 
apoptosis, as mRNA levels of Mcl-1 positively correlate to GM-CSF levels in RA synovial 
neutrophils211 and treatment of peripheral neutrophils with GM-CSF stabilizes Mcl-1 protein 
following cycloheximide treatment207. Additionally treatment with Seliciclib, an inhibitor of cyclin-
dependent kinases (CDKs), was shown to increase neutrophil apoptosis, decrease Mcp-1 
mRNA expression, and improve clinical scores in mouse models of arthritis214. Of note, 
methotrexate treatment also restored normal rates of apoptosis in isolated neutrophils205, which 
may represent an additional mechanism of action in preventing RA pathophysiology.  In 
summary, the prolonged lifespan of activated neutrophils in the synovial tissues may contribute 
to increased tissue damage.  
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Another mechanism to resolve acute inflammation is hypothesized to be initiated by a 
class switching of secreted lipid mediators (i.e., eicosanoids), although the mechanisms and cell 
sources of this process are incompletely understood209. Part of class switching of lipid mediators 
is the decrease in production of neutrophil-derived proinflammatory lipids like LTB4 and PGE2, 
and an increased synthesis of lipoxins. Lipoxins antagonizes continued neutrophil 
recruitment209,215, and promote recruitment of anti-inflammatory subsets of macrophages to 
remove apoptotic neutrophils, release anti-inflammatory cytokines, and initiate tissue repair210. 
Additionally, endogenous glucocorticoids promote resolution of inflammation. Endogenous 
glucocorticoids (e.g., cortisol) cause neutrophils to increase cell surface localization of annexin 
1, which inhibits continued neutrophil adhesion and transmigration216. Neutrophil-derived 
annexin 1 rich microparticles are released by the cell to inhibit continued neutrophil adhesion217. 
In RA, the activation of endogenous glucocorticoids is decreased by lower enzymatic activity of 
11β-hydroxysteroid dehydrogenase type 1 and an increase of 11β-hydroxysteroid 
dehydrogenase type 2, a glucocorticoid inactivating enzyme218. In summary, impaired neutrophil 
apoptosis and response to pro-resolving molecules in RA are likely involved in the development 




Neutrophils are classically associated with the host response to pathogenic microbes, 
but they also are becoming more accepted as an important modulator of sterile inflammatory 
diseases such as arthritis. Neutrophils represent the first class of circulating immune cells to be 
recruited to synovial tissues in RA, and continue to recruit additional neutrophils through a 
cytokine positive-feedback loop. Continued recruitment and activation of neutrophils allows the 
release of granule products capable of damaging local tissues. Further propagation of 
inflammation is exerted by neutrophil interaction with additional immune cells via cytokines or 
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cell-cell interactions. This process supports neutrophils as a key regulator of RA inflammation, 
and the therapeutic potential of disruption of neutrophil physiology in RA and other sterile 
inflammatory diseases.  
1.3 GPSM3 in cell physiology 
 
 
This work below was published in ref.219: 
 
Billard, M. J., Gall, B. J., Richards, K. L., Siderovski, D. P. & Tarrant, T. K. G protein signaling 
modulator-3 : a leukocyte regulator of inflammation in health and disease. Am J Clin Exp 
Immunol 3, 97–106 (2014). 
 
 
1.3.1 Signaling interactions 
Elucidating the function and regulation of G protein coupled receptors (GPCRs) was 
recently recognized with a 2012 Nobel Prize, and these proteins continue to be the largest class 
of cell-surface receptors successfully targeted for the treatment of human disease220,221. GPCRs 
are functionally associated with heterotrimeric G proteins composed of Gα, Gβ, and Gγ 
subunits. When the receptor is inactive, Gα is bound to guanosine diphosphate (GDP) in its own 
inactive state; GDP binding to Gα promotes its association with the Gβγ dimer, which inhibits 
spontaneous GDP release by Gα and also assists in receptor coupling. After ligand binding, the 
GPCR acts as a guanine nucleotide exchange factor (GEF) promoting the replacement of GDP 
with guanosine triphosphate (GTP) and leading to conformational changes that result in 
dissociation of Gβγ from the heterotrimeric complex. Both GTP-bound Gα and free Gβγ initiate 
signal cascades to downstream effectors. Hydrolysis of GTP to GDP returns Gα to its inactive 
state, allowing re-association with Gβγ and signal termination222,223.  
Chemokine receptors are GPCR family members that signal through Gαi-containing 
heterotrimers to regulate cellular migration, survival, and angiogenesis in inflammatory 
conditions224,225. However, as drug therapy targets in autoimmunity, chemokine receptors have 
had disappointing results in various neutralization strategies141,226 and, in particular, in the 
	
	 30	
development of chemokine signaling inhibitors as rheumatoid arthritis (RA) therapeutics227,228. 
This failure has been attributed, in part, to redundancy of chemokine receptor/ligand interactions 
in inflammation224, and so it has been proposed that a more efficacious strategy should target a 
shared pathway regulator of chemokine receptor signaling rather than neutralization of a 
specific chemokine or its receptor(s) per se229. 
GoLoco motif-containing proteins are regulators of GPCR signaling that share a 
signature 19-amino-acid sequence230,231, as well as a hallmark biochemical activity of inhibiting 
Gαi release of GDP223,232–234. One such member of this protein family with a highly-restricted 
expression pattern (Fig. 1.4), GPSM3 (a.k.a. AGS4235 or G18236), possesses three GoLoco 
motifs (but only two are functional236) and an additional LSL motif required for Gβ subunit 
binding237. The functional GoLoco motifs of GPSM3 allow the protein to bind Gαi·GDP and act 
as a GDP dissociation inhibitor (GDI)235,236 independent of Gαi·GDP interaction with the Gβγ 
dimer234,238, while the LSL motif interaction with monomeric Gβ subunits is suspected to regulate 
GPCR/G-protein heterotrimer association at the level of Gβγ dimer assembly237 (Fig. 1.5). The 
cellular and biologic effects of GPSM3 continue to be explored as recent research points to its 
important regulatory functions in chemokine receptor signaling, monocyte phenotypes, and 
autoimmune disease development. 
Recent studies by Giguere et al. have illustrated that GPSM3 deficiency affects the 
chemotactic response of myeloid cells activated through the chemokine receptors CCR2, 
CX3CR1, and CMKLR1239. Ongoing biochemical and cell biological research is helping to define 
the specific role that GPSM3 plays in the intracellular sequelae of chemokine receptor signaling 
and how this role ultimately affects cellular chemotaxis and viability. 
Not only does GPSM3 interact with Gαi·GDP and monomeric Gβ subunits, but from 
studies of local energy transfer between fusion proteins expressed in cells, it is hypothesized 
that GPSM3 may also help position Gα subunits at the cell membrane, proximal to GPCRs, and 
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thereby help provide a signaling substrate to ligand-activated receptors240; however, these latter 
results from ectopic overexpression of recombinant fusion proteins have yet to be confirmed in 
an endogenous expression context. More controversial is the suggestion that GPSM3 may 
regulate GPCR signaling pathways via GoLoco motif interactions that directly promote the 
dissociation of Gα and Gβγ independent of GPCR/ligand-stimulated GEF activity232; evidence 
from both structural biology studies234 and electrophysiological recordings of Gβγ-gated ion 
channels238 suggest that the GoLoco motif/Gαi·GDP interaction is mutually exclusive to the 
assembly of a traditional Gαi·GDP/Gβγ heterotrimer, but that the GoLoco motif cannot itself 
displace a preformed Gαi·GDP/Gβγ heterotrimer. 
A common outcome of chemokine receptor signaling is the mobilization of internal 
calcium stores via Gβγ-mediated activation of phospholipase-Cβ (PLCβ) (Fig. 1.5). Ectopic 
GPSM3 expression is seen to negatively affect GPCR signaling by decreasing PLCβ-mediated 
generation of the second messenger inositol trisphosphate (IP3)239. This inhibitory effect 
requires GPSM3 interaction with Gβ subunits, given that a specific loss-of-function mutation to 
the Gβ-interaction site within GPSM3 (i.e., mutation of the “LSL” motif) abrogates inhibition of 
IP3 accumulation after agonist stimulation; it is important to note that mutation to the LSL 
mutation does not affect the GPSM3/Gαi·GDP interaction239. Indeed, endogenous Gβ subunits 
are seen to co-immunoprecipitate with the endogenous GPSM3 expressed in the human 
monocytic THP-1 cell line; moreover, endogenous Gβ subunits co-localize with endogenous 
GPSM3 at the plasma membrane in THP-1 cells239. This plasma membrane colocalization is 
consistent with the proteomic detection of GPSM3 within cholesterol-rich, detergent-resistant, 
plasma membrane fragments from bovine leukocytes241, as well as an independent report of 
ectopically-expressed GPSM3 being able to form a G protein-dependent complex in proximity to 
membrane-delimited GPCRs240. Additional evidence that GPSM3 interacts with Gβ has been 
obtained by examining the direct activation of PLCβ2 via co-expression of free Gβ1γ2 subunits; 
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overexpression of wild-type GPSM3 (but not the loss-of-function LSL mutant) is seen to inhibit 
PLCβ2 activation by Gβ1γ2239. 
Another common Gβγ-mediated signaling effector is activation of the pro-survival kinase 
PKB/Akt pathway (Fig. 1.5) - an event that is often measured by serine-473 phosphorylation 
status242. When GPSM3 levels are decreased by RNA-interference in the monocytic THP-1 cell 
line, activation of PKB/Akt by treatment with fetal bovine serum is diminished239. The decrease 
in pro-survival PKB/Akt signaling in GPSM3-depleted THP-1 cells mirror the increased precence 
of early apoptotic markers observed in etoposide-treated GPSM3-deficient THP-1 cells239 and 
are consistent with the known role of GPCR/Gβγ-mediated activation of class IBPI3K and 
resultant PIP3-dependent activation of PKB/Akt and downstream survival signaling in 
leukocytes242,243 (Fig. 1.5). 
 
1.3.2 GPSM3 in Immune Cell Function and Cancer 
 
Myeloid-derived inflammation mediators and suppressors: GPSM3 expression is highly 
regulated during monocyte/macrophage differentiation ex vivo, and GPSM3 deficiency reduces 
monocyte survival as well as migration to specific chemokine ligands239. 
Ly6ChighCD11b+ monocytes are known to mobilize rapidly in response to infection and 
inflammation244; flow cytometry of splenocytes from GPSM3-deficient mice indicates that this 
population of Ly6ChighCD11b+ monocytes is significantly reduced in comparison to wild-type 
mouse controls239. Therefore, a role for GPSM3 in survival and/or differentiation of particular 
myeloid-lineage cells is likely, but the molecular mechanisms underlying this role remain to be 
elucidated. 
Myeloid cells, particularly macrophages and neutrophils, are known mediators of 
inflammation; conversely, a heterogenous, immature myeloid cell population, termed “myeloid-
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derived suppressor cells” (MDSCs) are able to suppress T cell and macrophage responses in 
inflammatory disease245,246. Work by Yan et al. revealed that in lysosomal acid lipase (lal) 
knockout mice, which exhibit expanded MDSC development, GPSM3 transcript abundandance 
is upregulated two-fold (along with other G protein-related genes) as part of a broader 
perturbation of myeloid development and homeostasis247. MDSCs have been shown to expand 
as a functional cell population in multiple pathological conditions including infection, 
autoimmunity, inflammation, and cancer246. In the mouse collagen-induced arthritis (CIA) model 
of rheumatoid arthritis (RA), MDSCs are seen to accumulate in the spleen concurrent with the 
apex of developed paw swelling, inhibit production of the inflammatory cytokines IFN-γ, IL-2, 
TNF-α, and IL-6, and suppress T helper 17 (Th17) pathogenic T cells248. 
MDSCs also affect tumor angiogenesis and metastasis, as well as promote the 
development of FOXP3+ regulatory T-lymphocytes (Tregs)249. MDSCs expand in numbers in 
many tumors and are believed to be recruited from the bone marrow by tumor-derived 
factors250; these increased levels of MDSCs can interfere with innate and adaptive anti-tumor 
responses by depressing immune responses to tumor burden, leading to the advancement of 
malignancy251. Data from mouse tumor models suggest that two populations of CD11b+ MDSCs 
predominate: “granulocytic” Ly6G+/Ly6Clo MDSCs and “monocytic” Ly6G-/Ly6C+ MDSC246. Both 
of these MDSC subsets are decreased in the spleens of GPSM3-deficient mice239. The ablation 
of GPSM3 protected mice from a monocyte-driven model of acute inflammatory arthritis239; 
however, it remains unknown whether these GPSM3-deficient mice possess a differential 
response to tumor burden. 
Although GPSM3 appears to be most highly expressed in developing monocytes and is 
also expressed in MDSCs, Lapan et al. have shown that prostatic cancer cells also 
increase GPSM3 expression greater than two-fold when co-cultured ex vivo with endothelial 
cells, in a model mimicking angiogenesis within the tumor microenvironment252. As a regulator 
of GPCR and G protein function, GPSM3 could therefore also influence invasive or migratory 
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phenotypes in different cancers, or their responses to survival or angiogenic factors that might 
be secreted as tumors grow. Therefore, whether tumor progression in GPSM3-deficient mice 
may be influenced by the decreased prevalence of MDSCs or by changes that occur in adaptive 
immune cells or the tumor cells themselves needs to be further examined. 
 
Lymphocytes: Although GPSM3 has its highest expression in monocytes, B- and T-
lymphocytes also have detectable GPSM3 235,239, suggesting that GPSM3 could also regulate 
GPCR/G protein signaling that mediate outcomes such as survival and chemotactic trafficking 
within these key lymphocyte classes required for full immune function. For example, in a study 
by Reif and Cyster253, activated B cells dynamically regulated the expression of multiple different 
regulators of G protein signaling altering responses to local chemokine gradients. 
Lymphocyte involvement in inflammatory diseases also involves the development of 
ectopic (tertiary) lymphoid structures. The architecture of these germinal center-like structures 
requires chemokine-driven organization and intercellular interactions254 likely to be impacted by 
GPSM3 function on GPCR signaling in vivo. While it is currently unknown exactly how GPSM3 
functions to regulate GPCR signaling in lymphocytes, the activity of this GPCR signaling 
modulator could influence inflammatory function, adaptive immune responses, and/or be 
involved in the protection against or exacerbation of lymphocyte-mediated inflammatory 
disease. 
 
1.3.3 GPSM3 Gene Variants in GWAS of Immune Diseases  
 
Compelling genome-wide association studies (GWAS) identified protective alleles 
located within the GPSM3 gene locus that are significantly less prevalent in patients with 
several autoimmune diseases76,255,256. In the most notable examples to-date, protective alleles of 
two GPSM3 single-nucleotide polymorphisms (SNPs rs204989, rs204991) have been 
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associated with a decreased incidence of RA76,255,256. Importantly, these same SNPs associate 
significantly with decreased incidence of developing other autoimmune diseases that share 
similar immunologic mechanisms with RA: namely, ankylosing spondylitis (AS), systemic lupus 
erythematosus (SLE), and multiple sclerosis (MS)76,255,256. Conversely, GPSM3 SNPs show risk 
association with type I diabetes and autoimmune thyroid disease255,256, and GPSM3 genetic 
polymorphisms have also been linked with atopic dermatitis and childhood obesity, two 
diseases also characterized by chronic inflammation257,258. The GPSM3 locus on chromosome 6 
is located very near to the Notch4 gene locus and is found within the densely-packed and 
disease-relevant human leukocyte antigen (HLA) region76,255,256, raising the possibility 
that GPSM3 SNP variants mark functional polymorphisms in other closely associated genes. 
However, increasing research into GPSM3 transcript abundance and function is revealing a 
consistent pattern of potential physiological involvement in immune cell types relevant to 
inflammatory diseases. Therefore, it is conceivable that sequence variation within GPSM3 could 
alter transcript expression or splicing, and/or GPSM3 protein sequences that could contribute 
directly to immune disease pathogenesis. 
Two different protein isoforms of GPSM3, with different N-terminal polypeptide 
sequences (Fig. 1.6), have been predicted to date in the human genomic sequence database 
curated by Ensembl (http://ensembl.org)259, as encoded by three 
different GPSM3 transcripts: GPSM3-001, -002, and GPSM3-004. It is presently unclear 
whether these different isoforms exert differential effects on GPCR signaling, cellular function, 
or disease. However, Zhao et al.260 reported that GPSM3 differentially affects the nucleotide 
state of Gαi vs Gαo subunits via its N-terminal proline-rich region - a region significantly different 
in the open-reading frames encoded by transcripts GPSM3-001 and-002 versus GPSM3-





1.3.4 GPSM3 in Autoimmune Arthritis 
 
Pre-clinical evidence suggests that neutralization of proinflammatory, monocyte-
attracting chemokines, or their cognate cell-surface receptors, would be beneficial for the 
treatment of RA224,261; however, clinical trials have revealed disappointing results both for 
neutralization of chemokines or for antagonism of their GPCR counterparts141,228,262–264. One 
explanation for this apparent discrepancy between pre-clinical evidence and clinical trial results 
has uses the known functional redundancy of the chemokine system in the inflammatory 
response, whereby many chemokines within a structural class can bind to multiple chemokine 
receptors sharing similar structural motifs224,225. Thus, targeting monocyte/macrophage 
recruitment in RA may be desirable, but current strategies using single chemokine or chemokine 
receptor blockade have produced limited results. 
GPSM3 appears restricted in its tissue transcript and protein concentration to 
leukocytes235,239,265, therefore may play role in inflammatory cell function. In particular, monocyte 
viability and chemotaxis are found to be affected in a GPSM3-deficient acute inflammatory 
arthritis model239, and GPSM3 SNPs are associated differentially between healthy persons and 
those with inflammatory arthritis from either RA, SLE, or AS76,255,256. Thus, understanding the 
regulatory roles of GPSM3 as a GPCR signaling modulator may help to promote this protein as 
a desirable therapeutic target for patients with autoimmune arthritis. 
In an acute, collagen antibody-induced arthritis (CAIA) mouse model, GPSM3-deficient 
mice (those either homozygous or heterozygous for the ablated GPSM3 allele) exhibit 
decreased clinical disease scores, paw swelling, as well as reduced histopathology with less 
inflammation in cartilage, less synovial damage, and less bone erosion239. Additionally, a 
decreased disease incidence was observed in Gpsm3-/- mice (34% for Gpsm3-/- mice vs 95% 
for control mice)239. Independent studies by Schmidt et al. report that GPSM3 expression 
decreases in the joints after anti-inflammatory treatment with dexamethasone in the chronic, 
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collagen-induced arthritis (CIA)266. Thus, both chronic and acute mouse models of inflammatory 
arthritis reveal a compelling role for GPSM3 involvement. 
GPSM3-deficient mice have reduced CAIA that is associated with a decreased transcript 
expression of the proinflammatory, monocyte-derived cytokines IL-6 and IL-1β, as well as of 
monocyte-specific chemokine receptors in the joints239. TNF-α, IL-1β, and IL-6 are all produced 
by monocytes/macrophages, which are recruited to the inflamed synovium by chemokines such 
as CCL2/MCP-1 and CX3CL1/fractalkine, among numerous others224,225. GPSM3 deficiency 
reduces monocyte chemotaxis toward CCL2, CX3CL1 and chemerin, and enhances etoposide-
induced apoptosis ex vivo239, providing evidence that GPSM3 affects monocytes through the 
regulation of chemokine-receptor signaling and its downstream intracellular sequelae. The 
critical nature of monocyte infiltration and pathogenesis in autoimmune arthritis267 is further 
underscored by the direct correlation between disease severity and the accumulation of 





1.4 Figures and Tables 
 
 
Figure 1.1 – Algorithm for treatment of RA patients according to the treat-to-target activity. This 
figure is adapted from Smolen et al. (2010)64.The green arrows indicate the primary goal of remission, 
while the alternative goal is indicated in red. Prior to reaching either goal, the patient is assessed for 
disease activity every 1-3 months and treatment is adjusted according to the disease activity (dark 
background). After reaching the initial goal, the patient is monitored every 3-6 months and treatment is 
adjusted to maintain disease activity (light background).  
 
Figure 1.2 – Algorithm for prescription-based therapies for RA. This figure is adapted from Singh et 
al. (2015)65. In this diagram MTX is considered the primary non-biologic, although other non-biologic 
DMARD options are available. In the event of successful remission with treatment, no further therapeutics 
are prescribed. If remission is not reached treatments are prescribed to maintain disease activity levels. 
Abbreviations: MTX = methotrexate, DMARD = disease-modifying antirheumatic drug, TNFi = tumor 










Adapt treatment to disease severity 
using a composite measure of 
disease activity every 1-3 months. 
Adapt treatment if state is lost 
using a composite measure of 







1.  MTX + non-biologic DMARD 
2.  TNFi +/- MTX 
3.  Non-TNFi biologic +/- MTX 
Failure of therapy 1 or 3: 
6. Another non-TNFi 
biologic +/- MTX 
Failure of therapy 2: 
4. Another TNFi biologic or  
5. non-TNFi biologic +/- MTX 
Failure of therapy 6: 
TNFi biologic or Tofacitnib 
+/- MTX 
Failure of therapy 5: 
Another non-TNFi biologic or 
Tofacitnib +/- MTX 
Failure of therapy 4: 
Non-TNFi biologic or 





Signaling molecule effects on neutrophil physiology 
 Priming Chemotaxis Activation Increase Lifespan 
MHCII 
Presentation 
C5a  X    
GM-CSF X   X X 
IFNγ X   X X 
Ig Complex  Indirectly X   
IL-1β X Indirectly X X  
IL-8 X X X   
TNF-α X Indirectly X X  
Table 1.1 – The effects of various signaling molecules (first column) on neutrophil 
physiology in inflammation. Adapted from Wright et al.81. 
	
Neutrophil granule enzymes involved in tissue damage 
Granule Protein Role in tissue damage 
Azurophilic 
(primary) 
Myeloperoxidase Produces HOCl (from H2O2 + Cl-)269 
Elastase Degradation of cartilage collagen and 
elastin166 




Collagenase Degradation of cartilage collagen166 
Gelatinase B (MMP9) Degradation of cartilage collagen168 
Gelatinase  
(tertiary) 
Gelatinase B (MMP9) Degradation of cartilage collagen168 
MMP25 Inactivates extracellular proteinases, 
prolonging half-life of elastase and 
cathepsin G271 
Table 1.2 – A non-inclusive list of neutrophil granule molecules that affect the 
pathogenesis of RA. The granule (first column), granule molecule (second column), 
and function of the granule molecule in tissue damage (third column) are reported. 






Neutrophil cytokine production and function 





CCL3112,272,128 TH1 cells Chemoattractant 
CCL4273 T cells and 
monocytes 
Chemoattractant 
CCL17274,275 TH2 cells and 
dendritic cells 
Chemoattractant 
CCL18128 Naïve T cells Chemoattraction of naïve T cells 
toward antigen presenting cells41 
CCL19276 B and T cells Potent chemoattractant for 
lymphocytes41 
CCL20276 B and T cells Potent chemoattractant for 
lymphocytes277 
C-X-C chemokines 
CXCL1278 Neutrophils and 
monocytes 
Chemoattractant 
CXCL2112 Neutrophils and 
monocytes 
Chemoattractant 
CXCL8128 (a.k.a. IL-8) Neutrophils and 
monocytes 
Chemoattractant 
CXCL9279,280 TH1 cells Chemoattractant 
CXCL10128,274 TH1 cells Chemoattractant 
CXCL11280 TH1 cells Chemoattractant 
Soluble CX3CL1*128 Leukocytes Chemoattractant for CX3CR1+ cells 
(e.g., monocytes and T cells) 
Interleukins 
IL-1β112 Multiple Described in text 
IL-4281 Naïve T cells41 Induces differentiation of naïve T cells 






Induces production of numerous 
cytokines 
(e.g., IL-6, IL-10, IL-12, CXCL1, 
CXCL2, CXCL8, CCL2, CCL5, PGE2; 
reviewed in Benedetti & Miossec283) 
IL-17B284 Fibroblasts284 Potentiates TNFα-induced production 
of cytokines (i.e., G-CSF, IL-6, IL-
1β)284 
IL-18*279 NK cells, T 
cells, and 
fibroblasts 
Promotes release of IFN-γ and 
CXCR2 agonists (reviewed in Volin & 
Koch285) 
IL-23286 Naïve T cells287 Promotes differentiation of naïve T 
cells toward the TH17 lineage287 
Others 
TRAIL288 Multiple Induction of caspase-8-dependent 
apoptosis288 
BLyS289 B cells290 Promotes B cell survival and 
maturation to plasma cell lineage290 
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APRIL291 B cells / Plasma 
cells291 
Modulates late humoral immune 
response via induction of 
immunoglobulin class switching and 
survival signals291 
CD40L292 B-cells41 Co-stimulatory ligand for B-cell 
activation41 





Degradation of extracellular matrix 
promoting neutrophil migration 
IFNγ184,183 Multiple41 Promotes macrophage activation, 
MHC class II expression, TH1 
adaptive immune response, and 
antibody isotype switching to IgG41. 
Neutrophil Granule Proteins 
Collagenase166 Cartilage 
collagen166 
Promotes tissue damage and 
degradation of synovial cartilage296 
Elastase166 Cartilage166 and 
cytokines297 
Promotes tissue damage by cleaving 
collagen and elastin296; activates 
CCL15298 and chemerin299. 
Cathepsin G Cytokines297 N-terminal truncation of CXCL5300, 
CCL15298, and chemerin299 resulting in 
full activation of these chemokines. 
α-Defensins197 T cells, 
dendritic cells, 
and fibroblasts 
Primarily an antimicrobial, but also 
recruits T cells and dendritic cells197 




Antibacterial, activates dendritic 
cells199,303 
Myeloperoxidase188 Macrophages Upregulates reactive oxygen 
production in neutrophils and induces 
production of reactive oxygen, TNF-α, 
and IL-1 by macrophages189 





Survival, proliferation, and 
differentiation of pre-neutrophil 
progenitors in bone marrow41. 
Adapted from86,304   Unless noted target cells and 
function identified in41, or reviewed 
in86,304,305. 
Table 1.3 – A non-inclusive list of cytokines and signaling molecules shown to be 
expressed at either the transcript or protein level in neutrophils. The signaling 
molecule (first column), effector cell/tissue (second column), and function of signaling 






Figure 1.3 – Diagram of neutrophil activation by soluble (above) or tissue-bound 
(below) autoimmune antibodies. Interaction between Fc receptors on the neutrophil 
and the Fc portion of autoimmune antibodies results in the release of granule 
components (Table 1.3) into the extracellular space. This release of reactive oxygen 
species (ROS) and proteolytic enzymes results in non-specific damage of local tissues 
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Figure 1.4 – GoLoco motif-containing proteins. Expression pattern as reported by 





Figure 1.5 – Model for GPSM3 function in regulating Gi-coupled chemokine 
receptors. Two of the three GoLoco motifs within GPSM3 (yellow) bind to Gαi·GDP 
subunits235,236. Additionally, the LSL motif within GPSM3 interacts with Gβ subunits 
toward their biosynthetic pathway in forming Gβγ dimers237. These interactions likely 
regulate ligand-activated chemokine receptor signaling pathways, including Gαi-
mediated inhibition of cAMP production by adenylyl cyclase, inositol phosphate 
production from Gβγ-mediated activation of phospholipase-Cβ, and/or cell survival 
signaling by Gβγ-mediated activation of class IB phosphatidylinositol-3’-kinase (PI3K) 
leading to PKB/Akt phosphorylation. 
 
	
Figure 1.6 – GPSM3 amino acid variation between transcript isoforms. The 
Ensembl database259 predicts two distinct wild-type human GPSM3 proteins that have 







1. Eyre, S., Bowes, J., Diogo, D., Lee, A., Barton, A., Martin, P., Zhernakova, A., Stahl, E., 
Viatte, S., McAllister, K., Amos, C. I., Padyukov, L., Toes, R. E. M., Huizinga, T. W. J., 
Wijmenga, C., Trynka, G., Franke, L., Westra, H.-J., Alfredsson, L., et al. High-density 
genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat. Genet. 44, 
1336–40 (2012). 
2. Silman, A. J. & Hochberg, M. C. Epidemiology of the rheumatic diseases. (Oxford 
University Press, 2001). 
3. Aviña-Zubieta, J. A., Choi, H. K., Sadatsafavi, M., Etminan, M., Esdaile, J. M. & Lacaille, 
D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of 
observational studies. Arthritis Rheum. 59, 1690–7 (2008). 
4. Libby, P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am. 
J. Med. 121, S21–31 (2008). 
5. Radovits, B. J., Fransen, J., Al Shamma, S., Eijsbouts,  a M., van Riel, P. L. C. M. & 
Laan, R. F. J. M. Excess mortality emerges after 10 years in an inception cohort of early 
rheumatoid arthritis. Arthritis Care Res. (Hoboken). 62, 362–70 (2010). 
6. Kekow, J. Rituximab is more effective than second anti-TNF therapy in rheumatoid 
arthritis patients and previous TNFα blocker failure. Biol. Targets Ther. 6, 191 (2012). 
7. Singh, J. A., Christensen, R., Wells, G. A., Suarez-Almazor, M. E., Buchbinder, R., 
Lopez-Olivo, M. A., Ghogomu, E. T. & Tugwell, P. A network meta-analysis of 
randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. C.  
Can. Med. Assoc. J. 181, 787–96 (2009). 
8. Crofford, L. J. Use of NSAIDs in treating patients with arthritis. Arthritis Res. Ther. 15 
Suppl 3, S2 (2013). 
9. Hochberg, M. C. New directions in symptomatic therapy for patients with osteoarthritis 
	
	 46	
and rheumatoid arthritis. Semin. Arthritis Rheum. 32, 4–14 (2002). 
10. Wessels, J. a M., Huizinga, T. W. J. & Guchelaar, H.-J. Recent insights in the 
pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. 
Rheumatology (Oxford). 47, 249–255 (2008). 
11. Charles F. Spurlock III, N. J. O. and T. M. A. Autoimmunity - Pathogenesis, Clinical 
Aspects and Therapy of Specific Autoimmune Diseases. (InTech, 2015). 
doi:10.5772/58718 
12. Shiroky, J. B. The use of folates concomitantly with low-dose pulse methotrexate. 
Rheum. Dis. Clin. North Am. 23, 969–80 (1997). 
13. Montesinos, M. C., Desai, A., Delano, D., Chen, J.-F., Fink, J. S., Jacobson, M. A. & 
Cronstein, B. N. Adenosine A2A or A3 receptors are required for inhibition of 
inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 48, 240–7 (2003). 
14. Riksen, N. P., Barrera, P., van den Broek, P. H. H., van Riel, P. L. C. M., Smits, P. & 
Rongen, G. A. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann. 
Rheum. Dis. 65, 465–70 (2006). 
15. Phillips, D. C., Woollard, K. J. & Griffiths, H. R. The anti-inflammatory actions of 
methotrexate are critically dependent upon the production of reactive oxygen species. Br. 
J. Pharmacol. 138, 501–11 (2003). 
16. Pfizer. Methotrexate package insert. 1–47 (2011). 
17. Aarbakke, J., Janka-Schaub, G. & Elion, G. B. Thiopurine biology and pharmacology. 
Trends Pharmacol. Sci. 18, 3–7 (1997). 
18. Ruderman, E. M. Overview of safety of non-biologic and biologic DMARDs. 
Rheumatology (Oxford). 51 Suppl 6, vi37–43 (2012). 
19. Smolen, J. S., Kalden, J. R., Scott, D. L., Rozman, B., Kvien, T. K., Larsen, A., Loew-
Friedrich, I., Oed, C. & Rosenburg, R. Efficacy and safety of leflunomide compared with 
placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, 
	
	 47	
multicentre trial. Lancet 353, 259–266 (1999). 
20. Sanofi-Aventis. ARAVA Prescribing Information. Package Insert 8 (1998). 
21. Kyburz, D., Brentano, F. & Gay, S. Mode of action of hydroxychloroquine in RA-evidence 
of an inhibitory effect on toll-like receptor signaling. Nat. Clin. Pract. Rheumatol. 2, 458–9 
(2006). 
22. Fox, R. I. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin. 
Arthritis Rheum. 23, 82–91 (1993). 
23. Das, K. M. & Dubin, R. Clinical pharmacokinetics of sulphasalazine. Clin. Pharmacokinet. 
1, 406–25 
24. Weber, C. K., Liptay, S., Wirth, T., Adler, G. & Schmid, R. M. Suppression of NF-kappaB 
activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and 
beta. Gastroenterology 119, 1209–18 (2000). 
25. Wahl, C., Liptay, S., Adler, G. & Schmid, R. M. Sulfasalazine: a potent and specific 
inhibitor of nuclear factor kappa B. J. Clin. Invest. 101, 1163–74 (1998). 
26. Swinson, C. M., Perry, J., Lumb, M. & Levi, A. J. Role of sulphasalazine in the aetiology 
of folate deficiency in ulcerative colitis. Gut 22, 456–61 (1981). 
27. Elliott, M. J., Maini, R. N., Feldmann, M., Long-Fox, A., Charles, P., Katsikis, P., Brennan, 
F. M., Walker, J., Bijl, H., Ghrayeb, J. & Woody, J. N. Treatment of rheumatoid arthritis 
with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 36, 
1681–1690 (1993). 
28. Siebert, S., Tsoukas, A., Robertson, J. & McInnes, I. Cytokines as therapeutic targets in 
rheumatoid arthritis and other inflammatory diseases. Pharmacol. Rev. 67, 280–309 
(2015). 
29. Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., 
Emery, P., Harriman, G., Feldmann, M. & Lipsky, P. Infliximab (chimeric anti-tumour 
necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients 
	
	 48	
receiving concomitant methotrexate: a randomised phase III trial. Lancet 354, 1932–1939 
(1999). 
30. Moreland, L. W. Etanercept Therapy in Rheumatoid Arthritis. Ann. Intern. Med. 130, 478 
(1999). 
31. Keystone, E., Heijde, D. van der, Mason, D., Landewé, R., Vollenhoven, R. Van, Combe, 
B., Emery, P., Strand, V., Mease, P., Desai, C. & Pavelka, K. Certolizumab pegol plus 
methotrexate is significantly more effective than placebo plus methotrexate in active 
rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, 
double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58, 3319–29 
(2008). 
32. Keystone, E. C., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S. T., Miranda, P. C., 
Pazdur, J., Bae, S.-C., Palmer, W., Zrubek, J., Wiekowski, M., Visvanathan, S., Wu, Z. & 
Rahman, M. U. Golimumab, a human antibody to tumour necrosis factor {alpha} given by 
monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate 
therapy: the GO-FORWARD Study. Ann. Rheum. Dis. 68, 789–96 (2009). 
33. Nam, J. L., Winthrop, K. L., van Vollenhoven, R. F., Pavelka, K., Valesini, G., Hensor, E. 
M. A., Worthy, G., Landewé, R., Smolen, J. S., Emery, P. & Buch, M. H. Current evidence 
for the management of rheumatoid arthritis with biological disease-modifying 
antirheumatic drugs: a systematic literature review informing the EULAR 
recommendations for the management of RA. Ann. Rheum. Dis. 69, 976–86 (2010). 
34. Vivar, N. & Van Vollenhoven, R. F. Advances in the treatment of rheumatoid arthritis. 
F1000 6, 31 (2014). 
35. Kikuchi-Ueda, T., Ubagai, T. & Ono, Y. Priming effects of tumor necrosis factor-α on 
production of reactive oxygen species during Toxoplasma gondii stimulation and receptor 




36. Okamoto, H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 
355, 2047; author reply 2048 (2006). 
37. Vandenabeele, P., Galluzzi, L., Vanden Berghe, T. & Kroemer, G. Molecular mechanisms 
of necroptosis: an ordered cellular explosion. Nat. Rev. Mol. Cell Biol. 11, 700–714 
(2010). 
38. Puimège, L., Libert, C. & Van Hauwermeiren, F. Regulation and dysregulation of tumor 
necrosis factor receptor-1. Cytokine Growth Factor Rev. 779, 16 (2014). 
39. Tracey, K. J. & Cerami, A. Tumor necrosis factor, other cytokines and disease. Annu. 
Rev. Cell Biol. 9, 317–343 (1993). 
40. Bendtzen, K., Geborek, P., Svenson, M., Larsson, L., Kapetanovic, M. C. & Saxne, T. 
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid 
arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis 
Rheum. 54, 3782–9 (2006). 
41. Parham, P. The Immune System. (Garland Science, 2009). 
42. Weinblatt, M. E., Schiff, M., Valente, R., van der Heijde, D., Citera, G., Zhao, C., 
Maldonado, M. & Fleischmann, R. Head-to-head comparison of subcutaneous abatacept 
versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, 
prospective, randomized study. Arthritis Rheum. 65, 28–38 (2013). 
43. Weiner, G. J. Rituximab: mechanism of action. Semin. Hematol. 47, 115–23 (2010). 
44. Pedersen, I. M., Buhl, A. M., Klausen, P., Geisler, C. H. & Jurlander, J. The chimeric anti-
CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells 
through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99, 1314–
9 (2002). 
45. Lee, Y. H. & Bae, S.-C. Comparative efficacy and safety of tocilizumab, rituximab, 
abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately 
responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of 
	
	 50	
randomized controlled tri. Int. J. Rheum. Dis. (2015). doi:10.1111/1756-185X.12822 
46. Polzer, K., Joosten, L., Gasser, J., Distler, J. H., Ruiz, G., Baum, W., Redlich, K., Bobacz, 
K., Smolen, J. S., van den Berg, W., Schett, G. & Zwerina, J. Interleukin-1 is essential for 
systemic inflammatory bone loss. Ann. Rheum. Dis. 69, 284–90 (2010). 
47. Vande Walle, L., Van Opdenbosch, N., Jacques, P., Fossoul, A., Verheugen, E., Vogel, 
P., Beyaert, R., Elewaut, D., Kanneganti, T.-D., van Loo, G. & Lamkanfi, M. Negative 
regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 512, 69–
73 (2014). 
48. Cohen, S. B., Moreland, L. W., Cush, J. J., Greenwald, M. W., Block, S., Shergy, W. J., 
Hanrahan, P. S., Kraishi, M. M., Patel, A., Sun, G. & Bear, M. B. A multicentre, double 
blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 
1 receptor antagonist, in patients with rheumatoid arthritis treated with background 
methotrexate. Ann. Rheum. Dis. 63, 1062–8 (2004). 
49. Fleischmann, R. M., Tesser, J., Schiff, M. H., Schechtman, J., Burmester, G.-R., Bennett, 
R., Modafferi, D., Zhou, L., Bell, D. & Appleton, B. Safety of extended treatment with 
anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65, 1006–12 (2006). 
50. Yoshida, Y. & Tanaka, T. Interleukin 6 and rheumatoid arthritis. Biomed Res. Int. 2014, 
698313 (2014). 
51. Palmqvist, P., Persson, E., Conaway, H. H. & Lerner, U. H. IL-6, leukemia inhibitory 
factor, and oncostatin M stimulate bone resorption and regulate the expression of 
receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-
kappa B in mouse calvariae. J. Immunol. 169, 3353–62 (2002). 
52. Suzuki, M., Hashizume, M., Yoshida, H., Shiina, M. & Mihara, M. IL-6 and IL-1 
synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 
production and IL-1 receptor I expression. Cytokine 51, 178–83 (2010). 
53. Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, 
	
	 51	
E., Woodworth, T. & Gomez-Reino, J. J. Interleukin-6 receptor inhibition with tocilizumab 
reduces disease activity in rheumatoid arthritis with inadequate response to disease-
modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-
modifying antirheumatic drug the. Arthritis Rheum. 58, 2968–80 (2008). 
54. Nishimoto, N., Hashimoto, J., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., 
Murata, N., van der Heijde, D. & Kishimoto, T. Study of active controlled monotherapy 
used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and 
radiographic benefit from an x ray reader-blinded randomised controlled trial of 
tocilizumab. Ann. Rheum. Dis. 66, 1162–7 (2007). 
55. Kremer, J. M., Blanco, R., Brzosko, M., Burgos-Vargas, R., Halland, A.-M., Vernon, E., 
Ambs, P. & Fleischmann, R. Tocilizumab inhibits structural joint damage in rheumatoid 
arthritis patients with inadequate responses to methotrexate: results from the double-blind 
treatment phase of a randomized placebo-controlled trial of tocilizumab safety and 
prevention of structu. Arthritis Rheum. 63, 609–21 (2011). 
56. Schiff, M. H., Kremer, J. M., Jahreis, A., Vernon, E., Isaacs, J. D. & van Vollenhoven, R. 
F. Integrated safety in tocilizumab clinical trials. Arthritis Res. Ther. 13, R141 (2011). 
57. Stubenrauch, K., Wessels, U., Birnboeck, H., Ramirez, F., Jahreis, A. & Schleypen, J. 
Subset analysis of patients experiencing clinical events of a potentially immunogenic 
nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an 
antidrug antibody ELISA using clinical adverse event-driven immunogenicit. Clin. Ther. 
32, 1597–609 (2010). 
58. Hiscott, J., Marois, J., Garoufalis, J., D’Addario, M., Roulston, A., Kwan, I., Pepin, N., 
Lacoste, J., Nguyen, H. & Bensi, G. Characterization of a functional NF-kappa B site in 
the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol. 
Cell. Biol. 13, 6231–40 (1993). 
59. Son, Y.-H., Jeong, Y.-T., Lee, K.-A., Choi, K.-H., Kim, S.-M., Rhim, B.-Y. & Kim, K. Roles 
	
	 52	
of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular 
smooth muscle cells. J. Cardiovasc. Pharmacol. 51, 71–7 (2008). 
60. Shen, F., Hu, Z., Goswami, J. & Gaffen, S. L. Identification of common transcriptional 
regulatory elements in interleukin-17 target genes. J. Biol. Chem. 281, 24138–48 (2006). 
61. Collart, M. A., Baeuerle, P. & Vassalli, P. Regulation of tumor necrosis factor alpha 
transcription in macrophages: involvement of four kappa B-like motifs and of constitutive 
and inducible forms of NF-kappa B. Mol. Cell. Biol. 10, 1498–506 (1990). 
62. Kirwan, J. R., Bijlsma, J. W. J., Boers, M. & Shea, B. J. Effects of glucocorticoids on 
radiological progression in rheumatoid arthritis. Cochrane database Syst. Rev. CD006356 
(2007). doi:10.1002/14651858.CD006356 
63. Rhen, T. & Cidlowski, J. A. Antiinflammatory action of glucocorticoids--new mechanisms 
for old drugs. N. Engl. J. Med. 353, 1711–23 (2005). 
64. Smolen, J. S., Aletaha, D., Bijlsma, J. W. J., Breedveld, F. C., Boumpas, D., Burmester, 
G., Combe, B., Cutolo, M., de Wit, M., Dougados, M., Emery, P., Gibofsky, A., Gomez-
Reino, J. J., Haraoui, B., Kalden, J., Keystone, E. C., Kvien, T. K., McInnes, I., Martin-
Mola, E., et al. Treating rheumatoid arthritis to target: recommendations of an 
international task force. Ann. Rheum. Dis. 69, 631–7 (2010). 
65. Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., 
Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., Curtis, J. R., Furst, D. E., 
Parks, D., Kavanaugh, A., O’Dell, J., King, C., Leong, A., Matteson, E. L., Schousboe, J. 
T., et al. 2015 American College of Rheumatology Guideline for the Treatment of 
Rheumatoid Arthritis. Arthritis Rheumatol. (Hoboken, N.J.) 68, 1–26 (2015). 
66. Silman, A. J., MacGregor, A. J., Thomson, W., Holligan, S., Carthy, D., Farhan, A. & 
Ollier, W. E. Twin concordance rates for rheumatoid arthritis: results from a nationwide 
study. Br. J. Rheumatol. 32, 903–7 (1993). 
67. MacGregor, A. J., Snieder, H., Rigby, A. S., Koskenvuo, M., Kaprio, J., Aho, K. & Silman, 
	
	 53	
A. J. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data 
from twins. Arthritis Rheum. 43, 30–37 (2000). 
68. Okada, Y., Wu, D., Trynka, G., Raj, T., Terao, C., Ikari, K., Kochi, Y., Ohmura, K., Suzuki, 
A., Yoshida, S., Graham, R. R., Manoharan, A., Ortmann, W., Bhangale, T., Denny, J. C., 
Carroll, R. J., Eyler, A. E., Greenberg, J. D., Kremer, J. M., et al. Genetics of rheumatoid 
arthritis contributes to biology and drug discovery. Nature 506, 376–81 (2014). 
69. Nagai, Y. & Imanishi, T. RAvariome: a genetic risk variants database for rheumatoid 
arthritis based on assessment of reproducibility between or within human populations. 
Database 2013, bat073–bat073 (2013). 
70. Gregersen, P. K., Silver, J. & Winchester, R. J. The shared epitope hypothesis. An 
approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. 
Arthritis Rheum. 30, 1205–13 (1987). 
71. Holoshitz, J. The rheumatoid arthritis HLA-DRB1 shared epitope. Curr. Opin. Rheumatol. 
22, 293–8 (2010). 
72. Kochi, Y., Suzuki, A. & Yamamoto, K. Genetic basis of rheumatoid arthritis: a current 
review. Biochem. Biophys. Res. Commun. 452, 254–62 (2014). 
73. Suzuki, A., Yamada, R., Chang, X., Tokuhiro, S., Sawada, T., Suzuki, M., Nagasaki, M., 
Nakayama-Hamada, M., Kawaida, R., Ono, M., Ohtsuki, M., Furukawa, H., Yoshino, S., 
Yukioka, M., Tohma, S., Matsubara, T., Wakitani, S., Teshima, R., Nishioka, Y., et al. 
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine 
deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 34, 395–402 (2003). 
74. Han, T.-U., Bang, S.-Y., Kang, C. & Bae, S.-C. TRAF1 polymorphisms associated with 
rheumatoid arthritis susceptibility in Asians and in Caucasians. Arthritis Rheum. 60, 
2577–84 (2009). 
75. Thomson, W., Barton, A., Ke, X., Eyre, S., Hinks, A., Bowes, J., Donn, R., Symmons, D., 
Hider, S., Bruce, I. N., Wilson, A. G., Marinou, I., Morgan, A., Emery, P., Carter, A., Steer, 
	
	 54	
S., Hocking, L., Reid, D. M., Wordsworth, P., et al. Rheumatoid arthritis association at 
6q23. Nat. Genet. 39, 1431–1433 (2007). 
76. Plenge, R. M., Seielstad, M., Padyukov, L., Lee, T., Remmers, E. F., Ding, B., Liew, A., 
Khalili, H., Chandrasekaran, A., Davies, L. R. L., Li, W. & Adrian, K. S. TRAF1-C5 as a 
Risk Locus for Rheumatoid Arthritis — A Genomewide Study. N. Engl. J. Med. 357, 
1199–1209 (2009). 
77. Gregersen, P. K., Amos, C. I., Lee, A. T., Lu, Y., Remmers, E. F., Kastner, D. L., Seldin, 
M. F., Criswell, L. A., Plenge, R. M., Holers, V. M., Mikuls, T. R., Sokka, T., Moreland, L. 
W., Bridges, S. L., Xie, G., Begovich, A. B. & Siminovitch, K. A. REL, encoding a member 
of the NF-kappaB family of transcription factors, is a newly defined risk locus for 
rheumatoid arthritis. Nat. Genet. 41, 820–3 (2009). 
78. Kochi, Y., Okada, Y., Suzuki, A., Ikari, K., Terao, C., Takahashi, A., Yamazaki, K., 
Hosono, N., Myouzen, K., Tsunoda, T., Kamatani, N., Furuichi, T., Ikegawa, S., Ohmura, 
K., Mimori, T., Matsuda, F., Iwamoto, T., Momohara, S., Yamanaka, H., et al. A 
regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat 
Genet 42, 515–519 (2010). 
79. Hughes, J. E., Stewart, J., Barclay, G. R. & Govan, J. R. W. Priming of neutrophil 
respiratory burst activity by lipopolysaccharide from Burkholderia cepacia. Infect. Immun. 
65, 4281–4287 (1997). 
80. Hallett, M. B. & Lloyds, D. Neutrophil priming: the cellular signals that say ‘amber’ but not 
‘green’. Immunol. Today 16, 264–8 (1995). 
81. Wright, H. L., Moots, R. J., Bucknall, R. C. & Edwards, S. W. Neutrophil function in 
inflammation and inflammatory diseases. Rheumatology 49, 1618–1631 (2010). 
82. Wright, H. L., Thomas, H. B., Moots, R. J. & Edwards, S. W. RNA-Seq Reveals Activation 
of Both Common and Cytokine-Specific Pathways following Neutrophil Priming. PLoS 
One 8, (2013). 
	
	 55	
83. Nathan, C. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 
6, 173–82 (2006). 
84. Paoliello-Paschoalato, A. B., Marchi, L. F., de Andrade, M. F., Kabeya, L. M., Donadi, E. 
A. & Lucisano-Valim, Y. M. Fcγ and Complement Receptors and Complement Proteins in 
Neutrophil Activation in Rheumatoid Arthritis: Contribution to Pathogenesis and 
Progression and Modulation by Natural Products. Evid. Based. Complement. Alternat. 
Med. 2015, 429878 (2015). 
85. Kowanko, I. C., Bates, E. J. & Ferrante, A. Mechanisms of human neutrophil-mediated 
cartilage damage in vitro: the role of lysosomal enzymes, hydrogen peroxide and 
hypochlorous acid. Immunol. Cell Biol. 67 ( Pt 5), 321–9 (1989). 
86. Wright, H., Moots, R. & Edwards, S. The multifactorial role of neutrophils in rheumatoid 
arthritis. Nat. Rev. Rheumatol. 10, 593–601 (2014). 
87. Sakkas, L. I., Bogdanos, D. P., Katsiari, C. & Platsoucas, C. D. Anti-citrullinated peptides 
as autoantigens in rheumatoid arthritis-relevance to treatment. Autoimmun. Rev. 13, 
1114–20 (2014). 
88. Tanaka, D., Kagari, T., Doi, H. & Shimozato, T. Essential role of neutrophils in anti-type II 
collagen antibody and lipopolysaccharide-induced arthritis. Immunology 119, 195–202 
(2006). 
89. Arancibia, S. A., Beltrán, C. J., Aguirre, I. M., Silva, P., Peralta, A. L., Malinarich, F. & 
Hermoso, M. A. Toll-like receptors are key participants in innate immune responses. Biol. 
Res. 40, 97–112 (2007). 
90. Zeytun, A., Chaudhary, A., Pardington, P., Cary, R. & Gupta, G. Induction of cytokines 
and chemokines by Toll-like receptor signaling: strategies for control of inflammation. Crit. 
Rev. Immunol. 30, 53–67 (2010). 
91. Williams, M. R., Azcutia, V., Newton, G., Alcaide, P. & Luscinskas, F. W. Emerging 




92. Kolaczkowska, E. & Kubes, P. Neutrophil recruitment and function in health and 
inflammation. Nat. Rev. Immunol. 13, 159–75 (2013). 
93. Pober, J. S., Bevilacqua, M. P., Mendrick, D. L., Lapierre, L. A., Fiers, W. & Gimbrone, M. 
A. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently 
induce biosynthesis and transient expression of the same antigen on the surface of 
cultured human vascular endothelial cells. J. Immunol. 136, 1680–7 (1986). 
94. Ley, K., Laudanna, C., Cybulsky, M. I. & Nourshargh, S. Getting to the site of 
inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678–89 
(2007). 
95. Sundd, P., Gutierrez, E., Koltsova, E. K., Kuwano, Y., Fukuda, S., Pospieszalska, M. K., 
Groisman, A. & Ley, K. ‘Slings’ enable neutrophil rolling at high shear. Nature 488, 399–
403 (2012). 
96. Johnson, Z., Proudfoot, A. E. & Handel, T. M. Interaction of chemokines and 
glycosaminoglycans: a new twist in the regulation of chemokine function with 
opportunities for therapeutic intervention. Cytokine Growth Factor Rev. 16, 625–36 
(2005). 
97. Constantin, G., Majeed, M., Giagulli, C., Piccio, L., Kim, J. Y., Butcher, E. C. & Laudanna, 
C. Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential 
regulation and roles in lymphocyte arrest under flow. Immunity 13, 759–69 (2000). 
98. Constantin, G. Chemokine signaling and integrin activation in lymphocyte migration into 
the inflamed brain. J. Neuroimmunol. 198, 20–6 (2008). 
99. Weber, C., Kitayama, J. & Springer, T. A. Differential regulation of beta 1 and beta 2 
integrin avidity by chemoattractants in eosinophils. Proc. Natl. Acad. Sci. U. S. A. 93, 
10939–44 (1996). 
100. Block, H., Stadtmann, A., Riad, D., Rossaint, J., Sohlbach, C., Germena, G., Wu, D., 
	
	 57	
Simon, S. I., Ley, K. & Zarbock, A. Gnb isoforms orchestrate a signaling pathway 
comprising Rac1 and Plcβ2/3 leading to LFA-1 activation and neutrophil arrest in vivo. 
Blood blood–2015–06–651034 (2015). doi:10.1182/blood-2015-06-651034 
101. Phillipson, M., Heit, B., Colarusso, P., Liu, L., Ballantyne, C. M. & Kubes, P. Intraluminal 
crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in 
the recruitment cascade. J. Exp. Med. 203, 2569–75 (2006). 
102. Massena, S., Christoffersson, G., Hjertström, E., Zcharia, E., Vlodavsky, I., Ausmees, N., 
Rolny, C., Li, J.-P. & Phillipson, M. A chemotactic gradient sequestered on endothelial 
heparan sulfate induces directional intraluminal crawling of neutrophils. Blood 116, 1924–
31 (2010). 
103. Dewey, C. F., Bussolari, S. R., Gimbrone, M. A. & Davies, P. F. The dynamic response of 
vascular endothelial cells to fluid shear stress. J. Biomech. Eng. 103, 177–85 (1981). 
104. Petri, B., Phillipson, M. & Kubes, P. The physiology of leukocyte recruitment: an in vivo 
perspective. J. Immunol. 180, 6439–46 (2008). 
105. Woodfin, A., Voisin, M.-B., Beyrau, M., Colom, B., Caille, D., Diapouli, F.-M., Nash, G. B., 
Chavakis, T., Albelda, S. M., Rainger, G. E., Meda, P., Imhof, B. A. & Nourshargh, S. The 
junctional adhesion molecule JAM-C regulates polarized transendothelial migration of 
neutrophils in vivo. Nat. Immunol. 12, 761–9 (2011). 
106. Burns, A. R., Bowden, R. A., MacDonell, S. D., Walker, D. C., Odebunmi, T. O., 
Donnachie, E. M., Simon, S. I., Entman, M. L. & Smith, C. W. Analysis of tight junctions 
during neutrophil transendothelial migration. J. Cell Sci. 113 ( Pt 1, 45–57 (2000). 
107. Wang, S., Voisin, M.-B., Larbi, K. Y., Dangerfield, J., Scheiermann, C., Tran, M., Maxwell, 
P. H., Sorokin, L. & Nourshargh, S. Venular basement membranes contain specific matrix 
protein low expression regions that act as exit points for emigrating neutrophils. J. Exp. 
Med. 203, 1519–32 (2006). 
108. Chakrabarti, S. & Patel, K. D. Regulation of matrix metalloproteinase-9 release from IL-8-
	
	 58	
stimulated human neutrophils. J. Leukoc. Biol. 78, 279–88 (2005). 
109. Delclaux, C., Delacourt, C., D’Ortho, M. P., Boyer, V., Lafuma, C. & Harf, A. Role of 
gelatinase B and elastase in human polymorphonuclear neutrophil migration across 
basement membrane. Am. J. Respir. Cell Mol. Biol. 14, 288–95 (1996). 
110. Proebstl, D., Voisin, M.-B., Woodfin, A., Whiteford, J., D’Acquisto, F., Jones, G. E., Rowe, 
D. & Nourshargh, S. Pericytes support neutrophil subendothelial cell crawling and 
breaching of venular walls in vivo. J. Exp. Med. 209, 1219–34 (2012). 
111. FitzGerald, O., Soden, M., Yanni, G., Robinson, R. & Bresnihan, B. Morphometric 
analysis of blood vessels in synovial membranes obtained from clinically affected and 
unaffected knee joints of patients with rheumatoid arthritis. Ann. Rheum. Dis. 50, 792–
796 (1991). 
112. Chou, R. C., Kim, N. D., Sadik, C. D., Seung, E., Lan, Y., Byrne, M. H., Haribabu, B., 
Iwakura, Y. & Luster, A. D. Lipid-Cytokine-Chemokine Cascade Drives Neutrophil 
Recruitment in a Murine Model of Inflammatory Arthritis. Immunity 33, 266–278 (2011). 
113. Sadik, C. D., Kim, N. D. & Luster, A. D. Neutrophils cascading their way to inflammation. 
Trends Immunol. 32, 452–460 (2011). 
114. Sadik, C. D., Kim, N. D., Iwakura, Y. & Luster,  a. D. Neutrophils orchestrate their own 
recruitment in murine arthritis through C5aR and Fc R signaling. Proc. Natl. Acad. Sci. 
109, E3177–E3185 (2012). 
115. Wright, H. L., Moots, R. J., Bucknall, R. C. & Edwards, S. W. Neutrophil function in 
inflammation and inflammatory diseases. Rheumatology 49, 1618–31 (2010). 
116. Mantovani, A., Cassatella, M. A., Costantini, C. & Jaillon, S. Neutrophils in the activation 
and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11, 519–31 (2011). 
117. Klickstein, L. B., Shapleigh, C. & Goetzl, E. J. Lipoxygenation of arachidonic acid as a 
source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in 
rheumatoid arthritis and spondyloarthritis. J. Clin. Invest. 66, 1166–1170 (1980). 
	
	 59	
118. Kim, N. D., Chou, R. C., Seung, E., Tager, A. M. & Luster, A. D. A unique requirement for 
the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J. 
Exp. Med. 203, 829–35 (2006). 
119. Shao, W.-H., Del Prete, A., Bock, C. B. & Haribabu, B. Targeted disruption of leukotriene 
B4 receptors BLT1 and BLT2: a critical role for BLT1 in collagen-induced arthritis in mice. 
J. Immunol. 176, 6254–61 (2006). 
120. Griffiths, R. J. Collagen-induced Arthritis Is Reduced in 5-Lipoxygenase-activating 
Protein-deficient Mice. J. Exp. Med. 185, 1123–1130 (1997). 
121. Chen, M., Lam, B. K., Kanaoka, Y., Nigrovic, P. a, Audoly, L. P., Austen, K. F. & Lee, D. 
M. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J. Exp. Med. 
203, 837–842 (2006). 
122. Griffiths, R. J., Pettipher, E. R., Koch, K., Farrell, C. a, Breslow, R., Conklyn, M. J., Smith, 
M. a, Hackman, B. C., Wimberly, D. J. & Milici,  a J. Leukotriene B4 plays a critical role in 
the progression of collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 92, 517–521 
(1995). 
123. Kuwabara, K., Yasui, K., Jyoyama, H., Maruyama, T., Fleisch, J. H. & Hori, Y. Effects of 
the second-generation leukotriene B4 receptor antagonist, LY293111Na, on leukocyte 
infiltration and collagen-induced arthritis in mice. Eur. J. Pharmacol. 402, 275–285 
(2000). 
124. Tsuji, F., Oki, K., Fujisawa, K., Okahara, A., Horiuchi, M. & Mita, S. Involvement of 
leukotriene B4 in arthritis models. Life Sci. 64, PL51–PL56 (1998). 
125. Díaz-González, F., Alten, R. H. E., Bensen, W. G., Brown, J. P., Sibley, J. T., Dougados, 
M., Bombardieri, S., Durez, P., Ortiz, P., de-Miquel, G., Staab, A., Sigmund, R., Salin, L., 
Leledy, C. & Polmar, S. H. Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, 
in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66, 628–32 (2007). 
126. Dalvie, D. K. & O’Donnell, J. P. Metabolism of CP-195,543, a leukotriene B4 receptor 
	
	 60	
antagonist, in the Long-Evans rat and Cynomolgus monkey. Xenobiotica. 29, 1123–40 
(1999). 
127. Bradley, J. D., Dmitrienko, A. A., Kivitz, A. J., Gluck, O. S., Weaver, A. L., Wiesenhutter, 
C., Myers, S. L. & Sides, G. D. A randomized, double-blinded, placebo-controlled clinical 
trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the 
treatment of rheumatoid arthritis. J. Rheumatol. 32, 417–23 (2005). 
128. Auer, J., Bläss, M., Schulze-Koops, H., Russwurm, S., Nagel, T., Kalden, J. R., 
Röllinghoff, M. & Beuscher, H. U. Expression and regulation of CCL18 in synovial fluid 
neutrophils of patients with rheumatoid arthritis. Arthritis Res. Ther. 9, R94 (2007). 
129. Joosten, L. A. B., Netea, M. G., Fantuzzi, G., Koenders, M. I., Helsen, M. M. A., Sparrer, 
H., Pham, C. T., van der Meer, J. W. M., Dinarello, C. A. & van den Berg, W. B. 
Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to 
caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum. 60, 
3651–62 (2009). 
130. Mitroulis, I., Kambas, K., Chrysanthopoulou, A., Skendros, P., Apostolidou, E., Kourtzelis, 
I., Drosos, G. I., Boumpas, D. T. & Ritis, K. Neutrophil extracellular trap formation is 
associated with IL-1β and autophagy-related signaling in gout. PLoS One 6, 1–10 (2011). 
131. Lande, R., Ganguly, D., Facchinetti, V., Frasca, L., Conrad, C., Gregorio, J., Meller, S., 
Chamilos, G., Riccieri, V., Bassett, R., Amuro, H. & Fukuhara, S. Neutrophils Activate 
Plasmacytoid Dendritic Cells by Releasing Self-DNA–Peptide Complexes in Systemic 
Lupus Erythematosus. Sci Transl Med 3, 1–20 (2012). 
132. Khandpur, R., Carmona-Rivera, C., Vivekanandan-Giri, A., Gizinski, A., Yalavarthi, S., 
Knight, J. S., Friday, S., Li, S., Patel, R. M., Subramanian, V., Thompson, P., Chen, P., 
Fox, D. A., Pennathur, S. & Kaplan, M. J. NETs Are a Source of Citrullinated 
Autoantigens and Stimulate Inflammatory Responses in Rheumatoid Arthritis. Sci. Transl. 
Med. 5, 178ra40–178ra40 (2013). 
	
	 61	
133. Garcia-romo, G. S., Caielli, S., Vega, B., Connolly, J., Xu, Z., Punaro, M., Baisch, J., 
Guiducci, C., Coffman, L., Barrat, F. J., Banchereau, J. & Pascual, V. Netting Neutrophils 
Are Major Inducers of Type I IFN Production in Pediatric Systemic Lupus Erythematosus. 
Sci Transl Med 3, 1–20 (2011). 
134. Jacobs, J. P., Ortiz-Lopez, A., Campbell, J. J., Gerard, C. J., Mathis, D. & Benoist, C. 
Deficiency of CXCR2, but not other chemokine receptors, attenuates autoantibody-
mediated arthritis in a murine model. Arthritis Rheum. 62, 1921–32 (2010). 
135. Falsone, A., Wabitsch, V., Geretti, E., Potzinger, H., Gerlza, T., Robinson, J., Adage, T., 
Teixeira, M. M. & Kungl, A. J. Designing CXCL8-based decoy proteins with strong anti-
inflammatory activity in vivo. Biosci. Rep. 33, (2013). 
136. Jura, J., Wegrzyn, P., Korostyński, M., Guzik, K., Oczko-Wojciechowska, M., Jarzab, M., 
Kowalska, M., Piechota, M., Przewłocki, R. & Koj, A. Identification of interleukin-1 and 
interleukin-6-responsive genes in human monocyte-derived macrophages using 
microarrays. Biochim. Biophys. Acta - Gene Regul. Mech. 1779, 383–389 (2008). 
137. Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D. R., 
Zlotnik,  a & Schall, T. J. A new class of membrane-bound chemokine with a CX3C motif. 
Nature 385, 640–644 (1997). 
138. Deshmane, S. L., Kremlev, S., Amini, S. & Sawaya, B. E. Monocyte chemoattractant 
protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 29, 313–326 (2009). 
139. Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K. I., Kitazawa, R., Kitazawa, S., 
Miyachi, H., Maeda, S., Egashira, K. & Kasuga, M. MCP-1 contributes to macrophage 
infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. 
Invest. 116, 1494–1505 (2006). 
140. Cambien, B., Pomeranz, M., Millet, M. A., Rossi, B. & Schmid-Alliana, A. Signal 




141. Lebre, M. C., Vergunst, C. E., Choi, I. Y. K., Aarrass, S., Oliveira, A. S. F., Wyant, T., 
Horuk, R., Reedquist, K. a. & Tak, P. P. Why CCR2 and CCR5 blockade failed and why 
ccr1 blockade might still be effective in the treatment of rheumatoid arthritis. PLoS One 6, 
e21772 (2011). 
142. Wolbink, G. J., Brouwer, M. C., Buysmann, S., ten Berge, I. J. & Hack, C. E. CRP-
mediated activation of complement in vivo: assessment by measuring circulating 
complement-C-reactive protein complexes. J. Immunol. 157, 473–479 (1996). 
143. Ballanti, E., Perricone, C., Greco, E., Ballanti, M., Di Muzio, G., Chimenti, M. S. & 
Perricone, R. Complement and autoimmunity. Immunol. Res. 56, 477–491 (2013). 
144. Wang, Y., Rollins, S. a, Madri, J. a & Matis, L. a. Anti-C5 monoclonal antibody therapy 
prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. 
Acad. Sci. U. S. A. 92, 8955–8959 (1995). 
145. Andersson, C., Wenander, C. S., Usher, P. a., Hebsgaard, J. B., Sondergaard, B. C., 
Rønø, B., Mackay, C., Friedrichsen, B., Chang, C., Tang, R. & Hornum, L. Rapid-onset 
clinical and mechanistic effects of anti-C5aR treatment in the mouse collagen-induced 
arthritis model. Clin. Exp. Immunol. 177, 219–233 (2014). 
146. Giles, J. L., Choy, E., van den Berg, C., Morgan, B. P. & Harris, C. L. Functional Analysis 
of a Complement Polymorphism (rs17611) Associated with Rheumatoid Arthritis. J. 
Immunol. 194, 3029–3034 (2015). 
147. Kurreeman, F. a S., Padyukov, L., Marques, R. B., Schrodi, S. J., Seddighzadeh, M., 
Stoeken-Rijsbergen, G., Van Der Helm-Van Mil, A. H. M., Allaart, C. F., Verduyn, W., 
Houwing-Duistermaat, J., Alfredsson, L., Begovich, A. B., Klareskog, L., Huizinga, T. W. 
J. & Toes, R. E. M. A candidate gene approach identifies the TRAF1/C5 region as a risk 
factor for rheumatoid arthritis. PLoS Med. 4, 1515–1524 (2007). 
148. Tak, P. P., Balanescu,  a., Tseluyko, V., Bojin, S., Drescher, E., Dairaghi, D., Miao, S., 
Marchesin, V., Jaen, J., Schall, T. J. & Bekker, P. Chemokine receptor CCR1 antagonist 
	
	 63	
CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo 
controlled clinical trial. Ann. Rheum. Dis. 337–344 (2012). doi:10.1136/annrheumdis-
2012-201605 
149. Hrdlickova, B., Kumar, V., Kanduri, K., Zhernakova, D. V., Tripathi, S., Karjalainen, J., 
Lund, R. J., Li, Y., Ullah, U., Modderman, R., Abdulahad, W., Lähdesmäki, H., Franke, L., 
Lahesmaa, R., Wijmenga, C. & Withoff, S. Expression profiles of long non-coding RNAs 
located in autoimmune disease-associated regions reveal immune cell type specificity. 
Genome Med. 6, 88–101 (2014). 
150. Mestas, J. & Hughes, C. C. W. Of Mice and Not Men: Differences between Mouse and 
Human Immunology. J. Immunol. 172, 2731–2738 (2004). 
151. Davey, M. S., Tamassia, N., Rossato, M., Bazzoni, F., Calzetti, F., Bruderek, K., Sironi, 
M., Zimmer, L., Bottazzi, B., Mantovani, A., Brandau, S., Moser, B., Eberl, M. & 
Cassatella, M. A. Failure to detect production of IL-10 by activated human neutrophils. 
Nat. Immunol. 12, 1017–1018 (2011). 
152. Quayle, J. A., Watson, F., Bucknall, R. C. & Edwards, S. W. Neutrophils from the synovial 
fluid of patients with rheumatoid arthritis express the high affinity immunoglobulin G 
receptor, Fc gamma RI (CD64): role of immune complexes and cytokines in induction of 
receptor expression. Immunology 91, 266–73 (1997). 
153. Belostocki, K., Pricop, L., Redecha, P. B., Aydin, A., Leff, L., Harrison, M. J. & Salmon, J. 
E. Infliximab treatment shifts the balance between stimulatory and inhibitory Fcγ receptor 
type II isoforms on neutrophils in patients with rheumatoid arthritis. Arthritis Rheum. 58, 
384–388 (2008). 
154. Radstake, T. R. D. J., Franke, B., Wenink, M. H., Nabbe, K. C. A. M., Coenen, M. J. H., 
Welsing, P., Bonvini, E., Koenig, S., van den Berg, W. B., Barrera, P. & van Riel, P. L. C. 
M. The functional variant of the inhibitory Fcgamma receptor IIb (CD32B) is associated 
with the rate of radiologic joint damage and dendritic cell function in rheumatoid arthritis. 
	
	 64	
Arthritis Rheum. 54, 3828–37 (2006). 
155. Fossati, G., Moots, R. J., Bucknall, R. C. & Edwards, S. W. Differential role of neutrophil 
Fc? receptor IIIB (CD16) in phagocytosis, bacterial killing, and responses to immune 
complexes. Arthritis Rheum. 46, 1351–1361 (2002). 
156. Wagner, C. & Hänsch, G. M. Genetic deficiency of CD16, the low-affinity receptor for 
immunoglobulin G, has no impact on the functional capacity of polymorphonuclear 
neutrophils. Eur. J. Clin. Invest. 34, 149–55 (2004). 
157. Robinson, J. M. Reactive oxygen species in phagocytic leukocytes. Histochem. Cell Biol. 
130, 281–97 (2008). 
158. van der Veen, B. S., de Winther, M. P. J. & Heeringa, P. Myeloperoxidase: molecular 
mechanisms of action and their relevance to human health and disease. Antioxid. Redox 
Signal. 11, 2899–937 (2009). 
159. Cedergren, J., Forslund, T., Sundqvist, T. & Skogh, T. Intracellular oxidative activation in 
synovial fluid neutrophils from patients with rheumatoid arthritis but not from other arthritis 
patients. J. Rheumatol. 34, 2162–2170 (2007). 
160. Chatham, W. W., Swaim, R., Frohsin, H., Heck, L. W., Miller, E. J. & Blackburn, W. D. 
Degradation of human articular cartilage by neutrophils in synovial fluid. Arthritis Rheum. 
36, 51–8 (1993). 
161. Schiller, J., Benard, S., Reichl, S., Arnhold, J. & Arnold, K. Cartilage degradation by 
stimulated human neutrophils: reactive oxygen species decrease markedly the activity of 
proteolytic enzymes. Chem. Biol. 7, 557–68 (2000). 
162. Filippin, L. I., Vercelino, R., Marroni, N. P. & Xavier, R. M. Redox signalling and the 
inflammatory response in rheumatoid arthritis. Clin. Exp. Immunol. 152, 415–422 (2008). 
163. Panasenko, O. M., Gorudko, I. V & Sokolov, A. V. Hypochlorous acid as a precursor of 
free radicals in living systems. Biochem. Biokhimii a  78, 1466–89 (2013). 
	
	 65	
164. Altindag, O., Karakoc, M., Kocyigit, A., Celik, H. & Soran, N. Increased DNA damage and 
oxidative stress in patients with rheumatoid arthritis. Clin. Biochem. 40, 167–71 (2007). 
165. Hilbert, N., Schiller, J., Arnhold, J. & Arnold, K. Cartilage degradation by stimulated 
human neutrophils: elastase is mainly responsible for cartilage damage. Bioorg. Chem. 
30, 119–32 (2002). 
166. Baici, A., Salgam, P., Cohen, G., Fehr, K. & Böni, A. Action of collagenase and elastase 
from human polymorphonuclear leukocytes on human articular cartilage. Rheumatol. Int. 
2, 11–6 (1982). 
167. Van den Steen, P. E., Dubois, B., Nelissen, I., Rudd, P. M., Dwek, R. A. & Opdenakker, 
G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 
(MMP-9). Crit. Rev. Biochem. Mol. Biol. 37, 375–536 (2002). 
168. Van den Steen, P. E., Proost, P., Grillet, B., Brand, D. D., Kang, A. H., Van Damme, J. & 
Opdenakker, G. Cleavage of denatured natural collagen type II by neutrophil gelatinase B 
reveals enzyme specificity, post-translational modifications in the substrate, and the 
formation of remnant epitopes in rheumatoid arthritis. FASEB J. 16, 379–89 (2002). 
169. Robinson, J., Watson, F., Bucknall, R. C. & Edwards, S. W. Activation of neutrophil 
reactive-oxidant production by synovial fluid from patients with inflammatory joint disease. 
Soluble and insoluble immunoglobulin aggregates activate different pathways in primed 
and unprimed cells. Biochem. J. 286, 345–51 (1992). 
170. Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D. S., 
Weinrauch, Y. & Zychlinsky, A. Neutrophil extracellular traps kill bacteria. Science 303, 
1532–5 (2004). 
171. Kaplan, M. J. & Radic, M. Neutrophil extracellular traps: double-edged swords of innate 
immunity. J. Immunol. 189, 2689–95 (2012). 
172. Nakashima, K. Nuclear Localization of Peptidylarginine Deiminase V and Histone 
Deimination in Granulocytes. J. Biol. Chem. 277, 49562–49568 (2002). 
	
	 66	
173. Papayannopoulos, V., Metzler, K. D., Hakkim, A. & Zychlinsky, A. Neutrophil elastase 
and myeloperoxidase regulate the formation of neutrophil extracellular traps. J. Cell Biol. 
191, 677–91 (2010). 
174. Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.-H., Homey, B., Cao, W., 
Wang, Y.-H., Su, B., Nestle, F. O., Zal, T., Mellman, I., Schröder, J.-M., Liu, Y.-J. & Gilliet, 
M. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. 
Nature 449, 564–9 (2007). 
175. Neeli, I., Khan, S. N. & Radic, M. Histone Deimination As a Response to Inflammatory 
Stimuli in Neutrophils. J. Immunol. 180, 1895–1902 (2008). 
176. Manolova, I., Dancheva, M. & Halacheva, K. Antineutrophil cytoplasmic antibodies in 
patients with systemic lupus erythematosus: prevalence, antigen specificity, and clinical 
associations. Rheumatol. Int. 20, 197–204 (2001). 
177. Pradhan, V. D., Badakere, S. S., Bichile, L. S. & Almeida, A. F. Anti-neutrophil 
cytoplasmic antibodies (ANCA) in systemic lupus erythematosus: prevalence, clinical 
associations and correlation with other autoantibodies. J. Assoc. Physicians India 52, 
533–7 (2004). 
178. Willis, V. C., Gizinski, A. M., Banda, N. K., Causey, C. P., Knuckley, B., Cordova, K. N., 
Luo, Y., Levitt, B., Glogowska, M., Chandra, P., Kulik, L., Robinson, W. H., Arend, W. P., 
Thompson, P. R. & Holers, V. M. N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine 
amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-
induced arthritis. J. Immunol. 186, 4396–404 (2011). 
179. Darrah, E. & Andrade, F. NETs: the missing link between cell death and systemic 
autoimmune diseases? Front. Immunol. 3, 428 (2012). 
180. Dwivedi, N. & Radic, M. Citrullination of autoantigens implicates NETosis in the induction 
of autoimmunity. Ann. Rheum. Dis. 73, 483–91 (2014). 
181. Kumar, V. & Sharma, A. Neutrophils: Cinderella of innate immune system. Int. 
	
	 67	
Immunopharmacol. 10, 1325–34 (2010). 
182. Kasama, T. Expression and regulation of human neutrophil-derived macrophage 
inflammatory protein 1 alpha. J. Exp. Med. 178, 63–72 (1993). 
183. Yeaman, G. R., Collins, J. E., Currie, J. K., Guyre, P. M., Wira, C. R. & Fanger, M. W. 
IFN-gamma is produced by polymorphonuclear neutrophils in human uterine 
endometrium and by cultured peripheral blood polymorphonuclear neutrophils. J. 
Immunol. 160, 5145–53 (1998). 
184. Ethuin, F., Gérard, B., Benna, J. E., Boutten, A., Gougereot-Pocidalo, M.-A., Jacob, L. & 
Chollet-Martin, S. Human neutrophils produce interferon gamma upon stimulation by 
interleukin-12. Lab. Invest. 84, 1363–71 (2004). 
185. Vogel, D. Y. S., Glim, J. E., Stavenuiter, A. W. D., Breur, M., Heijnen, P., Amor, S., 
Dijkstra, C. D. & Beelen, R. H. J. Human macrophage polarization in vitro: maturation and 
activation methods compared. Immunobiology 219, 695–703 (2014). 
186. Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat 
Rev Immunol. 8, 958–969 (2008). 
187. Li, J., Hsu, H.-C. & Mountz, J. D. Managing macrophages in rheumatoid arthritis by 
reform or removal. Curr. Rheumatol. Rep. 14, 445–54 (2012). 
188. Lefkowitz, D. L., Gelderman, M. P., Fuhrmann, S. R., Graham, S., Starnes, J. D., 
Lefkowitz, S. S., Bollen, A. & Moguilevsky, N. Neutrophilic Myeloperoxidase–Macrophage 
Interactions Perpetuate Chronic Inflammation Associated with Experimental Arthritis. Clin. 
Immunol. 91, 145–155 (1999). 
189. Grattendick, K., Stuart, R., Roberts, E., Lincoln, J., Lefkowitz, S. S., Bollen, A., 
Moguilevsky, N., Friedman, H. & Lefkowitz, D. L. Alveolar macrophage activation by 
myeloperoxidase: a model for exacerbation of lung inflammation. Am. J. Respir. Cell Mol. 
Biol. 26, 716–22 (2002). 
190. Takano, T., Azuma, N., Satoh, M., Toda, A., Hashida, Y., Satoh, R. & Hohdatsu, T. 
	
	 68	
Neutrophil survival factors (TNF-alpha, GM-CSF, and G-CSF) produced by macrophages 
in cats infected with feline infectious peritonitis virus contribute to the pathogenesis of 
granulomatous lesions. Arch. Virol. 154, 775–81 (2009). 
191. Odobasic, D., Yang, Y., Muljadi, R. C. M., O’Sullivan, K. M., Kao, W., Smith, M., Morand, 
E. F. & Holdsworth, S. R. Endogenous myeloperoxidase is a mediator of joint 
inflammation and damage in experimental arthritis. Arthritis Rheumatol. (Hoboken, N.J.) 
66, 907–17 (2014). 
192. van Gisbergen, K. P. J. M., Sanchez-Hernandez, M., Geijtenbeek, T. B. H. & van Kooyk, 
Y. Neutrophils mediate immune modulation of dendritic cells through glycosylation-
dependent interactions between Mac-1 and DC-SIGN. J. Exp. Med. 201, 1281–92 
(2005). 
193. Megiovanni, A. M., Sanchez, F., Robledo-Sarmiento, M., Morel, C., Gluckman, J. C. & 
Boudaly, S. Polymorphonuclear neutrophils deliver activation signals and antigenic 
molecules to dendritic cells: a new link between leukocytes upstream of T lymphocytes. J. 
Leukoc. Biol. 79, 977–88 (2006). 
194. Link, A., Vogt, T. K., Favre, S., Britschgi, M. R., Acha-Orbea, H., Hinz, B., Cyster, J. G. & 
Luther, S. A. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive 
T cells. Nat. Immunol. 8, 1255–65 (2007). 
195. Tian, J., Avalos, A. M., Mao, S.-Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., 
Golenbock, D., Sirois, C., Hua, J., An, L. L., Audoly, L., La Rosa, G., Bierhaus, A., 
Naworth, P., Marshak-Rothstein, A., Crow, M. K., Fitzgerald, K. A., et al. Toll-like receptor 
9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 
and RAGE. Nat. Immunol. 8, 487–96 (2007). 
196. Bianchi, M. E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. 
Leukoc. Biol. 81, 1–5 (2007). 
197. Yang, D., Chen, Q., Chertov, O. & Oppenheim, J. J. Human neutrophil defensins 
	
	 69	
selectively chemoattract naive T and immature dendritic cells. J. Leukoc. Biol. 68, 9–14 
(2000). 
198. Hoffmann, M. H., Bruns, H., Bäckdahl, L., Neregård, P., Niederreiter, B., Herrmann, M., 
Catrina, A. I., Agerberth, B. & Holmdahl, R. The cathelicidins LL-37 and rCRAMP are 
associated with pathogenic events of arthritis in humans and rats. Ann. Rheum. Dis. 72, 
1239–48 (2013). 
199. Ganguly, D., Chamilos, G., Lande, R., Gregorio, J., Meller, S., Facchinetti, V., Homey, B., 
Barrat, F. J., Zal, T. & Gilliet, M. Self-RNA-antimicrobial peptide complexes activate 
human dendritic cells through TLR7 and TLR8. J. Exp. Med. 206, 1983–94 (2009). 
200. Cross, A., Bucknall, R. C., Cassatella, M. A., Edwards, S. W. & Moots, R. J. Synovial fluid 
neutrophils transcribe and express class II major histocompatibility complex molecules in 
rheumatoid arthritis. Arthritis Rheum. 48, 2796–806 (2003). 
201. Oehler, L., Majdic, O., Pickl, W. F., Stöckl, J., Riedl, E., Drach, J., Rappersberger, K., 
Geissler, K. & Knapp, W. Neutrophil granulocyte-committed cells can be driven to acquire 
dendritic cell characteristics. J. Exp. Med. 187, 1019–28 (1998). 
202. Radsak, M., Iking-Konert, C., Stegmaier, S., Andrassy, K. & Hänsch, G. M. 
Polymorphonuclear neutrophils as accessory cells for T-cell activation: major 
histocompatibility complex class II restricted antigen-dependent induction of T-cell 
proliferation. Immunology 101, 521–30 (2000). 
203. Iking-Konert, C., Ostendorf, B., Sander, O., Jost, M., Wagner, C., Joosten, L., Schneider, 
M. & Hänsch, G. M. Transdifferentiation of polymorphonuclear neutrophils to dendritic-like 
cells at the site of inflammation in rheumatoid arthritis: evidence for activation by T cells. 
Ann. Rheum. Dis. 64, 1436–42 (2005). 
204. Tak, T., Tesselaar, K., Pillay, J., Borghans, J. A. M. & Koenderman, L. What’s your age 




205. Weinmann, P., Moura, R. a, Caetano-Lopes, J. R., Pereira, P. a, Canhão, H., Queiroz, M. 
V & Fonseca, J. E. Delayed neutrophil apoptosis in very early rheumatoid arthritis 
patients is abrogated by methotrexate therapy. Clin. Exp. Rheumatol. 25, 885–887 
(2007). 
206. Cross, A., Barnes, T., Bucknall, R. C., Edwards, S. W. & Moots, R. J. Neutrophil 
apoptosis in rheumatoid arthritis is regulated by local oxygen tensions within joints. J. 
Leukoc. Biol. 80, 521–8 (2006). 
207. Derouet, M., Thomas, L., Cross, A., Moots, R. J. & Edwards, S. W. Granulocyte 
macrophage colony-stimulating factor signaling and proteasome inhibition delay 
neutrophil apoptosis by increasing the stability of Mcl-1. J. Biol. Chem. 279, 26915–21 
(2004). 
208. Buckley, C. D., Ross, E. A., McGettrick, H. M., Osborne, C. E., Haworth, O., Schmutz, C., 
Stone, P. C. W., Salmon, M., Matharu, N. M., Vohra, R. K., Nash, G. B. & Rainger, G. E. 
Identification of a phenotypically and functionally distinct population of long-lived 
neutrophils in a model of reverse endothelial migration. J. Leukoc. Biol. 79, 303–11 
(2006). 
209. Serhan, C. N., Chiang, N. & Van Dyke, T. E. Resolving inflammation: dual anti-
inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8, 349–61 (2008). 
210. Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K. & Serhan, C. N. Lipid mediator class 
switching during acute inflammation: signals in resolution. Nat. Immunol. 2, 612–9 (2001). 
211. Abdgawad, M., Pettersson, Å., Gunnarsson, L., Bengtsson, A. A., Geborek, P., Nilsson, 
L., Segelmark, M. & Hellmark, T. Decreased neutrophil apoptosis in quiescent ANCA-
associated systemic vasculitis. PLoS One 7, e32439 (2012). 
212. Wright, H. L., Bucknall, R. C., Moots, R. J. & Edwards, S. W. Analysis of SF and plasma 
cytokines provides insights into the mechanisms of inflammatory arthritis and may predict 
response to therapy. Rheumatology (Oxford). 51, 451–9 (2012). 
	
	 71	
213. Wong, S. H., Francis, N., Chahal, H., Raza, K., Salmon, M., Scheel-toellner, D. & Lord, J. 
M. Lactoferrin is a survival factor for neutrophils in rheumatoid synovial fluid. 
Rheumatology 48, 39–44 (2009). 
214. Rossi, A. G., Sawatzky, D. A., Walker, A., Ward, C., Sheldrake, T. A., Riley, N. A., 
Caldicott, A., Martinez-Losa, M., Walker, T. R., Duffin, R., Gray, M., Crescenzi, E., Martin, 
M. C., Brady, H. J., Savill, J. S., Dransfield, I. & Haslett, C. Cyclin-dependent kinase 
inhibitors enhance the resolution of inflammation by promoting inflammatory cell 
apoptosis. Nat. Med. 12, 1056–64 (2006). 
215. Serhan, C. N., Chiang, N. & Dalli, J. The resolution code of acute inflammation: Novel 
pro-resolving lipid mediators in resolution. Semin. Immunol. 27, 200–15 (2015). 
216. Perretti, M. & Dalli, J. Exploiting the Annexin A1 pathway for the development of novel 
anti-inflammatory therapeutics. Br. J. Pharmacol. 158, 936–46 (2009). 
217. Liu, X., Ma, B., Malik, A. B., Tang, H., Yang, T., Sun, B., Wang, G., Minshall, R. D., Li, Y., 
Zhao, Y., Ye, R. D. & Xu, J. Bidirectional regulation of neutrophil migration by mitogen-
activated protein kinases. Nat. Immunol. 13, 457–64 (2012). 
218. Buttgereit, F., Zhou, H. & Seibel, M. J. Arthritis and endogenous glucocorticoids: the 
emerging role of the 11beta-HSD enzymes. Ann. Rheum. Dis. 67, 1201–3 (2008). 
219. Billard, M. J., Gall, B. J., Richards, K. L., Siderovski, D. P. & Tarrant, T. K. G protein 
signaling modulator-3 : a leukocyte regulator of inflammation in health and disease. Am J 
Clin Exp Immunol 3, 97–106 (2014). 
220. Jacoby, E., Bouhelal, R., Gerspacher, M. & Seuwen, K. The 7 TM G-protein-coupled 
receptor target family. ChemMedChem 1, 761–82 (2006). 
221. Lagerström, M. C. & Schiöth, H. B. Structural diversity of G protein-coupled receptors and 
significance for drug discovery. Nat. Rev. Drug Discov. 7, 339–57 (2008). 
222. Kimple, A. J., Bosch, D. E., Giguère, P. M. & Siderovski, D. P. Regulators of G-protein 
signaling and their Gα substrates: promises and challenges in their use as drug discovery 
	
	 72	
targets. Pharmacol. Rev. 63, 728–749 (2011). 
223. Siderovski, D. P. & Willard, F. S. The GAPs, GEFs, and GDIs of heterotrimeric G-protein 
alpha subunits. Int. J. Biol. Sci. 1, 51–66 (2005). 
224. Tarrant, T. K. & Patel, D. D. Chemokines and leukocyte trafficking in rheumatoid arthritis. 
Pathophysiology 13, 1–14 (2006). 
225. Szekanecz, Z., Koch, A. E. & Tak, P. P. Chemokine and chemokine receptor blockade in 
arthritis, a prototype of immune-mediated inflammatory diseases. Neth. J. Med. 69, 356–
66 (2011). 
226. Gladue, R. P., Brown, M. F. & Zwillich, S. H. CCR1 antagonists: what have we learned 
from clinical trials. Curr. Top. Med. Chem. 10, 1268–77 (2010). 
227. Proudfoot, A. E. I., Power, C. A. & Schwarz, M. K. Anti-chemokine small molecule drugs: 
a promising future? Expert Opin. Investig. Drugs 19, 345–55 (2010). 
228. Haringman, J. J., Gerlag, D. M., Smeets, T. J. M., Baeten, D., van den Bosch, F., 
Bresnihan, B., Breedveld, F. C., Dinant, H. J., Legay, F., Gram, H., Loetscher, P., 
Schmouder, R., Woodworth, T. & Tak, P. P. A randomized controlled trial with an anti-
CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with 
rheumatoid arthritis. Arthritis Rheum. 54, 2387–92 (2006). 
229. Hammaker, D. & Firestein, G. S. ‘Go upstream, young man’: lessons learned from the 
p38 saga. Ann. Rheum. Dis. 69, i77–i82 (2009). 
230. Siderovski, D. P., Diverse-Pierluissi, M. A. & De Vries, L. The GoLoco motif: a Gα-i/o 
binding motif and potential guanine-nucleotide exchange factor. Trends Biochem. Sci. 24, 
340–341 (1999). 
231. Takesono, A., Cismowski, M. J., Bernard, M., Chung, P., Hazard, S., Duzic, E. & Lanier, 
S. M. Receptor-independent Activators of Heterotrimeric G-protein Signaling Pathways. J. 
Biol. Chem. 274, 33202–33205 (1999). 
232. Blumer, J. B., Oner, S. S. & Lanier, S. M. Group II activators of G-protein signalling and 
	
	 73	
proteins containing a G-protein regulatory motif. Acta Physiol. 204, 202–218 (2012). 
233. Peterson, Y. K., Bernard, M. L., Ma, H., Hazard, S., Graber, S. G. & Lanier, S. M. 
Stabilization of the GDP-bound Conformation of Gi  by a Peptide Derived from the G-
protein Regulatory Motif of AGS3. J. Biol. Chem. 275, 33193–33196 (2000). 
234. Kimple, R. J., Kimple, M. E., Betts, L., Sondek, J. & Siderovski, D. P. Structural 
determinants for GoLoco-induced inhibition of nucleotide release by Galpha subunits. 
Nature 416, 878–881 (2002). 
235. Cao, X., Cismowski, M. J., Sato, M., Blumer, J. B. & Lanier, S. M. Identification and 
characterization of AGS4: a protein containing three G-protein regulatory motifs that 
regulate the activation state of Gialpha. J. Biol. Chem. 279, 27567–27574 (2004). 
236. Kimple, R. J., Willard, F. S., Hains, M. D., Jones, M. B., Nweke, G. K. & Siderovski, D. P. 
Guanine nucleotide dissociation inhibitor activity of the triple GoLoco motif protein G18: 
alanine-to-aspartate mutation restores function to an inactive second GoLoco motif. 
Biochem. J. 378, 801–808 (2004). 
237. Giguère, P. M., Laroche, G., Oestreich, E. a & Siderovski, D. P. G-protein signaling 
modulator-3 regulates heterotrimeric G-protein dynamics through dual association with 
Gβ and Gαi protein subunits. J. Biol. Chem. 287, 4863–74 (2012). 
238. Webb, C. K., McCudden, C. R., Willard, F. S., Kimple, R. J., Siderovski, D. P. & Oxford, 
G. S. D2 dopamine receptor activation of potassium channels is selectively decoupled by 
Gαi-specific GoLoco motif peptides. J. Neurochem. 92, 1408–1418 (2005). 
239. Giguère, P., Billard, M., Laroche, G., Buckley, B., Timoshchenko, R., McGinnis, M., 
Esserman, D., Foreman, O., Liu, P., Siderovski, D. & Tarrant, T. K. G-protein signaling 
modulator-3, a gene linked to autoimmune diseases, regulates monocyte function and its 
deficiency protects from inflammatory arthritis. Mol. Immunol. 54, 193–198 (2013). 
240. Oner, S. S., Maher, E. M., Breton, B., Bouvier, M. & Blumer, J. B. Receptor-regulated 




241. Nebl, T., Pestonjamasp, K. N., Leszyk, J. D., Crowley, J. L., Oh, S. W. & Luna, E. J. 
Proteomic analysis of a detergent-resistant membrane skeleton from neutrophil plasma 
membranes. J. Biol. Chem. 277, 43399–43409 (2002). 
242. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–101 (2005). 
243. Easton, D. F., Pooley, K. A., Dunning, A. M., Pharoah, P. D. P., Thompson, D., Ballinger, 
D. G., Struewing, J. P., Morrison, J., Field, H., Luben, R., Wareham, N., Ahmed, S., 
Healey, C. S., Bowman, R., Meyer, K. B., Haiman, C. A., Kolonel, L. K., Henderson, B. 
E., Le Marchand, L., et al. Genome-wide association study identifies novel breast cancer 
susceptibility loci. Nature 447, 1087–93 (2007). 
244. Sunderkötter, C., Nikolic, T., Dillon, M. J., Van Rooijen, N., Stehling, M., Drevets, D. A. & 
Leenen, P. J. M. Subpopulations of mouse blood monocytes differ in maturation stage 
and inflammatory response. J. Immunol. 172, 4410–7 (2004). 
245. Fujii, W., Ashihara, E., Hirai, H., Nagahara, H., Kajitani, N., Fujioka, K., Murakami, K., 
Seno, T., Yamamoto, A., Ishino, H., Kohno, M., Maekawa, T. & Kawahito, Y. Myeloid-
Derived Suppressor Cells Play Crucial Roles in the Regulation of Mouse Collagen-
Induced Arthritis. J. Immunol. 191, 1073–1081 (2013). 
246. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the 
immune system. Nat. Rev. Immunol. 9, 162–74 (2009). 
247. Yan, C., Ding, X., Dasgupta, N., Wu, L. & Du, H. Gene profile of myeloid-derived 
suppressive cells from the bone marrow of lysosomal acid lipase knock-out mice. PLoS 
One 7, e30701 (2012). 
248. Akata, K., Yatera, K., Aoki, T., Fujii, M., Kinoshita, S., Kawanami, T., Ishimoto, H., 
Hisaoka, M., Korogi, Y. & Mukae, H. Disseminated Pulmonary Penicilliosis in a 
Rheumatoid Arthritis Patient. J. Thorac. Imaging 29, W14–W16 (2014). 
	
	 75	
249. Corzo, C. A., Cotter, M. J., Cheng, P., Cheng, F., Kusmartsev, S., Sotomayor, E., 
Padhya, T., McCaffrey, T. V, McCaffrey, J. C. & Gabrilovich, D. I. Mechanism regulating 
reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 
182, 5693–701 (2009). 
250. Montero, A. J., Diaz-Montero, C. M., Kyriakopoulos, C. E., Bronte, V. & Mandruzzato, S. 
Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J. 
Immunother. 35, 107–15 
251. Bunt, S. K., Clements, V. K., Hanson, E. M., Sinha, P. & Ostrand-Rosenberg, S. 
Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through 
Toll-like receptor 4. J. Leukoc. Biol. 85, 996–1004 (2009). 
252. Lapan, P., Zhang, J., Hill, A., Zhang, Y., Martinez, R. & Haney, S. Image-Based 
Assessment of Growth and Signaling Changes in Cancer Cells Mediated by Direct Cell-
Cell Contact. PLoS One 4, e6822 (2009). 
253. Reif, K. & Cyster, J. G. RGS molecule expression in murine B lymphocytes and ability to 
down-regulate chemotaxis to lymphoid chemokines. J. Immunol. 164, 4720–9 (2000). 
254. Corsiero, E., Bombardieri, M., Manzo, A., Bugatti, S., Uguccioni, M. & Pitzalis, C. Role of 
lymphoid chemokines in the development of functional ectopic lymphoid structures in 
rheumatic autoimmune diseases. Immunol. Lett. 145, 62–67 (2012). 
255. Sirota, M., Schaub, M. a., Batzoglou, S., Robinson, W. H. & Butte, A. J. Autoimmune 
disease classification by inverse association with SNP alleles. PLoS Genet. 5, e1000792 
(2009). 
256. Corona, E., Dudley, J. T. & Butte, A. J. Extreme evolutionary disparities seen in positive 
selection across seven complex diseases. PLoS One 5, e12236 (2010). 
257. Comuzzie, A. G., Cole, S. A., Laston, S. L., Voruganti, V. S., Haack, K., Gibbs, R. A. & 
Butte, N. F. Novel genetic loci identified for the pathophysiology of childhood obesity in 
the Hispanic population. PLoS One 7, e51954 (2012). 
	
	 76	
258. Chang, W.-C., Lee, C.-H., Hirota, T., Wang, L.-F., Doi, S., Miyatake, A., Enomoto, T., 
Tomita, K., Sakashita, M., Yamada, T., Fujieda, S., Ebe, K., Saeki, H., Takeuchi, S., 
Furue, M., Chen, W.-C., Chiu, Y.-C., Chang, W. P., Hong, C.-H., et al. ORAI1 genetic 
polymorphisms associated with the susceptibility of atopic dermatitis in Japanese and 
Taiwanese populations. PLoS One 7, e29387 (2012). 
259. Cunningham, F., Amode, M. R., Barrell, D., Beal, K., Billis, K., Brent, S., Carvalho-Silva, 
D., Clapham, P., Coates, G., Fitzgerald, S., Gil, L., Giron, C. G., Gordon, L., Hourlier, T., 
Hunt, S. E., Janacek, S. H., Johnson, N., Juettemann, T., Kahari,  a. K., et al. Ensembl 
2015. Nucleic Acids Res. 43, D662–D669 (2014). 
260. Zhao, P., Nguyen, C. H. & Chidiac, P. The proline-rich N-terminal domain of G18 exhibits 
a novel G protein regulatory function. J. Biol. Chem. 285, 9008–9017 (2010). 
261. Rampersad, R. R., Tarrant, T. K., Vallanat, C. T., Quintero-Matthews, T., Weeks, M. F., 
Esserman, D. a., Clark, J., Padova, F., Patel, D. D., Fong, A. M. & Liu, P. Enhanced 
Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune 
arthritis. PLoS One 6, e25833 (2011). 
262. Vergunst, C. E., Gerlag, D. M., Lopatinskaya, L., Klareskog, L., Smith, M. D., van den 
Bosch, F., Dinant, H. J., Lee, Y., Wyant, T., Jacobson, E. W., Baeten, D. & Tak, P. P. 
Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-
controlled clinical trial. Arthritis Rheum. 58, 1931–9 (2008). 
263. Rogers, J. L., Serafin, D. S., Timoshchenko, R. G. & Tarrant, T. K. Cellular targeting in 
autoimmunity. Curr. Allergy Asthma Rep. 12, 495–510 (2012). 
264. van Kuijk, A. W. R., Vergunst, C. E., Gerlag, D. M., Bresnihan, B., Gomez-Reino, J. J., 
Rouzier, R., Verschueren, P. C., van der Leij, C., van de Leij, C., Maas, M., Kraan, M. C. 
& Tak, P. P. CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-
controlled clinical trial. Ann. Rheum. Dis. 69, 2013–6 (2010). 
265. Wu, C., Orozco, C., Boyer, J., Leglise, M., Goodale, J., Batalov, S., Hodge, C. L., Haase, 
	
	 77	
J., Janes, J., Huss, J. W. & Su, A. I. BioGPS: an extensible and customizable portal for 
querying and organizing gene annotation resources. Genome Biol. 10, R130 (2009). 
266. Schmidt, N., Art, J., Forsch, I., Werner, A., Erkel, G., Jung, M., Horke, S., Kleinert, H. & 
Pautz, A. The anti-inflammatory fungal compound (S)-curvularin reduces proinflammatory 
gene expression in an in vivo model of rheumatoid arthritis. J. Pharmacol. Exp. Ther. 343, 
106–14 (2012). 
267. De Rycke, L., Baeten, D., Foell, D., Kruithof, E., Veys, E. M., Roth, J. & De Keyser, F. 
Differential expression and response to anti-TNFα treatment of infiltrating versus resident 
tissue macrophage subsets in autoimmune arthritis. J. Pathol. 206, 17–27 (2005). 
268. Kim, J. S., An, H., Rieter, W. J., Esserman, D., Taylor-Pashow, K. M. L., Sartor, R. B., 
Lin, W. & Tarrant, T. K. Multimodal optical and Gd-based nanoparticles for imaging in 
inflammatory arthritis. Clin. Exp. Rheumatol. 27, 580–6 
269. Harrison, J. E. & Schultz, J. Studies on the chlorinating activity of myeloperoxidase. J. 
Biol. Chem. 251, 1371–4 (1976). 
270. Chaubey, S., Jones, G. E., Shah, A. M., Cave, A. C. & Wells, C. M. Nox2 is required for 
macrophage chemotaxis towards CSF-1. PLoS One 8, e54869 (2013). 
271. Nie, J. & Pei, D. Rapid inactivation of alpha-1-proteinase inhibitor by neutrophil specific 
leukolysin/membrane-type matrix metalloproteinase 6. Exp. Cell Res. 296, 145–50 
(2004). 
272. Hilda, J. N., Narasimhan, M. & Das, S. D. Neutrophils from pulmonary tuberculosis 
patients show augmented levels of chemokines MIP-1α, IL-8 and MCP-1 which further 
increase upon in vitro infection with mycobacterial strains. Hum. Immunol. 75, 914–22 
(2014). 
273. Chiba, K., Zhao, W., Chen, J., Wang, J., Cui, H. Y., Kawakami, H., Miseki, T., Satoshi, H., 
Tanaka, J., Asaka, M. & Kobayashi, M. Neutrophils secrete MIP-1 beta after adhesion to 




274. Adib-Conquy, M., Pedron, T., Petit-Bertron, A.-F., Tabary, O., Corvol, H., Jacquot, J., 
Clément, A. & Cavaillon, J.-M. Neutrophils in cystic fibrosis display a distinct gene 
expression pattern. Mol. Med. 14, 36–44 (2008). 
275. Mishalian, I., Bayuh, R., Eruslanov, E., Michaeli, J., Levy, L., Zolotarov, L., Singhal, S., 
Albelda, S. M., Granot, Z. & Fridlender, Z. G. Neutrophils recruit regulatory T-cells into 
tumors via secretion of CCL17--a new mechanism of impaired antitumor immunity. Int. J. 
Cancer 135, 1178–86 (2014). 
276. Scapini, P., Laudanna, C., Pinardi, C., Allavena, P., Mantovani, A., Sozzani, S. & 
Cassatella, M. A. Neutrophils produce biologically active macrophage inflammatory 
protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19. Eur. J. Immunol. 31, 1981–8 
(2001). 
277. Hieshima, K., Imai, T., Opdenakker, G., Van Damme, J., Kusuda, J., Tei, H., Sakaki, Y., 
Takatsuki, K., Miura, R., Yoshie, O. & Nomiyama, H. Molecular cloning of a novel human 
CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. 
Chemotactic activity for lymphocytes and gene localization on chromosome 2. J. Biol. 
Chem. 272, 5846–53 (1997). 
278. Gasperini, S., Calzetti, F., Russo, M. P., De Gironcoli, M. & Cassatella, M. A. Regulation 
of GRO alpha production in human granulocytes. J. Inflamm. 45, 143–51 (1995). 
279. Chen, L. & Sendo, F. Cytokine and chemokine mRNA expression in neutrophils from 
CBA/NSlc mice infected with Plasmodium berghei ANKA that induces experimental 
cerebral malaria. Parasitol. Int. 50, 139–143 (2001). 
280. Gasperini, S., Marchi, M., Calzetti, F., Laudanna, C., Vicentini, L., Olsen, H., Murphy, M., 
Liao, F., Farber, J. & Cassatella, M. A. Gene expression and production of the monokine 
induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and 
IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J. Immunol. 
	
	 79	
162, 4928–37 (1999). 
281. Brandt, E., Woerly, G., Younes, A. B., Loiseau, S. & Capron, M. IL-4 production by 
human polymorphonuclear neutrophils. J. Leukoc. Biol. 68, 125–30 (2000). 
282. Taylor, P. R., Roy, S., Leal, S. M., Sun, Y., Howell, S. J., Cobb, B. A., Li, X. & Pearlman, 
E. Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal 
infection is regulated by IL-6, IL-23, RORγt and dectin-2. Nat. Immunol. 15, 143–51 
(2014). 
283. Benedetti, G. & Miossec, P. Interleukin 17 contributes to the chronicity of inflammatory 
diseases such as rheumatoid arthritis. Eur. J. Immunol. 44, 339–47 (2014). 
284. Kouri, V.-P., Olkkonen, J., Ainola, M., Li, T.-F., Björkman, L., Konttinen, Y. T. & Mandelin, 
J. Neutrophils produce interleukin-17B in rheumatoid synovial tissue. Rheumatology 
(Oxford). 53, 39–47 (2014). 
285. Volin, M. V & Koch, A. E. Interleukin-18: a mediator of inflammation and angiogenesis in 
rheumatoid arthritis. J. Interferon Cytokine Res. 31, 745–51 (2011). 
286. Kvedaraite, E., Lourda, M., Ideström, M., Chen, P., Olsson-Åkefeldt, S., Forkel, M., 
Gavhed, D., Lindforss, U., Mjösberg, J., Henter, J.-I. & Svensson, M. Tissue-infiltrating 
neutrophils represent the main source of IL-23 in the colon of patients with IBD. Gut 
(2015). doi:10.1136/gutjnl-2014-309014 
287. Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J. & Gurney, A. L. Interleukin-23 
promotes a distinct CD4 T cell activation state characterized by the production of 
interleukin-17. J. Biol. Chem. 278, 1910–4 (2003). 
288. Kamohara, H., Matsuyama, W., Shimozato, O., Abe, K., Galligan, C., Hashimoto, S.-I., 
Matsushima, K. & Yoshimura, T. Regulation of tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils. 
Immunology 111, 186–94 (2004). 
289. Holden, N. J., Williams, J. M., Morgan, M. D., Challa, A., Gordon, J., Pepper, R. J., 
	
	 80	
Salama, A. D., Harper, L. & Savage, C. O. S. ANCA-stimulated neutrophils release BLyS 
and promote B cell survival: a clinically relevant cellular process. Ann. Rheum. Dis. 70, 
2229–33 (2011). 
290. Batten, M., Groom, J., Cachero, T. G., Qian, F., Schneider, P., Tschopp, J., Browning, J. 
L. & Mackay, F. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. 
Med. 192, 1453–66 (2000). 
291. Gabay, C., Krenn, V., Bosshard, C., Seemayer, C. A., Chizzolini, C. & Huard, B. Synovial 
tissues concentrate secreted APRIL. Arthritis Res. Ther. 11, R144 (2009). 
292. Puga, I., Cols, M., Barra, C. M., He, B., Cassis, L., Gentile, M., Comerma, L., Chorny, A., 
Shan, M., Xu, W., Magri, G., Knowles, D. M., Tam, W., Chiu, A., Bussel, J. B., Serrano, 
S., Lorente, J. A., Bellosillo, B., Lloreta, J., et al. B cell–helper neutrophils stimulate the 
diversification and production of immunoglobulin in the marginal zone of the spleen. Nat. 
Immunol. 13, 170–180 (2011). 
293. Chakravarti, A., Raquil, M.-A., Tessier, P. & Poubelle, P. E. Surface RANKL of Toll-like 
receptor 4-stimulated human neutrophils activates osteoclastic bone resorption. Blood 
114, 1633–44 (2009). 
294. Sabeh, F., Fox, D. & Weiss, S. J. Membrane-type I matrix metalloproteinase-dependent 
regulation of rheumatoid arthritis synoviocyte function. J. Immunol. 184, 6396–6406 
(2010). 
295. Miller, M.-C., Manning, H. B., Jain, A., Troeberg, L., Dudhia, J., Essex, D., Sandison, A., 
Seiki, M., Nanchahal, J., Nagase, H. & Itoh, Y. Membrane type 1 matrix 
metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis. 
Arthritis Rheum. 60, 686–697 (2009). 
296. Elsaid, K. ., Jay, G. . & Chichester, C. . Detection of collagen type II and proteoglycans in 
the synovial fluids of patients diagnosed with non-infectious knee joint synovitis indicates 
early damage to the articular cartilage matrix. Osteoarthr. Cartil. 11, 673–680 (2003). 
	
	 81	
297. Pham, C. T. N. Neutrophil serine proteases: specific regulators of inflammation. Nat. Rev. 
Immunol. 6, 541–50 (2006). 
298. Berahovich, R. D., Miao, Z., Wang, Y., Premack, B., Howard, M. C. & Schall, T. J. 
Proteolytic activation of alternative CCR1 ligands in inflammation. J. Immunol. 174, 7341–
51 (2005). 
299. Wittamer, V., Bondue, B., Guillabert, A., Vassart, G., Parmentier, M. & Communi, D. 
Neutrophil-mediated maturation of chemerin: a link between innate and adaptive 
immunity. J. Immunol. 175, 487–93 (2005). 
300. Nufer, O., Corbett, M. & Walz, A. Amino-terminal processing of chemokine ENA-78 
regulates biological activity. Biochemistry 38, 636–42 (1999). 
301. Murphy, C. J., Foster, B. A., Mannis, M. J., Selsted, M. E. & Reid, T. W. Defensins are 
mitogenic for epithelial cells and fibroblasts. J. Cell. Physiol. 155, 408–13 (1993). 
302. De Yang, Chen, Q., Schmidt, A. P., Anderson, G. M., Wang, J. M., Wooters, J., 
Oppenheim, J. J. & Chertov, O. LL-37, the neutrophil granule- and epithelial cell-derived 
cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract 
human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192, 1069–74 
(2000). 
303. Davidson, D. J., Currie, A. J., Reid, G. S. D., Bowdish, D. M. E., MacDonald, K. L., Ma, R. 
C., Hancock, R. E. W. & Speert, D. P. The cationic antimicrobial peptide LL-37 modulates 
dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. 172, 
1146–1156 (2004). 
304. Tecchio, C., Micheletti, A. & Cassatella, M. A. Neutrophil-Derived Cytokines: Facts 
Beyond Expression. Front. Immunol. 5, 508 (2014). 
305. Charo, I. F. & Ransohoff, R. M. The many roles of chemokines and chemokine receptors 








Genetic variations in GPSM3 associated with protection from 
rheumatoid arthritis affect its transcript abundance 
 
 
Original Article – in press Genes & Immunity 
 
BJ Gall1, A Wilson2, AB Schroer1, JD Gross1, P Stoilov3,  
V Setola1,4, CM Watkins2, DP Siderovski1 
1Department of Physiology & Pharmacology, 2Department of Orthopaedics, 
3Department of Biochemistry, and 4Department of Behavioral Medicine & 
Psychiatry, West Virginia University School of Medicine, Morgantown, WV, USA 
26506-9229 
 
Email:  dpsiderovski@hsc.wvu.edu 
 




2.1 – Abstract  
 
G protein signaling modulator 3 (GPSM3) is a regulator of G protein-coupled 
receptor signaling, with expression restricted to leukocytes and lymphoid organs. 
Previous genome-wide association studies have highlighted single-nucleotide 
polymorphisms (SNPs rs204989, rs204991) in a region upstream of the GPSM3 
transcription start site as being inversely correlated to the prevalence of rheumatoid 
arthritis (RA) -- this association is supported by the protection afforded to Gpsm3-
deficient mice in models of inflammatory arthritis. Here, we assessed the functional 
consequences of these polymorphisms. We collected biospecimens from 50 volunteers 
with RA diagnoses, 50 RA-free volunteers matched to the aforementioned group, and 
100 unmatched healthy young volunteers. We genotyped these individuals for GPSM3 
(rs204989, rs204991), CCL21 (rs2812378), and HLA gene region (rs6457620) 
polymorphisms, and found no significant differences in minor allele frequencies between 
the RA and disease-free cohorts. However, we identified that individuals homozygous 
for SNPs rs204989 and rs204991 had decreased GPSM3 transcript abundance relative 
to individuals homozygous for the major allele. In vitro promoter activity studies suggest 
that SNP rs204989 is the primary cause of this decrease in transcript levels. 
Knockdown of GPSM3 in THP-1 cells, a human monocytic cell line, was found to disrupt 





2.2 – INTRODUCTION  
 
Chemokine receptors comprise a subfamily of the G protein-coupled receptor 
(GPCR) superfamily of transmembrane receptors that are expressed on a number of 
leukocyte subsets and function predominantly to regulate chemotaxis1–5. Upon binding 
their cognate chemokine agonists, chemokine receptors transduce signals by inducing 
dissociation of their associated, intracellular Gi protein heterotrimers (Giα·GDP/Gβγ). 
This process is highly regulated through additional intracellular proteins that act upon 
the Giα subunit and ultimately affect the rate of signal inactivation4,6,7. In particular, 
proteins containing one or more conserved GoLoco motifs are capable of sequestering 
inactivated Giα·GDP, preventing its reassociation with Gβγ and GPCRs and thereby 
disrupting continued Giα-induced signaling without quenching Gβγ-mediated signaling6–
10. The importance of Gβγ-associated signaling to chemokine actions has recently been 
highlighted by reports that specific Gβγ-activating compounds are sufficient to induce 
neutrophil chemotaxis11 and, conversely, a Gβγ antagonist can inhibit fMLP-induced 
chemotaxis12. GoLoco proteins may directly regulate signaling pathways required for 
chemotaxis by sequestering Giα·GDP and prolonging Gβγ-mediated signaling 
processes13,14, thereby exacerbating inflammation. 
 
G protein signaling modulator 3 (GPSM3) contains two functional GoLoco motifs 
and is restricted in its expression to leukocytes and myeloid-derived cells15,16. Gpsm3-
deficient mice exhibit a profoundly blunted course of joint damage in an acute, collagen 
antibody-induced model of inflammatory arthritis16. Histologic analyses of affected 
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synovial tissues indicate a relative acellularity of synovial cavities in Gpsm3-deficient 
mice compared to wild type mice, which suggests a potential leukocyte migration deficit. 
These findings suggest a role for GPSM3 in the development of inflammation in 
rheumatoid arthritis, most likely through a key regulatory role on leukocyte chemotaxis 
to the synovium17. However, a direct demonstration of such a role has yet to be 
exhibited with human cells. 
 
Genome-wide association studies (GWAS) have identified two single-nucleotide 
polymorphisms (SNPs), rs204989 and rs204991, 5’ to the GPSM3 transcriptional start 
site that are significantly less prevalent in individuals with rheumatoid arthritis (and other 
autoimmune diseases; e.g., lupus and multiple sclerosis), implying a potential protective 
effect of these minor gene variations18–20. Notably, rs204989 and rs204991 both exist 
within the chromosome 6p21.3 band, a region previously attributed to a large portion of 
the heritable aspect of RA; specifically, HLA gene region polyallelic haploblocks within 
the chromosome 6p21.3 region represent some of the greatest risk factors for RA21 
(reviewed in ref. 22). In particular, the biallelic HLA gene locus polymorphism, rs6457620 
[C>G], has been identified as an RA risk factor in a meta-analysis of GWAS studies 
investigating multiple populations in the Wellcome Trust Case Control Consortium 
(WTCCC), North American Rheumatoid Arthritis Consortium (NARAC), and the 
Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA)23,24. Thus, the 
potential exists for linkage disequilibrium between GPSM3 and HLA gene region 
polymorphisms. In this study, we addressed whether GPSM3 SNPs result in a 
detectable phenotype that explains their inverse association with rheumatoid arthritis. 
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Furthermore, we assessed whether linkage disequilibrium with the known RA risk allele 
in the HLA gene region, rs645762023,24, may affect the inverse association of GPSM3 
SNP alleles with RA. Additionally, another RA risk allele, CCL21 rs2812378 [T>C], 
located on an unlinked chromosome, was analyzed as both a negative control for 
linkage and a positive control for RA disease risk24.  We recruited a group of 50 
volunteers with a diagnosis of RA, 50 RA-free volunteers who were matched to the 
aforementioned group by a ‘Bring-a-friend-to-clinic’ program, and 100 unmatched 
healthy young volunteers to donate biospecimens for analyses. Based on the location of 
the polymorphisms and previous reports of protection from inflammatory phenotypes in 
human GWAS18–20 and Gpsm3-deficient mouse studies16, we hypothesized that 
individuals homozygous for the minor alleles of rs204989 and rs204991 would exhibit 
decreased whole-blood GPSM3 transcript abundance. Additionally, we predicted that 
knockdown of GPSM3 would result in disruption of chemokine-induced migration in a 






2.3 – RESULTS   
 
2.3.1 – GPSM3 SNPs rs204989 and rs204991, each previously associated by 
GWAS with protection from rheumatoid arthritis, form a haploblock with rs204990 
  
The cohorts recruited for this study included an initial set of 100 unmatched 
healthy young volunteers, a group of 50 volunteers with a positive diagnosis of RA, and 
50 RA-free volunteers matched to the aforementioned group by a ‘Bring-a-friend-to-
clinic’ program. Upon genotyping all 200 volunteers recruited for this study, we found 
that GPSM3 SNPs rs204989 and rs204991, originally identified to be independently18–20 
associated with protection from RA, are in complete linkage disequilibrium within this 
population. Additionally, sequencing a 3.5-kb region 5’ to the GPSM3 transcriptional 
start site in eight volunteers revealed a total of four polymorphisms in this region: 
rs204989, rs204990, rs204991, and rs3096688 (Fig. 2.1A). All of these chromosome 6 
SNPs have been previously identified in the NCBI Database of Single Nucleotide 
Polymorphisms (dbSNPs) 25. In this study, three of these GPSM3 SNPs (rs204989, 
rs204990, rs204991) were seen to be inherited as a haploblock in complete linkage 
disequilibrium; therefore, we defined all individuals homozygous for the minor (lower 
frequency) alleles of all three SNPs as having the “m/m” genotype and all individuals 
homozygous for the major (higher frequency) allele for all three SNPs as having the 




2.3.2 – The GPSM3 rs204989/rs204991 haploblock is associated with decreased 
GPSM3 mRNA expression in whole blood 
 
In disease-free homozygotes for the minor alleles of GPSM3 SNPs, whole blood-
derived RNA contained only 75.9% (m/m; n = 11; 95% C.I. of ± 7.6%) of the average 
GPSM3 transcript level present in homozygotes for the major alleles (M/M; n = 53; 95% 
C.I. of ± 5.6%). This was a decrease of 24.1% (95% C.I. of 7.1% - 41.7%; t = 3.803; df = 
62; p = 0.0003) for individuals with the m/m genotype (n = 11) relative to individuals with 
the M/M genotype (Fig. 1B; n = 53). Heterozygous individuals (M/m genotype) exhibited 
an average of 82.0% of the GPSM3 transcript abundance of the M/M genotype, but had 
a marked amount of variability (data not shown; n = 6; 95% C.I. of ± 31.1%). In our 
analyses of GPSM3 mRNA abundance, we excluded RA patient samples to avoid 
potential confounding effects caused by anti-RA pharmacotherapy, as shown previously 
by RNA-seq26,27. According to the 1000 Genomes Project28, the minor allele frequencies 
(MAFs) in the general population of rs204989 and rs204991 are 23.3% and 23.4%, 
respectively. In our volunteer populations, the chromosome 6 rs204989 and rs204991 
SNPs occurred in a haploblock with a minor allele frequency (MAF) of 29% within the 
unmatched healthy young cohort (n=100), 23% within the rheumatoid arthritis cohort (n 
= 50), and 18% within the matched control (disease-free) cohort (n = 50). The MAF of 
the chromosome 9 CCL21 gene locus polymorphism rs2812378 [T>C] is 30.1% 
according to the 1000 Genomes Project28. In our recruited populations, the CCL21 gene 
polymorphism MAF was 31.5% within the unmatched healthy young population (n = 
100), 30.0% within the rheumatoid arthritis cohort (n = 50), and 25.0% within the 
matched control cohort (n = 50). The MAF of the chromosome 6 HLA gene region 
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polymorphism rs6457620 was 56.0% within the unmatched healthy young cohort (n = 
100), 35.0% within the rheumatoid arthritis cohort (n = 50), and 45.0% within the 
matched control population (n = 50). None of the differences in GPSM3 (p = 0.4839), 
CCL21 (p = 0.5267), and HLA gene region (p = 0.1938) polymorphism MAFs between 
the RA and matched, disease-free cohorts was statistically significant (Fig. 2.1C).  
 
2.3.3 – The  GPSM3 SNP haploblock is in weak linkage disequilibrium with HLA 
SNP rs6457620, but the latter is unlinked to GPSM3 transcript abundance 
 
Both the gene for GPSM3 and the HLA gene region SNP rs6457620 reside on 
chromosome 6, presenting the possibility of linkage disequilibrium; however, over 0.5 
megabases of DNA sequence separate rs6457620 from the GPSM3 
rs204989/rs204991 SNP haploblock25. In individuals homozygous for the GPSM3 SNPs 
(M/M), the HLA gene region SNP MAF was 41.3% (Figure 2.2). In heterozygotes for the 
GPSM3 SNPs (M/m), the HLA gene region SNP MAF was 56.3%, while homozygotes 
for the minor alleles of GPSM3 SNPs (m/m) exhibited a 60.7% HLA gene region SNP 
MAF. This distribution was significantly different from chance distribution of unlinked loci 
(Fig. 2.2A; p = 0.0066), suggesting the presence of weak linkage disequilibrium and 
consistent with data from the NCBI dbSNP 25 (Fig. 2.2D). Within the RA cohort, there 
was significant variation from chance distribution of GPSM3 SNPs MAF when stratified 
by HLA gene region SNP genotype (Fig. 2.2B; p = 0.0123), which was not observed 
within the matched control group (Fig. 2.2C; p = 0.2739). However, when stratified by 
HLA SNP rs6457620 genotype, GPSM3 transcript abundance in whole blood was not 
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significantly different (Fig. 2.2E; F = 1.219; p = 0.3050); this result is in contrast to the 
significant difference in GPSM3 transcript abundance observed when stratified by 
GPSM3 SNP haploblock genotype (Fig. 2.1B). 
2.3.4 – rs204989 of the GPSM3 SNP haploblock is solely linked to decreased 
GPSM3 transcript abundance 
 
A 3.5-kb region 5’ to the human GPSM3 transcription start site, spanning the 
region of the GPSM3 SNP haploblock under study (Figure 2.1A), was subcloned into a 
promoterless luciferase-reporter vector. Transfecting this construct into HEK293T cells, 
we found the normalized firefly luciferase activity induced by the “minor/polymorphic” 
GPSM3 promoter (pGL3-m; containing the minor rs204989/rs204990/rs204991 
haploblock as well as the minor allele of SNP rs3096688) was 26.5% less than that of 
the wild type promoter (pGL3-M; containing the major allele of all four SNPs) (p < 
0.0001; Fig. 3A). To assess the relative effect(s) of each of the four minor SNP variants 
within this GPSM3 promoter region, each individual polymorphism was separately 
introduced to the wild type promoter by site-directed mutagenesis (i.e., rs204989 [C>T], 
rs204990 [G>T], rs204991 [A>G], and rs3096688 [A>G]). Introduction of the minor allele 
of rs204990 (p = 0.1435), rs204991 (p = 0.2136), or rs3096688 (p = 0.6618) did not 
significantly alter the normalized firefly luciferase activity of the wild type promoter (Fig. 
2.3A). In contrast, introduction of the minor allele of rs204989 [C>T] into the wild type 
promoter significantly decreased promoter-induced luminescence (p < 0.0001; Fig. 
2.3A); conversely, introduction of the major allele of rs204989 [T>C] into the 
polymorphic promoter (“pGL3-m-989”) was found to restore wild type promoter-induced 
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luminescence (p = 0.9384; Fig. 2.3B). Using the JASPAR transcription factor binding 
profile database29, two potential transcription factor binding sites were found to overlap 
with the site of the rs204989 SNP: namely, AP1 and C/EBPβ consensus binding sites 
(Fig. 2.4).  
 
2.3.5 – Decreased GPSM3 abundance leads to a deficit in migration towards 
monocyte chemoattractant protein-1 (MCP-1) by the human monocytic THP-1 cell 
line 
 
The human monocytic THP-1 cell line has previously been shown to 
endogenously express GPSM3 16; we confirmed the presence of the GPSM3 ancestral 
(“major”) alleles of rs204989 and rs204991 within this cell line (data not shown). We 
established stable GPSM3 knockdown (and scrambled control) THP-1 cell lines (Fig. 
2.5A), using previously validated shRNA-expressing lentiviral vectors directed against 
GPSM3 (i.e., shRNA19 and shRNA20; ref. 47). Using these stable THP-1 cell lines in 
real-time Transwell plate migration assays, we measured vehicle-normalized relative 
fluorescence units (RFU) over a 30-minute timeframe to quantify MCP-1/CCL2-induced 
cell transmigration. After normalizing to vehicle-induced non-specific migration, the 
GPSM3 knockdown cell lines shRNA19 and shRNA20 exhibited disrupted migration to 
the chemokine MCP-1 (a.k.a. CCL2) relative to scrambled shRNA control lines (Fig. 
2.5B); these migration differences were independent of any changes in transcript 
abundance of the MCP-1 receptor (i.e., CCR2) between cell lines assayed (Fig. 2.5C; F 
= 2.40; p = 0.119).  This migratory deficit upon GPSM3 knockdown was observed both 
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by a decrease in initial rate of migration (Fig. 2.5D) and by a decrease in maximum 
transmigration-induced fluorescence achieved (Fig. 2.5E). 
 
2.4 – DISCUSSION 
 
Genome-wide association studies (GWAS) have empowered researchers to 
investigate complex non-Mendelian genetic disorders, including RA; however, these 
studies can be hampered by the identification of large numbers of noncoding variants 
with unknown effects, reproducibility across multiple populations being uncertain, and 
linkage with other risk alleles obscuring results30. In multiple GWAS reports, noncoding 
variants 5’ to the transcription start site of GPSM3 (Fig. 2.1A) have been identified as 
occurring less frequently in individuals with RA18–20. However, like many identified 
variants, no functional consequence has been elucidated to explain this association. In 
the current study, we addressed (1) genotype-dependent phenotypes of the identified 
chromosome 6 GPSM3 SNPs, (2) potential linkage with rs6457620, a biallelic RA risk 
allele with a large effect size in the HLA gene region on chromosome 6 (refs. 23,24), and 
(3) a functional effect of altered GPSM3 expression levels in a human monocytic cell 
line.  
 
We recruited 50 volunteers with confirmed RA diagnoses, 50 RA-free volunteers 
matched to the arthritis group, and 100 younger healthy individuals to analyze 
genotype-dependent functional consequences of GPSM3 SNP alleles. Our finding that 
homozygotes for the GPSM3 SNPs (m/m) have lower GPSM3 transcript abundance in 
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whole blood relative to homozygotes for the ancestral allele (M/M) (Fig. 2.1B) supports 
the hypothesis first put forth from GWAS18–20 that there is a potential functional 
consequence of the identified GPSM3 SNPs rs204989 and rs204991, namely protection 
from development of rheumatoid arthritis; we have previously demonstrated16 that 
lowered Gpsm3 expression in mice, as generated by gene knockout technology, results 
in protection from collagen-autoantibody induced inflammatory arthritis.  
 
 
While our present finding of lowered GPSM3 mRNA levels in the whole blood of 
homozygotes bearing the GPSM3 SNP haploblock is consistent with GWAS and mouse 
gene knockout studies, the observed frequencies of the rs204989/rs204991 haploblock 
within the various genotyped groups are seemingly discrepant, given the trend toward 
decreased GPSM3 minor allele frequency, albeit not significantly different, in the 
disease-free matched control (MAF = 18.0%; n = 50) compared to the RA cohort (MAF 
= 23.0%; n = 50). Considering the small sample size, the observed variability is not 
remarkable in light of the reported minor allele frequency in the general population being 
23.3%. Small sample size likely also affected our ability to assign statistical significance 
to the trend of increased frequency of the positive RA risk allele (Fig. 2.1C), CCL21 
gene rs2812378 [T>C] on chromosome 9 (i.e., unlinked to the human GPSM3 locus on 
chromosome 6; ref. 24).  
 
To address whether the GPSM3 SNP haploblock on chromosome 6 was serving 
as a surrogate marker for a linked and causal (yet unrelated) chromosome 6 variation 
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affecting GPSM3 mRNA abundance and/or RA disease status, additional genotyping 
was performed on another chromosome 6 biallelic allele, specifically near the well-
established risk region in the HLA gene region (reviewed by Holoshitz22 and Yuta, et 
al.33). This RA risk allele, rs6457620 [C>G]23,24 is reported by RegulomeDB34 (based on 
Hapmap2 metadata) to exist in complete linkage disequilibrium (D’ = 1.0; r2 = 1.0) with 
another HLA region RA risk allele rs6457617 [C>T]31,32 in a population of Americans 
with European ancestry (CEPH collection)35 that is very similar to the demographics of 
our West Virginia-based sample population. Both polymorphisms (rs6457617 & 
rs6457620) exist ~500 kb from the GPSM3 SNP haploblock (e.g., Fig. 2.2D). When 
stratifying the HLA region-associated SNP genotype by GPSM3 SNP genotype, a 
preferential coexistence is seen between the GPSM3 SNP haploblock minor allele and 
the minor allele (G) of rs6457620 (Fig. 2.2). Upon further stratification by disease state, 
we discovered the GPSM3 SNP alleles were more strongly associated with the minor 
allele of rs6457620 (G) in our RA cohort when compared to the matched control cohort 
(Fig. 2.2B vs. C). These findings suggest that the protective effect of the GPSM3 SNP 
haploblock minor allele is most likely masked in our small-sized cohort by the large 
effect size of the HLA gene region RA risk allele at rs6457620 (RA odds ratio of 2.5524) 
or other RA risk-related HLA gene haploblocks in linkage disequilibrium21,33. Previous 
GWAS studies have genotyped tens of thousands of ethnically-diverse volunteers to 
identify the two GPSM3 SNPs rs204989 and rs204991 as inversely associated with RA 
18–20. Therefore, we hypothesize that our inability to reproduce previous GWAS findings 
is most likely a consequence of the relatively small sample size we recruited for this 
functional study of GPSM3 phenotypes and/or a founder effect among the local 
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recruited volunteers36.  Regardless, our finding of a genotype-dependent decrease in 
GPSM3 mRNA abundance is supportive of the prior GWAS findings18–20, especially in 
light of the protection from inflammatory arthritis exhibited by Gpsm3-deficient mice16. 
 
To probe the molecular mechanism whereby presence of the minor allele of the 
rs204989/rs204991 haploblock leads to decreased GPSM3 transcript levels in whole 
blood, a 3.5-kb promoter region containing the haploblock region was tested for its 
promoter activity upon transfection into HEK293T cells (used given low transient 
transfection efficiency of the THP-1 cell line). There was a significant decrease in 
promoter activity in the reporter construct containing all four 5’ SNPs versus the 
ancestral sequence, in a direct parallel to decreased GPSM3 transcript abundance seen 
in whole blood samples from individuals homozygous for the minor rs204989/rs204991 
haploblock versus the ancestral (“major”) haploblock. The presence of rs204989 [C>T] 
was found to be the sole determinant responsible for the reduction in GPSM3 promoter 
activity. We did observe slight variability in the decrease in GPSM3 promoter-driven 
luciferase activity between experiments, most likely due to experimental variability, 
environmental factors (e.g., temperature differentially affecting firefly and Renilla 
luciferase activity), and elapsed time between experiments. Regardless, all constructs 
containing the minor allele of rs204989 [C>T] were not significantly different from the 
construct with all 4 GPSM3 SNP alleles. To our knowledge, this is the first reported 
functional connection between the GPSM3 rs204989 polymorphism and GPSM3 
transcript abundance in human cells and human samples. The singular effect of the 
rs204989 cytosine-to-thymine transition on GPSM3 promoter activity may reside in the 
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disruption of the consensus DNA-binding motif of AP-1 and/or C/EBPβ; this hypothesis 
is now the topic of future work. 
 
A potential functional consequence of this genotype-dependent decrease in 
GPSM3 abundance is dysregulated G protein-coupled receptor signaling via Giα6–10 – a 
common signaling system used by chemokine receptors. Considering the restricted 
expression of GPSM3 in leukocytes and lymphoid organs15,16 and the importance of of 
Giα-coupled chemokine receptors in leukocyte migration during RA pathogenesis37, we 
hypothesized that a reduction in GPSM3 expression in human monocytic THP-1 cells 
would result in perturbed chemokine-dependent chemotaxis. Given the role of monocyte 
chemoattractant protein-1 (MCP-1/CCR2) signaling in the recruitment of monocytes and 
macrophages during inflammatory bouts in RA patients38,39, we elected to examine 
MCP-1-induced chemotaxis. shRNA-induced knockdown of GPSM3 in THP-1 cells 
disrupted Transwell migration (both initial rate and maximal migration) toward MCP-1, 
but did not affect expression of its cognate receptor, C-C chemokine receptor 2 (CCR2) 
(Fig. 5). Taken together, these data support a role for GPSM3 in supporting MCP-1-
induced migration of human THP-1 cells. We note that the knockdown efficiency of the 
successful GPSM3-targeted shRNAs was significantly greater than the 24.1% decrease 
found in individuals homozygous for the minor alleles of the GPSM3 SNP haploblock. 
Therefore, we hypothesize that the functional effect of the rs204989 GPSM3 SNP in 
vivo is most likely more subtle, yet it likely plays a role in the pathogenesis of RA as a 




Based on our collective results, the GPSM3 SNPs rs204989 and rs204991, 
identified as protective against RA in prior GWAS studies, likely exhibit this protective 
effect via linkage to rs204989 and its alteration of GPSM3 transcription. An rs204989-
mediated decrease in GPSM3 transcript level likely decreases GPSM3 protein levels 
and thereby decreases chemokine-dependent leukocyte migration in inflammation. 
RNA-seq ‘transcriptomic’ datasets report the GPSM3 mRNA as being expressed at an 
appreciable level in all human leukocyte subsets examined (GEO accession 
GDS62408)40, suggesting that decreased GPSM3 mRNA transcript caused by SNP 
rs204989 may affect both the innate and adaptive immune responses that act 
sequentially in the pathogenesis of rheumatoid arthritis37. Future work will initially 
address whether the presence of rs204989 is functionally relevant in primary leukocytes 
isolated from patient samples or in CRISPR-mediated introduction of rs204989 in 
human leukocyte cell lines. Additionally, we will seek to establish whether one or both of 
the candidate transcription factors (i.e., AP1 or C/EBPβ) are indeed involved in GPSM3 
promoter regulation and whether such activity is directly affected by the major or minor 





2.5 – MATERIALS AND METHODS 
 
2.5.1 – Subjects: A WVU IRB-approved case-control study (IRB protocol #1304033165) 
recruited a total of 200 consenting local volunteers for buccal swabs and blood samples. 
The volunteer population was subdivided into three groups of 100 young, healthy 
control volunteers from among the WVU Health Sciences Center student population, 50 
rheumatoid arthritis patients (ICD-9 diagnosed and anti-RF-positive), and 50 
demographically matched controls. Inclusion criteria for the 100 healthy control 
volunteers included (1) at least 18 years of age, (2) self-reported good health, and (3) 
no family history of autoimmune disease. Inclusion criteria for the 50 rheumatoid arthritis 
individuals included (1) at least 18 years of age, (2) positive ICD-9 diagnosis and (3) 
rheumatoid factor positive. Inclusion criteria for the 50 demographically matched 
controls included (1) at least 18 years of age, (2) not a blood relative of a volunteer 
enrolled in the study, and (3) no family history of autoimmune disease. For buccal swab 
samples, volunteers were instructed to vigorously swab the inside of both cheeks for 15 
seconds on each side, and resultant samples were stored in a sterile nuclease-free 
container at -80ºC. Blood samples were collected by a trained phlebotomist sequentially 
into a K2EDTA tube (Becton Dickinson) and a PAXgene Blood RNA tube (BD); as per 
manufacturer’s suggested protocol, the PAXgene Blood RNA tube was incubated at 
room temperature for 120 minutes prior to archiving at -80 ºC. 
 
2.5.2 – Isolation and Quantification of gDNA: Isolation of genomic DNA (gDNA) from 
buccal swab samples was performed with the QIAamp DNA Blood Mini Kit (Qiagen) on 
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a QIAcube automated nucleic acid extraction/purification instrument (Qiagen; 
Germantown, MD). Briefly, buccal swabs were immersed in 400 µl of Buffer ATL 
(Qiagen) and treated with proteinase K by incubation at 56 ºC for 10 minutes. Following 
incubation, buccal swabs were removed, placed into QIAamp spin columns, and 
centrifuged at 13,000 RPM for 1 minute on a tabletop microfuge. Buccal swabs were 
then discarded. Cell lysates were then loaded into separate QIAamp spin columns as 
per manufacturer’s suggested protocols; purified gDNA was automatically collected 
using the custom QIAcube “buccal swab spin” protocol (Qiagen). Quantification of 
human gDNA was performed with the Investigator Quantiplex Kit (Qiagen) using the 
manufacturer’s suggested protocols. Briefly, buccal swab eluate was diluted 1:1 with 
nuclease-free water. Quantitative PCR to measure eluate gDNA content was performed 
using the Investigator Quantiplex Kit on a RotorGene Q-400 thermocycler (Qiagen) with 
an initial denaturation phase at 95ºC for 60 seconds, followed by 40 cycles of 95ºC for 1 
second and 60ºC for 10 seconds. DNA quantity was recorded as a mean of technical 
replicates. 
 
2.5.3 – SNP Genotyping of Subjects: SNP genotypes were determined using the Type-it 
Fast Probe PCR Kit (Qiagen), TaqMan SNP genotyping probes, and primers for 
rs204989 (GPSM3), rs204991 (GPSM3), rs2812378 (CCL21), and rs6457620 (HLA 
gene region) (Life Technologies; cat. #C_3293828_20, C_2412452_20, 
C_16113556_10, and C_29315329_10, respectively) using the manufacturer’s 
suggested protocols. Briefly, equal masses of human gDNA were added to each 
reaction and the manufacturer’s recommended cycling parameters were used to detect 
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both major and minor alleles in multiplex qPCR reactions performed in technical 
replicates on a RotorGene Q-400 thermocycler. Coded identifiers were used to blind 
investigators of the disease state of volunteers until all samples had been genotyped.  
 
2.5.4 – Isolation of Whole Blood RNA: To maintain homogeneity of sample treatment, all 
RNA was extracted from archived whole blood collected into PAXgene Blood RNA 
tubes with the PAXgene Blood RNA kit (Qiagen) using a modification of the 
manufacturer’s suggested protocol. Briefly, when possible genotypes (M/M and m/m) 
were prepared concurrently. Upon removal from cryostorage, PAXgene tubes were 
incubated on a rocker at room temperature for 15-18 hours, centrifuged at 5,000 x g for 
10 minutes at 4ºC, and the resulting cell pellet was resuspended in 4 ml of nuclease-
free water. The solution was then centrifuged at 5,000 x g for 10 minutes at 4 ºC, and 
the cell pellet was resuspended in 350 µl of the manufacturer’s resuspension buffer 
(BR1). Isolation of whole blood RNA was performed using an automated QIAcube 
workflow according to the manufacturer’s suggested protocol to minimize variability 
between preparations. Eluted nucleic acids were quantified by absorbance at 260 nm 
using a Nanodrop 2000 (Thermo Scientific) and assessed for purity using 260/280 nm 
ratio of ≥1.8. Immediately following isolation, a sample (250 ng) of eluted nucleic acids 
from each subject was used to synthesize complementary DNA (cDNA) with Thermo 
Verso Reverse Transcriptase Kit (Thermo Scientific). cDNA was then diluted 1:5 and 




2.5.5 – Quantitative Reverse Transcriptase PCR (qRT-PCR): A sample of cDNA, 
derived from equal masses of RNA from each volunteer, was amplified in duplicate (with 
an additional independent “no reverse transcriptase-treated” control) using the USB 
VeriQuest Fast SYBR Green qPCR Master Mix (Affymetrix, Cleveland, OH) and 
custom-designed, intron-spanning PCR primers (Supplemental Table S1 and Figure 
S1). Cycling conditions were modified from the manufacturer’s suggested protocol to 
establish linearity of transcript detection (Supplemental Figure S2A,B). Relative 
quantification of gene expression was performed using the ΔΔCT method41, and the 
specificity of each amplicon was verified by gel electrophoresis and melt curve tests 
(e.g., Supplemental Fig. S2C). 
 
 
2.5.6 – Cell lines and culture conditions: The human embryonic kidney 293T cell line 
(HEK293T) was obtained from the American Type Tissue Collection (ATCC). Cell lines 
were maintained at 37 ºC in a humidified atmosphere containing 5% CO2. The 
HEK293T cell line was maintained in DMEM supplemented with 10% fetal bovine 
serum, 100 IU penicillin, and 100 µg/ml streptomycin. Transient transfections of 
HEK293T cells were performed as previously described 42. Briefly, transfection of 
monolayers grown to 60-70% confluence was performed by incubating cells 15-18 
hours with Ca3(PO4)2 and plasmid DNA solution. The cell monolayers were then 
washed twice with phosphate buffered saline (pH 7.4), then fresh medium was added. 
THP-1 cells, from the ATCC, were maintained in an ATCC-modification of RPMI 
medium supplemented with 10% heat-inactivated fetal bovine serum, 100 IU penicillin, 
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100 µg/ml streptomycin, and 2 µg/ml puromycin. GPSM3 expression was stably 
knocked-down in THP-1 cells via lentiviral transduction (under the WVU IBC protocol # 
15-04-08) of Mission shRNA in the pLKO.1 vector (clones: TRCN0000036819 and 
TRCN0000036820). An additional two THP-1 monoclonal cell lines were established 
stably-expressing scrambled control (a gift from Dr. David Sabatini, ref. 43; Addgene 
plasmid # 1864). Briefly, transduction was performed at a multiplicity of infection of 10 
using the spinoculation protocol (described in ref. 44), transduced cells were selected 
with 2 µg/ml puromycin, and monoclonal populations were established by limiting 
dilution. All THP-1 monoclonal cell lines and HEK 293T cells were confirmed free of 
Mycoplasma spp. and Acholeplasma spp. contamination (Supplemental Figure S3) 
using Lookout® Mycoplasma PCR Detection kit following manufacturer’s protocols 




2.5.7 – Cloning and mutagenesis of plasmids: DNA from plasmids pGL3-basic-luc2P 
(Promega, Madison, WI) and pcDNA3.1(+) were digested at the HindIII and XhoI sites 
using FastDigest enzymes and buffers (Thermo Scientific, Pittsburgh, PA), and 
restricted DNA ends were phosphatase treated with calf intestinal alkaline phosphatase 
(Promega, Madison, WI). Vectors were purified via extraction from a 1% agarose gel 
(QIAquick, Qiagen). Sequences of the GPSM3 gene locus were retrieved from the NCBI 
reference sequence (NC_000006.12 c32195523-32190766). A 5010-bp region of the 
GPSM3 promoter was amplified from gDNA (“GPSM3 amplification primers”; 
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Supplemental Table S2) from one individual with the major GPSM3 alleles (“pGL3-M”) 
and another individual with all minor polymorphic alleles (“pGL3-m”); nested primers 
(Supplemental Table S2) were used to amplify a 3512-bp span of this promoter region 
(NC_000006.12 32192523 - 32196035) and thereby introduce flanking HindIII and XhoI 
cut sites (“GPSM3 cloning primers”). The resultant amplicons were digested with HindIII 
and XhoI, and ligated into both pGL3-luc2P and pcDNA3.1(+) vectors (Rapid DNA 
ligation kit; Roche, Basel, Switzerland). Mutagenesis was performed using the 
QuikChange Lightning Mutagenesis kit (Agilent Technologies, Santa Clara, CA) and 
manufacturer’s suggested protocols with primers (Supplemental Table S3). Briefly, 
mutagenesis of GPSM3 promoter inserts was performed within the pcDNA3.1(+) vector, 
sequenced by the Sanger method to confirm mutagenesis, and then subcloned into 
pGL3-luc2P vectors. 
 
2.5.8 – Promoter-driven luciferase assay: HEK293T cells were transiently transfected 
using the calcium phosphate method, as described previously42,45, with 5 µg of pGL3 
firefly luciferase-based reporter vector and 1 µg of pRL-TK Renilla luciferase-based 
reporter control vector (Promega, Madison, WI). Forty-eight hours following transfection, 
the cells were assayed for both firefly and Renilla luciferase activities using the 
manufacturer’s suggested protocol for the Dual-Luciferase Reporter Assay System 
(Promega, Madison, WI). Briefly, cells were harvested, washed in PBS pH 7.4, and 
lysed using the manufacturer’s “passive lysis” buffer. Using automatic injectors within a 
Flexstation-3 (Molecular Devices, Sunnyvale, CA), firefly luciferase substrate was 
added to the cellular lysate and luminescence was recorded in a white, clear-bottom 96-
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well plate for 10 seconds. Firefly luminescence was then quenched and Renilla 
luciferase substrate was added to the lysate and luminescence was recorded for 10 
seconds. Data were normalized to luminescence induced by Renilla luciferase activity 
and reported as fold-change from pGL3-M transfected HEK 293T cells. All data are 
representative of biologic triplicates. 
 
2.5.9 – Transcription factor bioinformatics: The 3.5 kb of sequence 5’ to the GPSM3 
transcription start site was acquired from the Genome Reference Consortium human 
genome 38 (GRCh38) and imported into JASPAR29. Predictions of consensus binding 
motifs for transcription factors were cut off at 20% dissimilarity. 
 
2.5.10 – Transwell migration assay: THP-1 cells stably expressing either GPSM3-
knockdown shRNA or scrambled shRNA control were serum-starved in HBSS + 1% 
BSA at 37°C for one hour and labeled with calcein-AM cell permeant fluorescent dye 
(494 nm/ 517 nm). Cells were washed and suspended in HBSS + 1% BSA + 10 mM 
HEPES, and 5 x 107 cells/ml were loaded into the upper well of a Falcon™ HTS 
FluoroBlok 96-Multiwell Insert System chemotaxis chambers (Corning, NY). Cells were 
allowed to migrate toward vehicle or 100 ng/mL MCP-1/CCL2 (R&D Systems, 
Minneapolis, MN) in the lower chamber. Fluorescence was measured at 2 minute 
intervals over the course of 60 minutes at 37°C using a Flexstation 3 microplate reader 
(Molecular Devices, Sunnyvale, CA). All data are representative of biological triplicates 




2.5.11 – Statistical analyses: Descriptive data from the case-control cohort were 
analyzed using SAS University Edition 3.1 (SAS Institute Inc., Cary, NC). Differences in 
2 x 2 discrete variables were determined using Fisher’s exact test, while 2 x 3 discrete 
variables were compared using the Fisher-Freeman-Halton exact test46. Regression 
analyses in Transwell migration assays were performed using 4 parameter logistic 
nonlinear regression analyses over the period of migration with post-hoc comparison by 
one-way ANOVA of the unshared maximum and time to 50% migration parameters. All 
nonlinear models were confirmed to have r-squared values >0.99, and accepted the null 
hypothesis of the Shapiro-Wilk normality test (p ≥ 0.05). All other analyses were 
performed in Prism 6.0 using a two-tailed independent t-test or one-way ANOVA with 
Bonnferroni or Dunnett’s post-hoc tests where indicated. 
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2.7 – Figures and Tables: 
 
Figure 2.1. GPSM3 transcript abundance in whole blood from individuals 
homozygous for the minor allele of the rs204989/rs204991 haploblock (the “m/m” 
genotype) is significantly lower than in whole blood from individuals 
homozygous for the major allele of the haploblock (the “M/M” genotype). (A) 
Schematic representation of identified polymorphisms with respect to the predicted 
transcription start site of the human GPSM3 gene. (B) Scatter plot representation of 
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the average level measured in M/M individuals. Individual results for homozygous major 
allele samples (M/M; n = 53) are depicted by solid circles, and homozygous minor allele 
samples (m/m; n=11) are depicted by open circles. An average decrease (Δµ) in 
GPSM3 transcript abundance of 24.1% (t = 3.80, df = 62, p = 0.0003) was observed in 
homozygous minor allele samples. Error bars represent S.E.M. (C) Descriptive statistics 
of the three cohorts of volunteers genotyped in this study: Minor allele frequencies were 
23% for rs204989 and rs204991 in the rheumatoid arthritis samples versus 18% in the 
disease-free controls (Fisher’s exact test; p = 0.4839). Risk/minor allele frequency for 
rs2812378 was 30.0% in the rheumatoid arthris samples versus 25.0% in the disease-
free controls (p = 0.5267). Risk/minor allele frequency for the HLA gene region biallelic 
SNP rs6457620 was 35.0% in the rheumatoid arthritis samples and 45.0% in the 






Figure 2.2. Linkage of the GPSM3 SNP haploblock and the known RA risk allele in 
the HLA gene region, rs6457620 [C>G], is more pronounced in RA samples than 
controls, but this linkage does not result in a rs6457620 genotype-dependent 
effect on GPSM3 transcript abundance in whole blood. (A) Descriptive statistics of 
all 200 volunteers, including the RA (n = 50), disease-free matched control (n = 50), and 
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stratified by GPSM3 SNP haplotype, showing that the rs6457620 [G] risk allele 
frequency amongst homozygous ancestral GPSM3 haploblock individuals (M/M) is 
41.3%, heterozygous individuals (M/m) is 56.3%, and homozygous minor GPSM3 
haploblock (m/m) is 60.7%. These data are significantly different from chance 
distribution (Fisher-Freeman-Halton exact test; p = 0.0066). (B) Analyses of GPSM3 
SNP haploblock linkage within RA samples stratified by rs6457620 genotype, again 
exhibiting statistically significant difference from chance distribution (Fisher-Freeman-
Halton exact test; p = 0.0123). (C) Within the disease-free matched control samples, 
GPSM3 SNP minor allele (m) frequency, as stratified by rs6457620 genotype, is not 
significantly different from chance distribution as determined by Fisher-Freeman-Halton 
exact test (p = 0.2739). (D) Graphical representation of minor allele frequencies (MAFs; 
of European [‘eu’] population), physical distance (in basepairs), and linkage 
disequilibrium (LD) value (as quantified by heatmap) between the three linked SNPs of 
the GPSM3 SNP haploblock (rs204989, rs204990, rs204991) and the HLA gene region 
SNP rs6547620, as obtained using the NIEHS SNPinfo webserver 
(http://snpinfo.niehs.nih.gov/) from NCBI dbSNP data (ref. 25). (E) Despite modest 
linkage between GPSM3 SNP minor alleles (m) and the rs6457620 risk allele (G), there 
is no effect of the genotype at HLA gene region SNP rs6457620 on GPSM3 transcript 




Figure 2.3. Functional consequences of SNPs rs204989, rs204990, rs204991, and 
rs3096688 on GPSM3 promoter activity. (A) Functional results upon subcloning a 3.5 
kb-region immediately 5’ to the GPSM3 transcription start site from M/M and m/m 
genotype volunteers, leading to wild type (pGL3-M) and “minor”/polymorphic (pGL3-m) 
promoter-driven expression of firefly luciferase in HEK293T cells. Luciferase activity is 































































































































control Renilla luciferase activity (pRL-TK control vector) and normalized to the average 
level measured from the wild type pGL3-M vector (set to 1.00; dotted line). Introduction 
of independent minor alleles (denoted “+###”) into the wild type pGL3-M vector is seen 
to differentially affect resultant firefly luciferase activity. (B) Restoration of the major 
allele at rs204989 in the pGL3-m vector (i.e., “pGL-m-989”) restores wild type GPSM3 
promoter activity. All data are compiled from three independent experiments. Error 
measure is S.E.M. Significance was determined using one-way ANOVA after controlling 




Figure 2.4. Putative transcription factor binding sites within the human GPSM3 
promoter potentially disrupted by the minor allele of SNP rs204989 (arrows), as 
predicted by the JASPAR database: (A) Fos/Jun (AP1) heterodimer; (B) C/EBP-β. 
C/EBPβ consensus motif
Fos/Jun (AP1) consensus motif
 Nucleotide 1 2 3 4 5 6 7 8 9 10 11
A 13 006 75 198 0 0 4 556 0 74 715 8 654 60 151 99 494 0
C 10 026 5 868 0 0 0 99 494 5 478 51 954 39 343 0 36 038
G 33 617 18 428 0 0 75 531 0 10 015 0 0 0 2 043
T 42 845 0 99 494 99 494 19 407 0 9 286 38 886 0 0 61 413
wild type A A G T G C T T C A T
rs204989 A A G T G C T T t A T
 Nucleotide 1 2 3 4 5 6 7
A 0 0 16 5 3 0 16
C 1 0 2 12 0 15 0
G 0 15 0 1 1 3 1
T 17 3 0 0 14 0 1
wild type T G C T T C A



















Figure 2.5. Lentiviral-mediated shRNA knockdown of endogenous GPSM3 
expression in the human monocytic THP-1 cell line disrupts migration toward 
MCP-1 (A) Western blot showing whole lysate (40 µg) immunoreactivity with mouse 
monoclonal anti-GPSM3 antibody 35.5.1 (ref. 47) and with anti-β-actin as a loading 
control. (B) Real-time Transwell migration analysis of indicated calcein-AM stained 
THP-1 cell lines as shown by change in the ratio of MCP-1-induced to vehicle-induced 
relative fluorescence units (RFU) over a 30 minute timeframe. (C) qRT-PCR data from 
indicated stable knockdown or scrambled control THP-1 cell line total RNA 
preparations. There was no significant difference in CCR2 mRNA abundance in the 
THP-1 cell lines as determined by one-way ANOVA (F = 2.40; p = 0.119). (D) 
Regression analysis-derived rate of THP-1 cell line transmigration over initial migratory 




















































































































































no significant difference 






























































































Regression analysis-derived maximum THP-1 cell transmigration over 30 minute 
timecourse; differences between each cell line were calculated by one-way ANOVA. All 
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Supplementary Materials and Methods: 
Quantitative Reverse Transcriptase PCR (qRT-PCR): Relative quantification of gene 
expression was performed using the ΔΔCT method using the indicated formula and 
primer pairs: 
Relative mRNA abundance =  2
(!"#$ !"#! !"#" !" !" !"#$%"& !"#$%-!"#$ !"#! !"#" !" !" !"#$%&')
(!"#$ !"# !"#" !" !" !"#$%"& !"#$%-!"#$ !"# !"#" !" !" !"#$%&')  
 
 
Table S2.1: Sequences of primers used in gene transcript detection 
 
Primers: Sequence (5’à3’) 
B2M Fwd tgctgtctccatgtttgatgtatct 
B2M Rev tctctgctccccacctctaagt (product=86 bp) 
GPSM3 Fwd ctccaaactccaccactct 
GPSM3 Rev cagtctgcagggagagcag (product=114 bp) 
 
 
Table S2.2: Sequences of primers used in subcloning GPSM3 promoter 
	
Primers: Sequence (5’à3’) 
Amplification Primer Forward tcaagcagtggtggttgaag 
Amplification Primer Reverse tgaggtccctacagggaatg 
Cloning Primer Forward ggtggtaagcttcccctagaggggagaaactg 
Cloning Primer Reverse ggtggtctcgaggatatcggccctggctct 
	
	
Table S2.3: Sequences of primers used in mutagenizing GPSM3 promoter 
	
Mutagenesis Primers Sequence (5’à3’) 
rs204989 (CàT) sense gtattcactatgcatcaagtgctttattacattattaatacatcaaccc 
rs204989 (CàT) anti-sense gggttgatgtattaataatgtaataaagcacttgatgcatagtgaatac 
rs204989 (TàC) sense gtattcactatgcatcaagtgcttcattacattattaatacatcaaccc 
rs204989 (TàC) anti-sense gggttgatgtattaataatgtaatgaagcacttgatgcatagtgaatac 
rs204990 (GàT) sense cttcctacctcagcctctcatttttccatatctatatctctta 
rs204990 (GàT) anti-sense taagagatatagatatggaaaaatgagaggctgaggtaggaag 
rs204991 (AàG) sense ccccttgtctgcactaaactgtaagtttccaaaatgaaccc 
rs204991 (AàG) anti-sense gggttcattttggaaacttacagtttagtgcagacaagggg 
rs3096688 (AàG) sense ccgcctcagcctcccaaagtgctaggattac 
















Figure S2.1. Schematic representation of the location of GPSM3 Fwd (à) and GPSM3 
Rev (ß) primers relative to the predicted exon/intron architecture described for 
established human GPSM3 gene transcripts (as per ENSEMBL database record 
ENSG00000213654). Open rectangles, exons encoding 5’ or 3’ UTRs; closed 








































Figure S2.2. Template dilution-based tests of qRT-PCR primer efficiencies. 
Threshold values for custom B2M (A) and GPSM3 (B) primers (Table S1) over log10 
serial dilution of cDNA synthesized from whole blood RNA show similar primer 
efficiencies. (C) PCR products from whole blood cDNA following qRT-PCR amplification 
and electrophoretic separation performed on a 4-12% tris/borate/EDTA (TBE) gel: well 1 
– DNA ladder, well 2 – GPSM3 SYBR Green PCR amplicon (114 bp predicted), well 3 – 
















































B2M SYBR Green qPCR Primers
Ct = -3.645(Dilution) + 14.20
R2 = 0.9982




















GPSM3 SYBR Green qPCR Primers







Figure S2.3. PCR confirmation of lack of Mycoplasma spp. and Acholeplasma 
spp. contamination. PCR amplification of highly conserved 16S rRNA coding region 
(lower band) and internal control DNA (upper band) was performed using Lookout® 
Mycoplasma PCR Detection Kit (Sigma-Aldrich, St. Louis, MO), which is sensitive to 10 
genomes per 1 µl. Performed by directly adhering to the manufacturer’s instructions. 
Lane 1: (Positive control) PCR amplification of both the internal control (upper band) 
and Mycoplasma orale DNA fragments (lower band). Lane 2: (Negative control) PCR 
amplification of only the internal control. Lanes 3-7: (Culture supernatants) PCR 
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3.1 - Abstract  
 
G Protein Signaling Modulator 3 (GPSM3) is a leukocyte-specific regulator of G 
protein-coupled receptors, which binds inactivated Gαi·GDP subunits, precluding their 
reassociation with Gβγ subunits. GPSM3 deficiency protects mice from inflammatory 
arthritis and, in humans, GPSM3 single nucleotide polymorphisms (SNPs) are inversely 
associated with rheumatoid arthritis incidence; recently, these polymorphisms were 
linked to one particular SNP (rs204989) that decreases GPSM3 transcript abundance. 
However, the precise role of GPSM3 in leukocyte biology is unknown. Here we show 
that GPSM3 is induced in the human promyelocytic leukemia NB4 cell line following 
retinoic acid treatment, which differentiates this cell line into a neutrophil-like cell line 
(NB4*). Reducing GPSM3 expression in NB4* cells disrupts their migration toward 
leukotriene B4, a chemoattractant involved in initial recruitment of neutrophils to arthritic 
joints, but not migration toward formylated peptides. Our results suggest that the 
arthritis-protective GPSM3 SNP rs204989 may act to decrease neutrophil 




3.2 - Introduction  
Genome-wide association studies (1-3) have highlighted single-nucleotide 
polymorphisms (SNPs rs204989 & rs204991) in a region upstream of the GPSM3 
transcription start site as being inversely correlated to the prevalence of rheumatoid 
arthritis (RA). This GPSM3 SNP association is supported by the protection afforded to 
Gpsm3-deficient mice in an acute model of inflammatory arthritis (4). Histologic analysis 
of synovial tissue from Gpsm3-deficient mice revealed a marked acellularity (4), 
suggesting that protection from developing inflammation relies on a potential cellular 
trafficking defect.  
Neutrophils are leukocytes critical to the activation of inflammation in RA and 
many other autoimmune-related diseases (reviewed in (5)). Neutrophils elicit this 
function following their initial recruitment by early-phase proinflammatory 
chemoattractants. In RA, this early-phase recruitment is mediated primarily by 
leukotriene B4 (LTB4), followed by a LTB4 positive-feedback loop in which recruited 
neutrophils secrete LTB4 and additional chemoattractants (reviewed in (6)). To date, 
work to identify the role of GPSM3 in disease pathophysiology has exclusively focused 
on circulating monocytes, which compose less than 10% of circulating leukocytes (7). 
However, mice made deficient in one of several monocyte chemokine receptors (i.e., 
CCR1, CCR2, and CCR5) do not exhibit significant protection from models of RA 
inflammation (8); furthermore, mice depleted of Ly6Chigh monocytes have no change in 
histopathology (9). Moreover, the initial class of leukocytes recruited to synovial tissues 
in human arthritis is thought to be neutrophils, which migrate in response to a sequential 
cascade of LTB4, IL-1β, and CXCR2 agonists (6). Further support for the primary role of 
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neutrophils in initiating RA inflammation comes from protection afforded to mouse 
strains that are deficient in various proteins required for the recognition or synthesis of 
LTB4, including the LTB4 receptor BLT1 (10), 5-lipoxygenase activating protein (11), 5-
lipoxygenase (12), and leukotriene A4 hydrolase (12).  
The LTB4 receptor, BLT1, is a G protein-coupled receptor linked to pertussis 
toxin-sensitive Gi-subfamily heterotrimers (13), and therefore sensitive to potential 
regulation by GoLoco motif-containing proteins (like GPSM3) that act as Gαi-selective 
guanine nucleotide dissociation inhibitors (14). The role of GPSM3 in neutrophil function 
has not previously been assessed. Here, we identify the expression of GPSM3 in an 
immortalized cell line that can be differentiated towards neutrophil-like function, and 
further identify a selective role for GPSM3 in its migration toward proinflammatory LTB4. 
 
3.3 - RESULTS  
 
3.3.1 - Identification of GPSM3 expression in the ATRA-differentiated NB4 cell 
model of neutrophils 
 
 GPSM3 was undetectable within whole cell lysates of the human acute promyelocytic 
leukemia NB4 cell line. However, upon treatment of NB4 cell cultures with all-trans 
retinoic acid (ATRA), GPSM3 transcript (Fig. 3.1A) and GPSM3 protein (Fig. 3.1B) 
increased in a differentiation-dependent manner concurrently with the established 
differentiation marker CD11b. This ATRA-dependent induction of GPSM3 expression 
also paralleled the acquisition of other markers of differentiated neutrophil function: 
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specifically, the activity of intracellular oxidoreductase enzymes that can reduce 
nitroblue tetrazolium to colored formazan dye (Fig. 3.1C) and morphologic changes 
(Fig. 3.1D; e.g., invagination of the nucleus), both of which have been reported 
previously in ATRA-differentiated NB4* cells (15). 
 
3.3.2 - GPSM3 deficiency impairs LTB4, but not fMLP-induced migration	  
 
We established stable, monoclonal daughter lines from the parental NB4 cell line 
using previously validated short hairpin RNA (shRNA)-expressing lentiviral vectors 
directed against GPSM3 (16). After ATRA treatment, all daughter lines exhibited 
equivalent upregulation of CD11b and equivalent expression of Gβ subunits (Fig. 2A, 
right panel); therefore, the established interaction between GPSM3 and neo-
synthesized, free Gβ subunits (16) does not affect steady-state Gβ levels in this cell 
line. In addition, all daughter lines exhibited equivalent induction of intracellular 
oxidoreductase activity upon ATRA treatment (Fig. 3.2B, right panel). Four NB4* 
monoclonal lines with successful knockdown of GPSM3 expression were each found to 
have disrupted migration towards LTB4 in Transwell migration assays (Fig. 3.2C), 
compared both to scrambled shRNA control lines and to a line expressing an ineffective 
shRNA (i.e., daughter line NB4*-shRNA22.2; Fig. 3.2A&B). Diminished migratory 
response to LTB4 was not correlated with any decrease in mRNA expression of the 
high-affinity LTB4 receptor 1 (LTB4R1); for example, compared to the scrambled 
shRNA control lines, only the NB4*-shRNA19.5 line exhibited a significant difference in 
LTB4R1 mRNA expression (Fig. 3.2C inset, Δ = +56.5%, p < 0.0001) and this difference 
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was an increase in expression. In contrast to the diminished migratory response 
towards LTB4 elicited by GPSM3 knockdown, no significant differences were observed 
in formylated peptide (fMLP)-induced migration toward a number of fMLP 
concentrations (e.g., Fig. 3.2D and S3.2), despite statistically significant differences 
observed in mRNA expression of the high-affinity, Gi-coupled formylated peptide 
receptor 1 (FPR1; Fig. 3.2D inset). 
 
3.3.3 – The phospholipase C inhibitor, U73122, disruptes LTB4-induced migration 
 
Inhibition of phosphoinositide 3-kinase (PI3K) or Mitogen-activated protein kinase 
kinase (MKK), does not significantly affect LTB4-induced Transwell migration; however, 
inhibition of phospholipase C (PLC) ameliorates LTB4-induced migration (Fig. 3.3). 
When m-3M3FBS, a receptor-independent PLC activator, was added to the lower 





3.4 - DISCUSSION 
 
Before its mRNA was cloned (17), GPSM3 protein was first detected in neutrophil 
detergent-resistant fractions by mass spectrometry (18). More recently, RNA-seq 
datasets indicate that human neutrophils have greater GPSM3 mRNA than all other 
types of circulating leukocytes (e.g., NCBI GEO accession number GSE62408 (19)). 
These findings sparked our interest in determining whether GPSM3 was functioning to 
regulate aspect(s) of neutrophil biology. Using RNA-interference to negate the GPSM3 
upregulation found to occur normally in the promyelocytic NB4 cell line upon ATRA 
differentiation, we have now established that GPSM3 is required for the full migratory 
response of a neutrophil-like cell line toward pathophysiologically relevant 
concentrations of LTB4 (20). The migratory response to LTB4 is believed to be 
dependent on the abundance of GPSM3 protein in these cells, given that the NB4*-
shRNA20 monoclonal lines were seen to have an intermediate level of GPSM3 
knockdown efficiency and, in parallel, an intermediate migratory phenotype. Given our 
findings here, we surmise that the synovial acellularity seen in anti-collagen antibody 
challenged GPSM3-deficient mice (4) and the inverse association between RA 
development and the GPSM3 expression-lowering SNP rs204989 (21) could be the 
result of reduced neutrophil recruitment by LTB4. 
 During infections, neutrophil responsiveness to bacterial-derived formylated 
peptides is mediated via formyl peptide receptors (22):  i.e., GPCRs coupled to Gαi-
containing heterotrimers in a similar fashion to LTB4 receptors. However, GPSM3 
knockdown in NB4* cells does not affect migration initiated through the formyl peptide 
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receptor across a gradient of concentrations (Fig. S3.2). We therefore conclude that 
GPSM3 knockdown does not globally affect the chemotactic machinery of NB4* cells, 
but instead leads to a selective abrogation of responsiveness to certain 
chemoattractants, like LTB4 shown here. Future investigations will be directed at 
identifying the specific signaling mechanism(s) regulated by GPSM3 that differentially 
affect LTB4- vs fMLP-induced migration. The effect of GPSM3 deficiency on NB4* 
LTB4-induced migration, coupled with the established role that LTB4 plays in the 
pathogenesis of RA, supports the therapeutic potential of GPSM3-targeted inhibitors in 
the treatment of RA, as we have proposed previously (21).  
 
3.5 – MATERIALS AND METHODS 
 
 
3.5.1 - Cell lines and culture conditions  
 
The human acute promyelocytic leukemia cell line (NB4) was obtained from the Leibniz 
Institute German Collection of Microorganisms and Cell Cultures. Preliminary studies 
were performed on NB4 cells that were a generous gift from Dr. Sherman Weissman. 
Cells were maintained at 37ºC in a humidified, 5% CO2 atmosphere in an ATCC-
modification of RPMI medium supplemented with 10% heat-inactivated fetal bovine 
serum, 100 IU penicillin, 100 µg/ml streptomycin, and 2 µg/ml puromycin. GPSM3 
expression was stably knocked-down via lentiviral transduction (WVU IBC protocol 15-
04-08) as described previously (21). Additional NB4 cell lines were established 
expressing a scrambled shRNA control (Addgene plasmid 1864). Briefly, transduction 
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was performed at a multiplicity of infection of 10 using spinoculation (ref. (23)); 
transduced cells were selected with 2 µg/ml puromycin and monoclonal populations 
established by limiting dilution. All NB4 lines were confirmed free of Mycoplasma spp. 
and Acholeplasma spp. contamination using the Lookout® Mycoplasma PCR Detection 
kit (Sigma-Aldrich, St. Louis, MO; Fig. S3.1). NB4 differentiation was performed as 
previously reported (24) by treatment with complete media containing 1 µM all-trans 
retinoic acid (Acros Organics, Geel, Belgium). Cell density was maintained between 4 x 
105 and 1 x 106 cells/mL. 
 
3.5.2 - Nitroblue Tetrazolium (NBT) reduction 
 
Cells (5 x 105) were resuspended in PBS with 1 mg/ml NBT and 300 nM PMA, then 
incubated at 37ºC and 5% CO2 for 30 minutes. Cells were then washed in PBS twice 
and mounted on slides for visualization of 500 cells per cell population per experiment. 
Formazan-positive (black), -intermediate (gray), and -negative (colorless) cells were 
scored under brightfield microscopy. 
 
3.5.3 - Wright-Giemsa staining 
 
Cells were fixed with 100% methanol for 1 minute, then allowed to air-dry briefly. Cells 
were then stained using Wright-Giemsa stain for 2 minutes, after which 1.5 volumes of 
PBS, pH 6.8 was added, and the cells were allowed to incubate for another 2 minutes. 





3.5.4 - RNA isolation, cDNA synthesis, and quantitative reverse transcriptase PCR 
(qRT-PCR) 
 
RNA was extracted from ATRA-differentiated NB4 cells with the RNeasy kit (Qiagen). 
Briefly, cells were centrifuged at 200 x g for five minutes, and the supernatant was 
removed. Cells were then washed with 1X PBS and centrifuged again to remove 
supernatant. The cell pellet was resuspended in 600 µl of the manufacturer’s lysis buffer 
(RLT) with 1% β-mercaptoethanol. RNA isolation was performed using an automated 
QIAcube workflow according to the manufacturer’s suggested protocol to minimize 
variability between preparations. Eluted nucleic acids were quantified by absorbance at 
260 nm using a Nanodrop 2000 (Thermo Scientific) and assessed for purity using a 
260/280 nm cut-off ratio ≥1.8. Immediately following isolation, a sample of eluted nucleic 
acids (250 ng) from each group of cells was used to synthesize complementary DNA 
(cDNA) with the Thermo Verso Reverse Transcriptase Kit (Thermo Scientific). cDNA 
was then diluted 1:5 and used immediately for qRT-PCR analyses. Samples of cDNA, 
derived from equal mass of input RNA from each sample, were amplified in duplicate 
(with an additional, independent, “no reverse transcriptase-treated” control) using the 
USB VeriQuest Fast SYBR Green qPCR Master Mix (Affymetrix, Cleveland, OH) and 
commercially-validated PCR primers (Qiagen, Hilden, Germany). Cycling conditions 
were established following the manufacturer’s suggested protocol. Relative 
quantification of gene expression was performed using the ΔΔCT method (25) with β-




3.5.5 - Transwell migration assay 
 
shRNA-expressing NB4 cell lines were serum-starved in HBSS + 1% BSA at 37°C for 
one hour and labeled with calcein-AM cell-permeant fluorescent dye (ex. 494 nm/em. 
517 nm). Cells were washed and suspended in HBSS + 1% BSA + 10 mM HEPES, and 
2.5 x 106 cells/ml were loaded into the upper well of Falcon™ HTS FluoroBlok 96-
Multiwell Insert System chemotaxis chambers (Corning, NY). Cells were allowed to 
migrate toward vehicle or 100 nM LTB4 or 100 ng/ml fMLP (R&D Systems, Minneapolis, 
MN) in the lower chamber. Fluorescence was measured at 2-minute intervals over the 
course of 60 minutes at 37°C using a Flexstation 3 microplate reader (Molecular 
Devices, Sunnyvale, CA). All data are representative of biological triplicates with 
technical replicates (i.e., n = 6).  
 
3.5.6 - Antibodies and Western blot 
 
Antibodies targeting GPSM3 (UNC Immunology Core; clone 35.5.1; 1:200 dilution), 
CD11b (Developmental Studies Hybridoma Bank; clone H5A4; 1:200 dilution), pan-
Gbeta (T-20; Santa Cruz Biotechnology; 1:500 dilution) and β-actin (Sigma; 1:2000 
dilution) were purchased from the indicated sources. Horseradish peroxidase (HRP)-
conjugated anti-mouse IgG was purchased from Sigma. Cells were lysed with ice-cold 
RIPA buffer with protease inhibitor (ThermoScientific, Waltham, MA), sonicated on ice, 
then clarified by centrifugation at 20,000 X g for 5 minutes. Protein content was 
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quantified by the Bradford protein assay (ThermoScientific, Waltham, MA) using BSA as 
a standard. Lysates were diluted in Laemmli buffer (BioRad, Hercules, CA) and 
resolved on 8-16% pre-cast SDS-polyacyrlamide gels (BioRad), transferred to 
nitrocellulose membranes, immunoblotted with primary (overnight, 4ºC) and HRP-
conjugated secondary (1:2000 dilution, 2 h at room temperature) antibodies, and 
visualized by chemiluminescence (ECL, ThermoScientific, Waltham, MA).  
 
3.5.7 - Statistical analyses 
 
Area-under-the-curve analyses of Transwell migration assay data were performed over 
the period of migration with post-hoc comparison by one-way ANOVA and accepted the 
null hypothesis of the Brown-Forsythe normality test (p ≥ 0.05). Significance was 
reported as NB4*-shRNA monoclonal line response compared to those of scrambled 2 
and scrambled 3 cell lines. Nonlinear modeling could not be used in these analyses 
because r-squared values were <0.9. All analyses were performed in GraphPad Prism 
6.0 using one-way ANOVA with Bonnferroni or Dunnett’s post-hoc tests where 
indicated. 
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Figure 3.1 – GPSM3 transcript and protein expression are increased during all-
trans retinoic acid (ATRA) differentiation of NB4 cells toward a neutrophil-like 
physiology.  
(A) GPSM3 mRNA abundance in NB4 cells over treatment time with 1 µM ATRA; 
relative expression normalized to cells treated with vehicle (DMSO) for 120 hours. (B) 
Levels of GPSM3 protein and the differentiation marker CD11b both increase with 
ATRA-induced differentiation. (C) ATRA-induced differentiation over time increases the 
neutrophil-specific ability to reduce nitroblue tetrazolium to formazan, as observed by a 
steady increase in formazan-positive (dark) NB4 cells over time. (D) Wright-Giemsa 
stained NB4* cells indicating the acquisition over time of ATRA-induced morphological 




















































































































































F = 0.023; p = 0.9998 






















































































































































































Figure 3.2 – GPSM3 deficiency disrupts NB4* cell migration toward LTB4.  
(A) Immunoblot revealing undetectable GPSM3 and CD11b immunoreactivity within 
whole cell lysates from all shRNA-expressing monoclonal cell lines when these lines 
were mock-differentiated with vehicle only (0.01% DMSO; left panels). Immunoblot 
revealing decreased GPSM3 immunoreactivity after 120 hours of all-trans retinoic acid 
(ATRA) treatment of NB4* cells stably expressing GPSM3-targeted shRNAs shRNA19 
or shRNA20 (right panels). (B) Nitroblue tetrazolium reduction assay indicating that 
>90% of cells within each NB4-shRNA monoclonal cell line are incapable of reducing 
nitroblue tetrazolium after mock-differentiation with vehicle only (0.01% DMSO; left bar 
graph). Following differentiation with all-trans retinoic acid, >87% of differentiated NB4* 
cells were capable of reducing nitroblue tetrazolium, irrespective of expressed shRNA 
species (right bar graph). (C) Real-time Transwell migration towards 100 nM LTB4 over 
60 minutes by indicated NB4* cell lines (after 120 hours of ATRA differentiation). 
Significance (p < 0.05) determined by one-way ANOVA analyses of area under the 
curve with Bonferroni post-hoc. (C insert) Post-differentiated NB4* transcript abundance 
of the LTB4 receptor BLT1 (LTB4R); significance (p < 0.05) determined by Kruskal-
Wallis test (unequal group variances, Brown-Forsythe p < 0.05) with Dunn’s post-hoc. 
All data plotted as mean ± S.E.M. (D) Real-time Transwell migration towards 100 ng/mL 
fMLP over 60 minutes by indicated NB4* cell lines (after 120 hours of ATRA 
differentiation). (D insert) Post-differentiated NB4* transcript abundance of the fMLP 
receptor (FPR1); significance (p < 0.05) determined by Kruskal-Wallis test (unequal 
group variances, Brown-Forsythe p < 0.05) with Dunn’s post-hoc. All data plotted as 




Figure 3.3 – LTB4-induced Transwell migration is disrupted by a phospholipase C 
inhibitor, but not inhibitors of MEK or PI3K. Real-time Transwell migration of NB4* 
cells, pretreated for 30 minutes with indicated inhibitor or vehicle (DMSO), towards 100 
nM LTB4 in the presence of (A) 2 µM U73122 (PLC inhibitor), (B) 10 µM U0126 (MEK 
inhibitor), or (C) 5 µM LY294002 (PI3K inhibitor)(Mean ± S.E.M.). Closed circles indicate 
cells pretreated with vehicle for 30 minutes, and open circles indicate cells pretreated 
with indicated inhibitor. 
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Figure S3.1. PCR confirmation of lack of Mycoplasma spp. and Acholeplasma 
spp. contamination. PCR amplification of highly conserved 16S rRNA coding region 
(lower band) and internal control DNA (upper band) was performed using Lookout® 
Mycoplasma PCR Detection Kit (Sigma-Aldrich, St. Louis, MO), which is sensitive to 10 
genomes per 1 µl. Performed by directly adhering to the manufacturer’s instructions. 
Lane 1: (Positive control) PCR amplification of both the internal control (upper band) 
and Mycoplasma orale DNA fragments (lower band). Lane 2: (Negative control) PCR 
amplification of only the internal control. Lanes 3-9: (Culture supernatants) PCR 
amplification of only the internal control, including HEK 293T cells previously tested to 
be free of Mycoplasma spp. contamination. Lane 10: (Media control) PCR amplification 





















































































Figure S3.2. GPSM3 deficiency does not decrease Transwell migration across a 
concentration gradient of fMLP. Real-time Transwell migration towards fMLP over 60 
minutes by indicated NB4* cell lines (after 120 hours of ATRA differentiation). fMLP 
concentrations included (A) 250 ng / ml, (B) 100 ng / ml, (C) 50 ng / ml, (D) 10 ng / ml, 
(E) 1 ng / ml, and (F) vehicle (DMSO). 
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4.1 – Abstract  
 
NOD-like receptor family, pyrin domain containing 3 (NLRP3) is an 
inflammasome protein that is released from an inactive complex of chaperones in 
response to a wide variety of endogenous and pathogen-derived danger signals.  
G protein signaling modulator 3 (GPSM3) is another leukocyte-restricted protein 
that is a component of the complex that sequesters NLRP3 in the inactive state. 
To initiate an NLRP3-dependent inflammasome response, cells must first be 
‘primed’ to increase transcription of genes coding for components (e.g., NLRP3) 
and substrates (e.g., IL1B) of the inflammasome. Using qRT-PCR and Western 
blot, we identified GPSM3 transcript and protein abundance both decrease when 
human and mouse monocyte cell lines and cells are primed with 
lipopolysaccharide (LPS). Therefore, the decrease in GPSM3 transcription 
probably reduces the stability of the complex of proteins that sequesters NLRP3 
in an inactive state and results in an increase of NLRP3-dependent inflammasome 
activity. 
 
4.2 – Introduction  
 
G protein signaling modulator-3 (GPSM3) is a newly identified signaling regulator 
with prominent expression in myeloid lineage cells, and at lower relative levels in a 
variety of lymphoid tissues 1. GPSM3 (a.k.a. AGS4 or G18;2,3) possesses two functional 
“GoLoco motifs” 3  for binding inactive Gαi-GDP subunits and additionally binds to Gβ 
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subunits during their synthetic pathway towards forming mature Gβγ dimers 4; these 
interactions with heterotrimeric G protein subunits are thought to underlie the effects of 
GPSM3 on chemokine receptor signaling that is critical to the development of 
inflammatory arthritis 1. We previously investigated the role of GPSM3 in NLRP3-
mediated IL-1β secretion, and further identified GPSM3 as a component of the 
chaperone complex that maintains NLRP3 in an inactive state (Appendix 1). Thus, 
establishing a negative regulatory function of GPSM3 on NLRP3-dependent IL-1β 
generation in mice 5. NLRP3 priming with lipopolysaccharide (LPS) and activation with 
S. aureus α hemolysin (HLA) have been shown to increase IL-1β secretion through 
NLRP3-dependent caspase-1 activity 5,6. Furthermore a greater increase of IL-1β 
secretion is observed in Gpsm3-deficient mice 5. It is unknown how this treatment, that 
activates the NLRP3 inflammasome, would affect the transcription of GPSM3 in human 
or mouse cells endogenously transcribing GPSM3. Because GPSM3 is a negative 
regulator of NLRP3 activity, prolonged priming and/or activation of the NLRP3 
inflammasome may decrease transcript abundance of GPSM3 to increase the 
sensitivity of the NLRP3 inflammasome. Here, we investigate the transcriptional 





4.3 – Results and Discussion 
 
4.3.1 – Increased Nlrp3 and Il1b transcript abundance in mouse BMDMs following 
LPS and HLA treatment. 
  
Despite the involvement of GPSM3 in the migration of innate immune cells and in 
mouse models of RA 1, little is known about the regulation of GPSM3 transcription. 
Treatment of mouse bone marrow-derived macrophages (BMDMs) with LPS alone or 
HLA alone resulted in the increase in Nlrp3 and Il1b transcript abundance. BMDM 
priming with LPS and activation with HLA resulted in an additional increase in transcript 
abundance of Nlrp3 and Il1b. This increase was independent of Gpsm3 genotype (Fig. 
4.1A and B). Therefore, GPSM3 is not required to increase the transcript abundance of 
Nlrp3 or Il1b. The lack of effect of GPSM3 is likely due to the G protein-coupled 
receptor-independent mechanisms of action of LPS and HLA, which act through toll-like 
receptor 4 (TLR4; i.e., receptor tyrosine kinase) 7,8 and by forming pores in the cell 
membrane 9, respectively. Nevertheless, GPSM3 deficiency increases secretion of IL-
1β in mouse peritonitis models and isolated BMDMs 5; therefore, GPSM3 probably 






4.3.2 – LPS and HLA treatment decreases GPSM3 transcript and protein 
concentration in human monocyte-like cells. 
 
 Considering the differences in mouse and human immune systems 10, the effects 
of LPS on human THP-1 monocyte-like cell line was investigated to test similarities in 
response between species. In THP-1 cells, treatment with LPS increased IL1B (Fig. 
4.1D) and trended toward increasing NLRP3 transcript abundance (Fig. 4.1E). This 
mimicked the increase in transcript abundance seen in mouse BMDMs. Although not 
addressed, LPS probably primes THP-1 cells by increasing NLRP3 and pro-IL-1β 
protein, thus increasing the amount of IL-1β secreted following activation of the NLRP3 
inflammasome. LPS treatment of THP-1 cells also significantly decreased GPSM3 
transcript abundance (Fig. 4.1C) and protein concentration (Fig. 4.1F). In the absence 
of a priming event, NLRP3 activity is nominal (reviewed in 11); therefore, priming is 
required to mount an effective NLRP3-dependent response to various danger-
associated molecular patterns. When priming occurs prior to activation the translation of 
additional proteins can potentiate NLRP3-dependent IL-1β secretion, with pro-IL-1β 
protein detection in monocytes 30 minute after LPS priming 12. Because GPSM3 is a 
negative regulator of NLRP3-dependent IL-1β secretion 5, LPS-induced decreases in 
GPSM3 transcript and protein abundance may result in increased sensitivity of NLRP3 
to activation stimuli. 
 There is a greater magnitude of decrease of GPSM3 transcript abundance by 
LPS pretreatment followed by HLA, a NLRP3 activator. Although, there is no difference 
in GPSM3 transcript abundance of LPS or vehicle pretreated THP-1 cells prior to HLA 
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treatment (Fig. 4.2). The additional decrease in GPSM3 transcript abundance is likely 
relevant only during prolonged treatment with HLA, and may act to further decrease the 
negative regulation on NLRP3 to prolong secretion of IL-1β. It is also likely that the 
decrease in GPSM3 in the presence of bacterial LPS and HLA results in impaired 
migration once the leukocyte reaches foci of bacterial infections 1 (Fig. 2.5 and 3.2). 
Whether this is protective to the host or the bacteria has not been investigated, but 
could act to prevent leukocytes from migrating away from bacteria. 
 In summary, LPS-induced increases in NLRP3 and IL-1β transcript abundance 
are conserved between human and mouse myeloid cells and cell lines (Fig. 4.1A-E). 
LPS treatment also decreases transcript and protein abundance of GPSM3 (Fig. 4.1C 
and F), a negative regulator of the NLRP3 inflammasome activity. Therefore, decreases 
in GPSM3 concentration likely increases the activity of the NLRP3 inflammasome by 
reducing the inhibitory effect of GPSM3 (Fig. 4.3). Additional studies will be required to 
determine if HLA-induced decreases in GPSM3 transcript abundance (Fig. 4.2) are 
relevant in IL-1β secretion; however, induction of the NLRP3 inflammasome following 
HLA treatment is probably too rapid for transcriptional changes to affect protein levels. 
Nevertheless, continued interest in the affects of other NLRP3 priming agents will be of 
interest. Particularly TNFα, which is involved in the pathology of a number of chronic 





4.4 – Materials and Methods  
 
4.4.1 – Commercial antibodies, constructs, and other reagents. HRP-conjugated goat 
anti-mouse and goat anti-rabbit antibodies were from GE Healthcare (Piscataway, NJ). 
Monoclonal anti-GPSM3 antibody was produced by the UNC Antibody Core Facility and 
has been previously described 14. Recombinant S. aureus α hemolysin was generated 
as previously described 15.  
 
4.4.2 – Cell culture. The human THP-1 cell line was each obtained from the American 
Type Culture Collection (ATCC) and maintained in ATCC-modification of RPMI-1640 
media (Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum (Cellgro, 
Manassas, VA) at 37°C in a humidified atmosphere containing 5% CO2.  
 
4.4.3 – Ex-vivo transcriptional activation. BMDMs and THP-1 cells were resuspended in 
serum-free RPMI 1640 and seeded in 24-wells plate at a density of 1x106 cells/ml/well. 
LPS (100 ng/ml) was added for 3 hours. Subsequently, cells were stimulated with α 
hemolysin (10 µg/ml) for 1 hour.  
 
4.4.4 – Quantitative RT-PCR. THP-1 or bone marrow-derived macrophage (BMDM) 
cells were activated as previously described with LPS (100 ng/ml) and/or α hemolysin 
(10 µg/ml). Cells were harvested and lysed in buffer RLT (Qiagen) + 1% 2-
mercaptoethanol (Fisher Chemical) before immediately being placed on ice. RNA 
extraction was performed using the Qiagen RNeasy kit following manufacturer’s 
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instructions, and isolated RNA was DNase I treated and used to synthesize cDNA 
immediately (Thermo Verso cDNA synthesis kit). Relative gene expression was 
quantified using Veriquest Fast Probe PCR master mix (Affymetrix) and Taqman probes 
(Life Technologies) for GPSM3, NLPR3, and pro-IL-1β normalized to multiplexed β2-
microglobin. Fold change in target gene expression was calculated using threshold 
values by the 2-ΔΔCt method, described by Livak & Schmittgen 16, and statistical 
significance was determined by one-way ANOVA with Bonferroni post-hoc (p<0.05). 
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4.6 – Figures 
	
Fig. 4.1. Transcriptional consequence of LPS treatment in mouse and human 
leukocytes.  Bone marrow derived macrophages (BMDMs) were generated from wild 
type (WT) or Gpsm3-/- mice and primed with LPS for 3 hours with 100 ng/ml and/or 
subsequently treated with α -hemolysin (HLA) for 1 hour, as indicated. Pro-IL-1β and 
NLRP3 mRNA levels in each cell line were assessed using quantitative RT-PCR as 
described in the materials and methods (panels A and B). THP1 cells were treated with 
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were assessed by quantitative RT-PCR (panels C, D, and E).  Data are expressed in 
pg/ml using the means ± S.E.M. of three different experiments (n=8-10); *p<0.05, 
**p<0.01 and ***p<0.001 by one-way ANOVA.GPSM3, NLRP3, and actin (loading 
control) protein levels were also assessed using immunoblot analysis with the indicated 





Fig. 4.2. Transcriptional consequence of a NLRP3 activation treatment on THP-1 
cells.  THP1 cells were treated with LPS (100ng/ml) or vehicle for 3 hours. Then treated 





























































Fig. 4.3. Model of GPSM3 regulation by lipopolysaccharide, and proposed 
influence on NLRP3 inflammasome.  Formation of a network between GPSM3, 
chaperones, and NLRP3 maintains the steady-state level of NLRP3 by stabilizing it 
within the complex. Activation of the inflammasome requires two independent signals. 
Toll-like receptors (TLR) and tumor-necrosis factor receptors (TNFR) are known to 
trigger priming signals leading to up-regulation of NLRP3 and pro-IL1b through a NFkB-
dependent pathway as well as down regulation of GPSM3. The NLPR3 activation signal 
is triggered by endogenous (‘danger-associated molecular patterns’; DAMPs) or 
exogenous (‘pathogen-associated molecular patterns’; PAMPs) danger signals. 
Activation of NLRP3 can also be mediated by bacterial pore-forming toxins such as the 








































































multiprotein complex containing oligomerized NLRP3, the adaptor ASC, and caspase-1. 
Once activated, caspase-1 cleaves pro-IL1b (and pro-IL-18), releasing the biological 




































































Chapter 5: Project insights and future directions 
 
5.1 Functional consequences of GPSM3 gene variants in the clinical setting 
 
Although a great deal of insight has been gained since the advent of minimally 
biased genome-wide association studies (GWAS), there is much research that still 
needs to be completed to fully elucidate the complex genetics of RA. A small sampling 
of milestone GWAS achievements includes the identification of HLA-DRB1 haploblock 
SNP tags, which are in linkage disequilibrium with risk haploblocks and may represent a 
diagnostic mimic for expensive direct HLA typing in the future 1,2. Additionally, the 
discovery of risk alleles in peptidylarginine deaminase (PADI4) 3 supports the previous 
discovery that PADI4 is involved in post-translational citrullination of proteins. 
Citrullination of proteins, in RA, often precedes the production of anti-citrullinated 
peptide antibodies (ACPA) that are often present in patient samples and are used as 
part of the diagnostic panel of tests for RA 4. Despite the successes of GWAS, there are 
a number of limitations of the technique, including the number of false-positive results 
from multiple comparison statistics and linkage disequilibrium 5, which necessitate 
additional confirmation studies, similar to what was performed in PADI4, to identify 
causal gene variants from those simply associated with causal genetic or epigenetic 
variants (e.g., Chapter 2). Once these causal gene variants are identified, additional 
studies are then required to identify their biological significance before they can properly 
be translated to a clinical setting as a genetic biomarker or identify the gene product as 
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a therapeutic target. Multiple prior GWAS publications had identified two single 
nucleotide polymorphisms (SNPs) within the GPSM3 gene locus as inversely 
associated with a number of autoimmune diseases including RA, multiple sclerosis, 
systemic lupus erythematosus, and ankylosing spondylitis in multiple populations 
including European, North American, and Swedish cohorts 6–8. The reproducibility of 
these GPSM3 gene variants warranted further investigation, because Gpsm3-deficient 
mice are afforded a significant protection from joint tissue swelling and proinflammatory 
cell influx into synovial tissues in an acute model of collagen autoantibody-induced 
inflammatory arthritis using the C57Bl/6 mouse strain 9, and in a chronic model of 
heterologous collagen-induced inflammatory arthritis within the DBA-1 background 
(unpublished; Billard, Gall, et al.). We sought to address the translational potential of 
GPSM3 gene variants by initially confirming a functional consequence of inheritance of 
GPSM3 gene variants (Chapters 2 & 5.1.1), and proposing additional valuable 
experiments to identify the mechanisms of action of the identified GPSM3 gene variants 
(Chapter 5.1.2). 
 
5.1.1 – Study of GWAS-identified GPSM3 single nucleotide polymorphisms 
 
 To address transcriptional consequences of previously identified GPSM3 SNPs, 
rs204989 7 and rs204991 6,8, we addressed (1) disease state-dependent differences in 
minor allele frequencies within a case-control cohort of RA patients and matched 
controls, (2) transcriptional consequences of these SNPs, as well as (3) the potential 
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genetic linkage of GPSM3 SNPs with other polymorphisms within the chromosome 
6p21 region with large effect sizes (Fig. 5.1 10; e.g., HLA-DRB1 haplotypes) 11.  
To minimize the chances of not identifying a transcriptionally relevant 
polymorphism in linkage disequilibrium with the previously identified GPSM3 SNPs, we 
performed Sanger sequencing of a 3.5 kb region 5’ to the GPSM3 transcription start site 
that revealed the existence of a novel haploblock of 3 previously reported GPSM3 
SNPs, rs204989 (MAF = 0.2328 12), rs204990 (MAF = 0.2330 12), and rs204991 (MAF = 
0.2348 12; Fig. 2.1A). All 200 volunteers recruited in this study were confirmed to have 
the same minor allele (m) and the major allele (M) genotype for rs204989 and 
rs204991, and all 8 volunteers that were Sanger sequenced were confirmed to have the 
same genotype for each of the 3 GPSM3 SNPs 13. We elected not to sequence the 
coding region of the GPSM3 gene locus, even given that NCBI dbSNP 14 reports three 
polymorphisms with a MAF ≥ 0.01 in that region. Of those three rs22694420 (MAF = 
0.01) and rs117877134 (MAF = 0.01) are intronic and of low frequency, supporting a 
lack of linkage disequilibrium. The final polymorphism, rs3134605 (MAF = 0.23), occurs 
in the second exon of GPSM3 and has a similar frequency of rs204989/rs204991 
haploblock, but is not predicted to be in strong linkage disequilibrium with said 
haploblock 15. Furthermore, rs3134605 is not predicted to affect mRNA secondary 
structure 16 (Fig. 5.2), and results in a synonymous proline-to-proline mutation. The 
effects of rs3134605 will need to be further investigated to better understand its effects 
on GPSM3 mRNA stability, translation efficiency, and role in intron splicing. Precedence 
has been set for synonymous mutations affecting mRNA stability (reviewed in 17). 
However, detecting the rs204989-dependent effect on transcription supports our 
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hypothesis that rs204989 is responsible for the decreased GPSM3 transcript 
abundance observed in whole blood.  
 
Individuals with the m/m genotype of the GPSM3 SNP haploblock were shown to 
have a 24.1% decrease in GPSM3 transcript abundance in whole blood relative to M/M 
volunteers (Fig. 2.1B). The affect the m/m genotype has in the decreased GPSM3 
transcript abundance, potentially mimics the some of the protection afforded by Gpsm3 
deficiency in mouse models of RA. Both the GPSM3 SNP haploblock and genotype-
dependent decrease in transcript abundance were novel findings. From the genotype-
associated decrease in GPSM3 transcript and the 5’ location of the GPSM3 SNPs, we 
developed the hypothesis that the presence of the minor alleles perturbed the normal 
activity of DNA binding proteins, such as histones or transcription factors. We set out to 
first test the hypothesis that these SNPs affected transcription factor interactions with 
each of the GPSM3 SNP loci.  
In determining the role of non-chromosomal protein interaction with the GPSM3 
5’ region containing either the major (pGL3-M) or minor alleles (pGL3-m), we subcloned 
this region into a luciferase vector with minimal promoter activity (pGL3-basic) and the 
firefly luciferase open reading frame. When transiently transfected, the construct 
containing the minor alleles (pGL3-m) resulted in a decrease in firefly luciferase activity 
(Fig. 2.3). From these data, we hypothesize the presence of one or more GPSM3 minor 
allele(s) resulted in a decrease in transcriptional activity of the subcloned region; 
however, the presence of the GPSM3 SNP haploblock meant that we were unable to 
assess the effects of individual SNPs on GPSM3 transcript abundance in collected 
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whole blood, and therefore raised the question of which SNP(s) was/were causing this 
identified genotype-dependent phenotype. This confounder was addressed using 
mutagenesis in the in vitro promoter-driven luciferase model of transcriptional activity 
(Fig. 2.3), where we identified a functional consequence for one of the SNPs, rs204989, 
in the impaired transcriptional activity of the GPSM3 5’ region (Fig. 2.3A and Fig. 2.3B). 
We concluded that the reduced transcriptional activity of the GPSM3 5’ region 
containing the minor allele of rs204989 further supports our findings of genotype-
dependent decrease in GPSM3 transcript abundance in volunteers’ whole blood (Fig. 
2.1B); however, these results were confounded by experimental limitations of our study. 
We encountered difficulties in transfection of leukocyte cell lines (endogenously 
expressing GPSM3) that are resistant to plasmid transfection, potentially via RIG-like 
receptor- or TLR9-dependent immune activation and degradation of plasmid dsDNA 
produced in E. coli, as reported previously in myeloid cell lines 18,19. This resistance 
resulted in low transfection efficiencies in the large reporter plasmids containing the 3.5 
kb region 5’ to GPSM3 (>8 kb total size), and therefore yielded a low signal-to-noise 
ratio when detecting luciferase activity in THP-1 cells (Fig. 5.3). Furthermore, the pGL3 
plasmid used in these experiments lacked a eukaryotic resistance gene (e.g., 
Neomycin-resistance [neo]), which prevented the establishment of stable expressing 
cell lines of each construct, although establishing stable monoclonal cell lines of each 
construct would result in plasmid incorporation into the genome that could result in 
chromatin-induced silencing.   
To counter the difficulties in THP-1 electroporation/transfections, HEK 293T cells 
were used. Although HEK 293T cells do not endogenously express GPSM3 protein or 
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transcript, the activity of the non-genomic plasmid containing each of the GPSM3 
promoters in HEK 293T cells suggests these cells have compatible transcription 
machinery (i.e., transcription factors) to transcribe GPSM3, but there is a genomic 
modification that silences its expression. Correlative bioinformatic data suggests the 
GPSM3 locus is associated with transcriptionally active trimethylated histone H3 lysine 
4 (H3K4me3) 20 in CD14+ monocytes endogenously transcribing GPSM3, but not HEK 
293T cells in ChIP-Seq studies (Fig. 5.4) 21. The association of the GPSM3 gene locus 
with condensed regions of chromatin likely prevents endogenous transcription of 
GPSM3 in HEK 293T cells. Thus, the use of chromatin-independent plasmids for 
transcriptional activity in HEK 293T cells is most likely a viable alternative model that 
mimics the genotype-dependent decreases in GPSM3 transcript abundance from whole 
blood. In cell types that do transcribe the GPSM3 gene, we hypothesized the minor 
allele of rs204989 disrupts transcription factor association and result in the observed 
decrease in GPSM3 transcript abundance in whole blood (Fig. 2.1B). Based on the 
JASPAR transcription factor database 22, we predicted, the AP-1 or C/EBPβ 
transcription factors were most likely to be affected by the minor allele of rs204989 (Fig. 
2.4). AP-1 has been shown previously to undergo nuclear translocation in HEK 293T 
cells 23,24. However, a PubMed search (“[C/EBP] AND [beta] AND [HEK]”) did not return 
a report showing C/EBPβ activity in HEK 293T cells. The paucity of findings indicating 
C/EBPβ activity in HEK293T cells, led us to think the AP-1 transcription factor is 
involved in differential GPSM3 transcription in m/m individuals. We do note that 
transcription factors often bind to relatively promiscuous motifs (Fig. 2.4 and 25) and in 
certain conditions act to repress transcription. Therefore, the involvement of individual 
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transcription factors in GPSM3 transcription requires substantial follow-up in cells 
endogenously transcribing GPSM3 (Chapter 5.1.2a).  
In our case-control cohort we report the GPSM3 minor allele frequencies 
(predicted to be ‘protective’) were trending toward being greater in the RA cohort (Fig. 
2.1C). This trend was the opposite of reports in GWAS in large multiethnic cohorts 6–8. 
We found it surprising that the genotype-dependent decreases in GPSM3 transcript 
abundance and promoter activity (believed to be ‘protective’ in RA) were not reflected 
by decreased minor allele frequencies of GPSM3 SNPs in our RA cohort (Fig. 2.1C). 
Our findings are confounded by the known limitations of small population genetic 
association studies 26 and potential founders’ effect within our local population 27. With 
the IRB restrictions, we could not increase recruitment to address the small population 
size in what was designed to be a primarily functional study. Instead we attempted to 
address potential linkage of the GPSM3 SNPs with rs6457620 [C>G] 28,29 (Odds Ratio = 
2.55 29), an established RA risk locus ~500 kb from the GPSM3 SNPs in the HLA region 
of chromosome 6p21.3 (Fig. 5.1). This HLA region SNP was chosen because of the 
repeated association of HLA region polymorphisms with RA, and to counter the critique 
that GPSM3 SNPs may associate with RA due to linkage disequilibrium with the HLA 
region. We found an association between the GPSM3 SNP minor alleles with the minor 
allele of rs6457620 that was greater than chance distribution within the RA cohort (Fig. 
2.2B), but was not statistically different in the matched cohort (Fig. 2.2C). These 
findings are contrary to RegulomeDB metadata 30 that reports minimal linkage exists 
between the GPSM3 SNP loci and rs6457620. This observed association between 
GPSM3 SNPs and the HLA SNP in our RA population was likely a result of a small 
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sample size or Founder’s effect. Regardless, the coexistence of these two minor alleles 
in our RA population, but not the matched controls, may have masked the protective 
benefits of the GPSM3 SNPs minor alleles by the larger effect size of rs6457620 in the 
RA cohort (reviewed by Holoshitz 11 and Yuta, et al. 31).  
 
From the combined results of: (1) decreased GPSM3 transcript abundance in 
whole blood samples (Fig. 2.1B) and (2) ex vivo analyses of GPSM3 5’ region 
transcriptional activity (Fig. 2.3), we conclude that the GPSM3 SNP rs204989 [C>T] is 
impairing transcription factor binding (Fig. 2.4) likely resulting in the observed decrease 
in GPSM3 transcript abundance in whole blood samples of individuals with the m/m 
genotype. This conclusion is based on our findings of: (1) decreases in activity of 
GPSM3 promoters with the minor allele of rs204989 in HEK293T cells was markedly 
similar to the decrease in whole blood GPSM3 transcript abundance, and (2) because 
transfection of non-genomic plasmids does not assess normal histone or epigenetic 
regulation of gene expression. Confirmation of this hypothesis will be the aim of future 
studies (Chapter 5.1.2a).  
Considering the small effect size of rs204989 on GPSM3 transcript abundance, 
the minor allele of rs204989 in RA may be considered as a clinical biomarker of RA risk 
as part of a larger genetic panel in conjunction with some of the over 100 confirmed RA 
risk alleles 32,33 (reviewed in 31). Regardless, rs204989 is: (1) inversely correlated with 
RA in multiple, large, multiethnic cohorts 6–8, (2) does result in a decrease in GPSM3 
transcript abundance in whole blood (Fig. 2.1B), (3) Gpsm3-deficient mice are protected 
from two models of inflammatory arthritis (unpublished and 9), and (4) GPSM3 depletion 
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disrupts human leukocyte cell line migration toward chemoattractants relevant in RA 
(Figs. 2.5 and 3.2C). Therefore, GPSM3 may rather be a target for pharmaceutical 
inhibition to provide therapeutic benefits in RA patients, rather than a genetic marker. 
This portion of my thesis represents a link between our lab group’s previous findings of 
protection from arthritis-like paw swelling in Gpsm3-deficient mice and begins to 
translate them to humans with natural GPSM3 polymorphisms resulting in deficiency of 
GPSM3 transcript in whole blood.  
 
5.1.2 – Future directions for rs204989 
 
 Future directions for GPSM3 genetics research will be important to confirm our 
findings reported in chapter 2. To address this I propose two individual aims: to identify 
transcription factors affected by rs204989 (5.1.2a) and to determine the consequences 
of the minor allele of rs204989 in leukocyte biology (5.1.2b). 
 
5.1.2a – Identification of transcription-relevant proteins affected by rs204989 
 
 Rationale – 5.1.2a Experiments 1-3: The plasmid-based techniques, employed to 
assess the role of rs204989 on transcription of GPSM3, focused exclusively on HEK 
293T cells and factors independent of epigenetics. Although the plasmid-based model 
in HEK 293T cells is most likely effective in determining transcriptional activity of the 
GPSM3 promoter, follow-up is required to determine which transcription-relevant 
protein’s function is affected by the minor allele of rs204989. In an attempt to identify 
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potential DNA:protein interactions that are disrupted by rs204989, future studies will 
most likely require (5.1.2a Experiment 1) electrophoretic mobility shift assays (EMSA), 
(5.1.2a Experiment 2) electrophoretic mobility super-shift assays (EMSSA), and (5.1.2a 
Experiment 3) transcription factor pull down assays 34.  
5.1.2a Experiment 1: Initially EMSA will be employed to confirm that oligonucleotide 
probes, containing the major allele of rs204989, associate with a nuclear protein within 
NB4* and THP-1 cell line nuclear extracts. We will synthesize a biotin-conjugated 
oligonucleotide sequence that corresponds to either the major or minor allele of 
rs204989. This oligonucleotide will be incubated with nuclear extract from THP-1 or 
NB4* cells, then the mixture will be resolved on a polyacrylamide gel. Based on the 
decreased luciferase activity of plasmids containing the minor allele of rs204989 (Fig. 
2.3), there will likely be a shift in migration patterns of the oligonucleotides incubated 
with nuclear extracts that correspond to a nuclear protein association with the 
oligonucleotide. If no transcription factor can be identified, ChIP-qPCR analyses can be 
performed to determine relative differences between the major and minor allele of 
rs204989 with respect to active (e.g., H3K4me3 20,21) versus inactive (e.g., H3K27me3 
35) states of histones; selection of histone methylation or acetylation states to interrogate 
in these experiments will be based on publically-available ChIP-seq datasets. This line 
of experimentation would be nearly identical to 5.1.2a experiment 3, and address 
whether association with inactive chromatin (heterochromatin) is different in the major 
and minor alleles of rs204989. Therefore, explaining the decreased transcript 
abundance in clinical samples, without a rs204989-localized nuclear protein extract-




5.1.2a Experiment 2: Identification of the transcription-relevant proteins can be 
completed via EMSSA with anti-c-fos (part of AP-1 heterodimer) and anti-CEBP/β 
antibodies (predicted in fig. 2.4) 22. Antibody binding with these proteins would create a 
supershifted band pattern that would confirm the protein associated with the 
oligonucleotides representing the major or minor allele of rs204989. Differential EMSA 
and EMSSA results from oligonucleotide probes containing the major versus minor 
alleles of rs204989 would be indicative of disruption of transcription factor binding. From 
the decreased promoter-driven luciferase activity of rs204989-containing promoters, we 
predict the oligonucleotide containing the minor allele of rs204989 would have 
decreased intensity. If neither antibody induces a super-shifted migration pattern, an 
additional bioinformatics search will be used to identify additional potential transcription-
relevant proteins that may be associating with this oligonucleotide sequence.  
5.1.2a Experiment 3: Primary human leukocytes can then be used to confirm differential 
association of the transcription-relevant protein association with the rs204989 locus can 
be completed with chromatin immunoprecipitation (ChIP). This immunoprecipitation 
would utilize antibodies specific for proteins identified in (5.1.2a Experiment 2) EMSSA 
to precipitate chromosomal DNA associated with that protein. The collected precipitate 
is then analyzed by qPCR determination of relative abundance of the rs204989 locus 
co-precipitated from volunteer leukocytes with either the M/M or m/m genotype36. We 
predict the relative DNA abundance co-precipitated from whole blood of the m/m 
genotype will be less than the M/M genotype. Future identification of a transcription 
factor or chromatin interaction at this locus would validate our previous findings of an 
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apparent decrease in GPSM3 promoter activity and develop a more in-depth 
understanding of transcriptional control of GPSM3. 
  
 Rationale – 5.1.2 Experiment 4: Little is known of processes that regulate the 
transcription of GPSM3. Findings in the literature suggests that lipopolysaccharide37 and 
methotrexate (GEO: GSE35455) both decrease relative GPSM3 transcript, but it is 
inconclusive as to whether that is a GPSM3 promoter repression or a dilution of 
transcript. Identification of a bona fide transcription factor interaction with GPSM3 
promoter elements would provide more conclusive understanding of GPSM3 
transcriptional regulation. This would also confirm the findings in 5.1.2 experiments 1-3, 
by testing how activators or inhibitors of this transcription factor affect GPSM3 transcript 
and protein concentration differently in the presence of the minor allele of rs204989.  
5.1.2 Experiment 4: Insight into proteins involved in transcription whose binding 
to DNA is impaired by the minor allele of rs204989 may lead to additional follow-up 
experiments to determine natural and synthetic molecules that regulate transcription of 
GPSM3. To identify a molecule that affects GPSM3 transcription, we would search 
previous literature for compounds that affect the activity of transcriptional protein(s), 
identified in the proposed EMSA and ChIP experiments, that associate with the major 
allele of rs204989.  For example, if AP-1 is found to differentially associate with the 
major vs minor allele of rs204989, we could treat NB4* and THP-1 cells with an AP-1 
activator, like flagellin (a TLR5 agonist) 38, in the presence or absence of an AP-1 
inhibitor (e.g., SR 11302 39) to confirm AP-1 specificity. If GPSM3 transcript or protein 
levels are affected by this treatment, we can then perform the same experiment using 
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either primary leukocytes (e.g., neutrophils and monocytes) or CRISPR/Cas9-modified 
NB4* and THP-1 cell lines of the M/M and m/m genotypes, to see if there are differential 
effects of these treatments. This experiment would test our hypothesis that the minor 
allele of rs204989 affects transcription factor binding, and further our understanding of 
regulation of GPSM3 transcription.  
  
5.1.2b – Determine the consequences of rs204989 in leukocyte recruitment  
 
 Rationale – 5.1.2b Experiment 1: Our current understanding is that the GPSM3 
SNP rs204989 modulates GPSM3 gene transcription level, but we have yet to answer 
what effects the SNP-dependent decrease in transcription has on the function of 
leukocytes. Classical protein biochemistry has revealed that the GoLoco motifs within 
GPSM3 act to sequester inactive Gαi·GDP, preventing its reassociation into the Gαβγ 
heterotrimer to transact GPCR signaling 40,41. An important class of Gαi-coupled 
receptors in leukocytes is the chemokine receptor class, which initiate various 
processes including chemotaxis 42 and activation of adhesion molecule high affinity 
states 43,44. Previous studies indicated that Gpsm3+/- mice (i.e., heterozygous for 
GPSM3 deficiency) are afforded an intermediate level of protection from an acute model 
of inflammatory arthritis 9; our conclusion, based on these data, is that a ~50% decrease 
in GPSM3 protein expression is still protective from RA-like inflammation in mice. In 
unpublished data there is a time sensitive component to GPSM3 detection by Western 
blot; therefore, it appears that GPSM3 protein is fairly labile and steady-state GPSM3 
protein levels are sensitive to changes in transcript abundance. Therefore, rs204989 
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may decrease transcription of GPSM3 in humans enough to (1) decrease steady-state 
concentrations of GPSM3 protein and (2) confer some protection from RA. However, 
the effect a 24% decrease in GPSM3 mRNA will have on steady-state GPSM3 protein 
levels is unknown. Furthermore, we cannot directly translate the protection afforded to 
Gpsm3+/- mice in CAIA to humans, because there are marked differences between 
mouse and human immunology that must be considered (e.g., differences in blood cell 
subset composition 45 and in chemokine receptor expression 46). Therefore, it is 
important to address how the minor allele of rs204989 affects normal leukocyte 
physiology in relevant human models (e.g., ex vivo leukocyte isolation or CRISPR/Cas9 
genome editing). 
 5.1.2b Experiment 1: With prior approval from the WVU IRB, isolation of primary 
neutrophils and monocytes from M/M and m/m volunteers would be possible by 
negative selection of peripheral blood leukocyte. We will seek assistance from the WVU 
Flow Cytometry core to confirm leukocyte cell type purity. With primary leukocytes from 
these individuals, the effect that the minor allele of rs204989 has on GPSM3 protein 
abundance in leukocytes can be determined. Assuming the decrease in GPSM3 
transcript correlates to a decrease in GPSM3 protein, assessment of leukocyte 
physiology can be performed using these primary leukocytes with previously reported 
techniques including Transwell migration toward neutrophil chemoattractants (e.g., 
LTB4 and IL-8), and adhesion of chemokine-activated leukocytes (e.g., with LTB4 and 
IL-8) to activated vascular endothelial cells. The latter of which would require 
collaboration with a lab group with experience in vascular endothelial cell to leukocyte 
interaction, like the Nurkiewicz lab. If the isolation of primary cells were not feasible, an 
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alternative approach would be to use CRISPR/Cas9-mediated gene editing to introduce 
the minor allele of rs204989 into NB4* and THP-1 immortalized cell line models, 
confirmed to be M/M genotype (unpublished), for use in the same experiments. 
However, the phenotypic effects of the minor allele of rs204989 may be too small to be 
detected at the sensitivity of a Transwell migration assay. Additionally, as discussed 
previously (Chapter 1), leukocytes in vivo are subject to a number of additional barriers 
to migration including (1) vascular shear stress, (2) vascular endothelial cells, (3) 
extracellular matrix, (4) cartilage, and (5) synovial tissues and fluid. Alternatively, 
modifications to the Transwell experimental design may be more representative of 
physiologic conditions and quantitate any minor differences more effectively. To better 
mimic some of these barriers in vitro, modifications can be made to the current 
Transwell migration assay by the addition of Matrigel (a basement membrane extract) to 
the upper chamber of the Transwell plate. A cultured monolayer of vascular endothelial 
cells (i.e., human umbilical vein endothelial cells [HUVEC]) will overlay the Matrigel. The 
addition of relevant chemoattractants to the lower chamber will mimic the 
transendothelial and trans-extracellular matrix migration required for these cells to 
migrate into inflamed synovial tissues. With the additional barriers to migration, this 
modified assay will also likely be more sensitive to small changes in migration rate 
resulting from a minor disruption in signaling owing to the rs204989 allele, potentially 
undetectable in static Transwell migration assays. Additionally, rs204989-dependent 
effects on migration may still be relevant in the context of vascular flow and/or additional 




5.2 – GPSM3 function in leukocytes 
 
 GPSM3 has previously been shown to function in GPCR signaling as a guanine 
nucleotide dissociation inhibitor for Gαi/o subunits: i.e, the protein’s GoLoco motifs 
sequester inactive Gαi/o-GDP subunits inhibiting their reassociation with Gβγ subunits 
41,47. This process is believed to prolong Gβγ-mediated signaling 9, which has been 
shown to be important in the migration of leukocytes toward proinflammatory signals 
44,48,49.  
The highly restricted expression pattern of GPSM3 to leukocytes and lymphoid 
organs led us to hypothesize that GPSM3 acts as a regulator of chemokine receptor 
signaling – one of the most highly expressed classes of Gαi-coupled GPCRs in 
leukocytes 50. Furthermore, our laboratory’s work resulted in the discovery that the 
minor allele of rs204989 (i.e., one of the GWAS-identified GPSM3 gene locus 
polymorphisms) resulted in a decrease in GPSM3 transcript abundance in cells from 
whole blood (Fig. 2.3). Although our laboratory’s collaborative work points to a role for 
GPSM3 in the pathogenesis of RA in mouse models 9 and in negative regulation of 
NLRP3 (appendix I) 37, the effects of GPSM3 deficiency on human leukocytes has yet to 





5.2.1 – GPSM3 deficiency affects neutrophil and monocyte cell line migration 
toward select chemoattractants 
 
Depletion of GPSM3 from the human THP-1 monocyte-like cell line disrupts 
migration toward a gradient of proinflammatory MCP-1 (Fig. 2.5B). The decreased 
migration to MCP-1 was not elicited by changes in mRNA expression of the MCP-1 
cognate receptor, C-C chemokine receptor 2 (CCR2) (Fig. 2.5D). MCP-1 is a 
chemokine known to induce migration of primary monocytes in RA 51,52. However, 
inhibition of MCP-1 signaling through CCR2 has had little success in clinical trials 53, 
likely because of the redundant functions of CCR1 51 and CCR5 51 agonists in monocyte 
/ macrophage recruitment to synovial tissues. Importantly, the role of a single 
chemokine in monocyte migration was studied, in isolation of the pathophysiologic 
conditions where many chemoattractants may be present. However, the advantage that 
GPSM3 deficiency has over mouse Ccr2 knockout models 54, is that Gpsm3-deficient 
mouse monocytes have significantly decreased migration toward multiple 
proinflammatory chemokines (i.e., soluble fractalkine, chemerin, MCP-1) or trending 
toward being decreased (i.e., macrophage inflammatory protein-1α, RANTES) 9. 
Although these studies are in mouse monocytes, a similar global deficit in migration is 
likely replicated in human monocytes. Therefore, disruption of GPSM3 expression or 
function in RA patients may result in inhibition, or reduction in, monocyte migration to 
inflamed synovial tissues in response to multiple pathophysiologic chemoattractants. 
This type of inhibition has not been found with previous clinical trials with single 
monocyte chemokine receptor inhibitors 51,55.  
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However, our findings of impaired in vitro migration in GPSM3 deficient primary 
mouse monocytes did not completely explain the protective phenotype seen in acute 
and chronic models of arthritis. In mouse models of arthritis, prior recruitment of other, 
more abundant, peripheral blood cell types (e.g., neutrophils) may be capable of 
initiating inflammation in the synovial tissues without monocyte migration 54,56–59. From 
these data and the previous mouse model data showing Gpsm3 deficiency protects 
mice from acute and chronic induced-arthritis models, we predicted neutrophils would 
express GPSM3 and deficiency of GPSM3 would result in an impaired GPCR-
dependent migratory phenotype.  Five observations led us to consider neutrophils as 
another leukocyte that expresses GPSM3 including (1) the established involvement of 
neutrophils in the development of human rheumatoid arthritis (Chapter 1.2) 60,61, (2) 
GPSM3 transcript in neutrophils from RNA-seq datasets 50, (3) the detection of GPSM3 
protein in bovine neutrophils 62, (4) higher than expected levels of GPSM3 transcript 
abundance in whole blood vs isolated monocytes (Fig. 2.1B), and (5) the shared 
myeloid lineage of monocytes and neutrophils 45.  
In the immortalized NB4 cell line model of ATRA-differentiated neutrophil-like 
cells (NB4*), we showed that GPSM3 transcript and protein concentrations increase 
with differentiation towards a neutrophil-like state (Fig. 3.1). Similar to the THP-1 
monocyte-like cell line, GPSM3-deficient NB4* cells exhibit an impaired migration 
toward LTB4, a proinflammatory chemoattractant (Fig. 3.2B). The critical involvement of 
LTB4 in the early migration of neutrophils in RA 56–58,63–66, may represent the strongest 
connection between GPSM3 depletion and near acellularity of synovial tissues in mouse 
models of arthritis 9. Furthermore, disruption in neutrophil function by decreased 
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migration may represent another protective function for individuals with the genetic 
variant, rs204989, shown to influence GPSM3 transcript abundance (Chapter 2). 
However, the clinical relevance of rs204989 (and its apparent ~25% reduction in 
GPSM3 expression) may be small, due in part to the observed GPSM3-dependent 
disruption of migration (i.e., shRNA19-mediated knockdown being more complete and 
phenotypically more obvious versus shRNA20-mediated knockdown being less 
complete and phenotypically less robust; Fig. 3.2B). Additionally, the decrease in static 
Transwell migration may be amplified in vivo. At the whole organism level, 
chemoattractant signaling is required to adhere to vascular endothelial cells44,67, release 
enzymes to degrade extracellular matrix molecules68, and to migrate. If GPSM3 
deficiency decreases each of these responses, there will likely be an additive or 
synergistic effect that is not modeled in this study, but will be addressed in future 
experiments (Chapters 5.2.1b and 5.2.2a). 
 Regardless, the clinical relevance of the rs204989-dependent 24.1% decrease 
in GPSM3 transcript should be considered. In the THP-1 cell line, LPS treatment for 3 
hours was shown to decrease transcript abundance by 25% (Fig. 4.1C) and that 
resulted in a reduction of protein concentration (Fig. 4.1F), thus a natural reduction of 
24.1% in whole blood likely decreases protein concentration in these individuals. Such a 
reduction of GPSM3 may not impair Transwell migration of proinflammatory leukocytes 
enough to be considered as a single RA-relevant genetic factor regardless of additional 
effects (e.g., adhesion); however, rs204989 may be useful as part of a genetic 
screening panel in conjunction with other RA genetic risk factors 31. Based on our 
present collection of data, we believe a more promising avenue for GPSM3 is as a 
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target for inhibition by small molecule compounds, which could disrupt chemoattractant 
signaling of proinflammatory cells. This inhibition of signaling through multiple 
chemoattractants simultaneously would likely result in decreased migration. Inhibited 
signaling may also decrease other chemoattractant-dependent processes, for example 
tight leukocyte adhesion44,67 and matrix metalloprotease release68 in RA.  
 However, this assumption may not pertain to all chemoattractant receptors, 
because GPSM3 deficiency did not decrease migration toward N-formylmethionine-
leucyl-phenylalanine (fMLP; Fig. 3.2C). N-formylated peptides (e.g., fMLP) can be 
released from eukaryotic cell mitochondria in necrosis; therefore, may be involved only 
in the late-phase (e.g., once significant necrosis begins) of inflammation 56,69. In host 
defense from bacteria, N-formylated peptides are typically a bacterial-derived 
chemoattractant peptide involved in leukocyte recruitment. The ability of GPSM3-
deficient NB4* cells to migrate toward formylated peptides may represent a novel cell 
response, that is likely due to the constitutively high numbers of formylated peptide 
receptors on neutrophils 50. This could turnover a large amount of G proteins at once, 
thus resulting in Gβγ signaling sufficient to induce migration in the absence of GPSM3 
sequestering inactive Gα subunits. Thus, inhibition of GPSM3 by small molecules could 
have little effect on neutrophil migration toward certain bacterial infections 70, and spare 
the patient from global immunosuppression and risk of infection as is currently found 
with RA biologics.  
Additionally, we must consider the effects of GPSM3 deficiency in the chronic, 
collagen-induced antibody (CIA) model of inflammatory arthritis. It has been shown that 
CIA is dependent on lymphocytes (reviewed in 71), which is further supported by the 
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model’s requirement to be conducted with certain strains of mice (e.g., DBA-1) that 
express specific haploblocks of mouse MHC 72,73 (e.g., H-2q and H-2r) or transgenic 
human HLA 74 (e.g., HLA-DR1) on lymphocytes. Considering GPSM3 is expressed in 
lymphocytes75 and GPSM3 deficiency protects mice from the lymphocyte-dependent 
CIA model (unpublished), GPSM3 may also influence normal B- and T-lymphocyte 
physiology. Thus, the GPSM3-deficient mouse may be afforded an additional level of 
protection from the adaptive immune response in RA. This is supported by observations 
of GPSM3 expression in human lymphocytes and immortalized lymphocytic cell lines 
9,75, as well as the impaired migration observed in mouse lymphocytes deficient in 
GPSM1, a functionally similar GoLoco motif protein 76. Research into the functions of 
GPSM3 in lymphocyte migration and response to autoantigens may represent another 
potential avenue for further investigations, which is currently beyond the scope of this 
project. In summary, GPSM3 may be a highly desirable target for small molecule 
inhibitors. In the clinical setting, GPSM3 inhibition in RA could circumnavigate the 
failures of previous single chemokine receptor-targeted therapeutics 51,77 by working 
downstream of multiple chemokine receptors (e.g., LTB4 and MCP-1) and cell types 
(e.g., neutrophils and monocytes).  
Beyond the role of GPSM3 in the migratory behaviors of monocytes and 
neutrophils, our collaborators have shown that GPSM3 deficiency in mouse bone 
marrow-derived macrophages (BMDMs) results in increased IL-1β release after priming 
with lipopolysaccharide (LPS) and subsequent treatment with NLRP3-activating 
compounds such as S. aureus α-hemolysin (HLA) (Fig. 4.5A-C). This inhibitory effect of 
GPSM3 on NLRP3 function is presumably mediated through a direct or indirect 
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interaction between the leucine-serine-leucine motif of GPSM3 and the 8th leucine-rich 
region of NLRP3 (LRR; Fig. 4.2C, 4.3, and 4.4), as part of a larger NLRP3-inactivating 
complex. Our experimental contributions to this work support the notion that GPSM3 
deficiency does not affect the transcriptional upregulation of Nlrp3 nor pro-il1b in LPS 
+/- HLA treated GPSM3 deficient mouse BMDMs (Fig. 4.6A and B). Thus GPSM3 acts 
to regulate NLRP3 protein activity independent of transcriptional changes. We also 
showed an increase in NLRP3 and pro-IL-1β mRNA abundance in THP-1 human 
monocyte-like cells upon LPS treatment, while GPSM3 transcript and protein 
abundance decreased (Fig. 4.6C and D). Thus, the inhibitory effect of GPSM3 on 
NLRP3 function is a post-transcriptional event. The findings that GPSM3 deficiency 
increases release of IL-1β supports the role of GPSM3 as a negative regulator of 
NLRP3 activity; however, any apparent increase in IL-1β levels is not manifested as 
exacerbated inflammation in the challenged GPSM3-deficient mouse. In contrast, 
protection afforded GPSM3-deficient mice to collagen- and collagen-autoantibody 
models of inflammatory arthritis runs counter to the known proinflammatory effects of IL-
1β in RA (e.g., the clinicial effectiveness of the anti-IL-1 biologic anakinra 78 and the 
blunted course of chronic inflammatory arthritis exhibited by IL-1β-/- mice 79). 
Furthermore, development of collagen-induced arthritis in mice is not altered in either 
NLRP3-deficient or caspase-1-deficient mice 80. Therefore, chronic arthritis models are 
probably dependent on IL-1β production but not dependent on IL-1β from the NLRP3 
inflammasome. The disruption of leukocyte migration in GPSM3-deficient mice probably 
resulted in an apparent inability of proinflammatory cells to reach the synovial tissues. 
Therefore, cells releasing NLRP3-dependent IL-1β in the synovial tissues were 
	
	 184	
presumably restricted to resident tissue leukocytes that are present in relatively small 
numbers compared to what is seen in inflamed tissues. This small number of cells 
would result in a small net change of synovial IL-1β levels upon GPSM3 loss and would 
likely not overcome the effects of GPSM3 deficiency in curbing migration toward 
proinflammatory chemoattractants. To better understand the clinical effects of GPSM3 
on NLRP3 activity, additional studies will need to be performed in human-derived cells.  
 
5.2.2 – Future directions 
 
In summary of 5.2.1, we have shown a role for GPSM3 in the migratory 
phenotypes of neutrophil- and monocyte-like leukocytes toward some (but not all) 
proinflammatory chemoattractants. These studies have confirmed a similarity between 
immune cell dysfunction in our GPSM3-deficient mouse strain and in GPSM3-depleted, 
human-derived cell lines. Although these are correlative data, they may represent a 
causal link between GPSM3 SNP frequency and the prevalence of RA in large 
populations. A role for GPSM3 as a negative regulator of NLRP3 activity in mouse cells 
has also been identified. To address questions that still remain about the function of 
GPSM3 in the immune system, I propose two individual aims: to investigate cell 
migration-relevant phenotypes that are differentially affected by GPSM3 deficiency 
(5.2.2a), and to discover the effects GPSM3 deficiency has on NB4* and THP-1 




5.2.2a – Investigate chemoattractant-relevant functions that are differentially 
affected by GPSM3 deficiency  
 
Rationale – experiment 1 (different migration patterns toward LTB4 and fMLP): 
Our findings that GPSM3 deficiency disrupts LTB4 migration, but not fMLP-induced 
migration, was unexpected (Fig. 3.2B and C). Two possibilities exist here: (1) high 
amounts of formylated peptide receptors in neutrophils turn over enough G proteins to 
negate the role of GPSM3 in prolonging Gβγ signaling (i.e., excess of signaling Gβγ 
subunits) or (2) an uncharacterized mechanism within fMLP signaling is acting that is 
not present for LTB4 signaling. One mechanism may be altered Gβ stability.  In support 
of this hypothesis, GPSM3 has been shown to associate with neosynthesized Gβ 
subunits in intact cells, and with each Gβ isoform (i.e., Gβ1-4) in heterologous 
overexpression studies 81. This observation led to the conclusion that GPSM3 acts as a 
chaperone for neosynthesized Gβ subunits 81. However, GPSM3 knockdown in NB4* 
cells had no omnibus effect on steady-state Gβ protein levels. Considering the different 
isoforms of Gβ have significantly different efficacy at activating some effector molecules, 
like PLCβ isoforms 82,83, GPSM3 may affect the stability and signaling availability of 
certain Gβ isoforms preferentially in vivo. Based on the Gβ isoform that couples to the 
receptor, some receptors may be more affected by GPSM3 depletion thereby affecting 
cell migration differently. 
Experiment 1: To address the (1) first hypothesis (i.e., high number of receptors 
minimizes the necessity of GPSM3) we plan to partially inhibit formylated peptide 
receptor 1 signaling using either shRNA or small molecule inhibition (e.g., 
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BVT17318784). This experiment may determine if fewer responsive receptors may result 
in decreased migration in GPSM3-deficient cells. To follow up on the (2) second 
hypothesis (i.e., a GoLoco-independent function of GPSM3 is affecting signaling), we 
propose restoring expression of either wild-type GPSM3 or variant GPSM3 species with 
lentiviral transduction of various loss-of-function mutations (e.g., crippling one or more 
of the GoLoco motifs responsible for Gαi·GDP binding, or the LSL motif involved in the 
Gβ and NLRP3 interaction). Given that the shRNA19 hairpin used to knockdown 
GPSM3 expression in NB4* cells targets the 3’UTR rather than the open-reading frame, 
we have the ability to restore plasmid-based GPSM3 expression without interference 
from the shRNA. Further experiments would be dependent on the results of which 
GPSM3 mutant(s) do(es) not restore wild-type levels of migration. Alternatively, we can 
investigate the Gβ stability hypothesis using Gβ-isoform specific antibodies to determine 
if there are any changes to specific Gβ isoform levels, indicative of decreased stability in 
the absence of GPSM3 function.  
Rationale – experiments 2 and 3 (physiologic leukocyte migration): Another 
aspect of leukocyte migration that needs to be addressed is the role GPSM3 might play 
in GPCR signaling within a physiologically relevant conditions. Leukocyte recruitment to 
inflamed synovium in pathophysiological conditions requires migration toward multiple 
chemoattractants (experiment 2) and through multiple barriers that were not present in 
Transwell assays (experiment 3). To address this, a modified Transwell migration assay 
will be developed coating the Transwell membrane with Matrigel and vascular 
endothelial cells, to mimic basement membrane and vascular endothelial respectively. 
The requirement of chemoattractant signaling for adherence to vascular endothelial 
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cells44 and to release enzymes to degrade extracellular matrix68 may mean GPSM3 
deficiency affects multiple processes involved in leukocyte transmigration to inflamed 
tissues85. Therefore, GPSM3 deficiency could prevent proinflammatory leukocyte 
migration with greater magnitude than had been seen in previous simple Transwell 
migration assays, although this hypothesis has yet to be addressed directly. 
Experiment 2: To address the role GPSM3 plays in migration toward various 
chemoattractants we propose sequential experiments. First, we propose investigating 
the effects of GPSM3 deficiency in leukocyte migration towards additional disease-
relevant chemoattractants (e.g., complement factor 5a, CXCL8), to better understand 
the broader effects of GPSM3 function in neutrophil-like cells and their migratory 
responsiveness. Additional investigation in the role GPSM3 plays in multiple chemokine 
signaling can be performed in collaboration with the WVU Department of Orthopedics, if 
they are able to collect RA and osteoarthritis patient synovial fluid (SF) for future 
studies. Following characterization of the chemokine content of SF samples, diluted RA 
or osteoarthritis SF will serve as the chemoattractant on the bottom well of a Transwell 
plate, with control and GPSM3-deficient NB4* or THP-1 cells in the upper chamber. 
Alternatively, THP-1-derived macrophage conditioned media could act as another 
source of multiple chemokines. With knowledge of how GPSM3 affects migration toward 
multiple chemoattractants, we may be able to glean further knowledge of its signaling 
function. 
Experiment 3: A modified Transwell migration assay will be used to address the 
effects of GPSM3 deficiency on migration through more physiologic barriers (e.g., 
vascular endothelial cells and basement membrane). To mimic the physiologic 
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vasculature, a sequential layering on the Transwell membrane of Matrigel, a basement 
membrane extract, and TNF-α activated vascular endothelial cells will be used. THP-1 
or NB4* cells will be induced to migrate to the lower chamber by MCP-1 or LTB4, 
respectively. If GPSM3 deficiency results in a decrease greater than what was observed 
in simple Transwell migration assays, we will further investigate the chemoattractant-
induced matrix metalloprotease activity (i.e., measure basement membrane degradative 
enzyme activity)68 and adhesion to vascular endothelial cells (i.e., interaction prior to 
transendothelial migration; experiment 4) (reviewed in 85). Physiologic migration of 
leukocytes in RA is directly addressed in Chapter 1.2.2. A decrease in Transwell 
migration is expected in GPSM3 deficient cell lines based on (1) decreased migration in 
simple Transwell migration assays (Fig. 2.5B and 3.2C), (2) requirement of 
chemoattractant signaling in adhesion to vascular endothelial cells44, and (3) 
involvement of chemoattractant signaling in protease release during migration through 
extracellular matrix68. 
 
Rationale – experiment 4 (adhesion to vascular endothelial cells): A cascade of 
events must occur for leukocyte recruitment to tissues to occur; for example, prior to 
any migration, circulating leukocytes must first adhere to vascular endothelial cells 
proximal to inflamed tissues. Initial, GPCR-independent, sequential, weak interactions 
with constitutively expressed binding molecules occur to promote neutrophil “rolling”. In 
vessels supplying inflamed tissues (e.g., arthritic synovial tissues), chemokines and 
cytokines from the underlying tissue are transported and bound to the luminal surface of 
vascular endothelial cells by glycoaminoglycans 86. Endothelial-bound chemokines 
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induce of β2-integrins to adopt a high-affinity conformation allowing firm adhesion of 
leukocytes, thus allowing transendothelial migration toward inflamed tissues to begin 
87,88. This activation of β2-integrins occurs via intracellular signaling networks – reported 
in recent studies to be mediated (in part) through G protein βγ signaling 44, which is 
hypothesized to be prolonged by the Gαi·GDP-sequestering action of GPSM3. It is 
important to address whether there is a GPSM3-dependent effect on leukocyte firm 
adhesion, because adhesion is an obligatory first step to leukocyte recruitment; 
therefore, an impairment in adhesion of GPSM3-deficient leukocytes may have an 
additive or even synergistic effect with the observed impairment in migration on total 
leukocyte recruitment in vivo.   
Experiment 4: In collaboration with the Nurkiewicz laboratory, establishment of 
an ex vivo flow chamber is possible to assess NB4* and THP-1 cell adhesion to 
activated Human Umbilical Vein Endothelial Cells (HUVEC). Use of TNF-α, an activator 
of endothelial cells, will be used to activate HUVEC cells, and pretreatment of NB4* or 
THP-1 cells with a relevant chemoattractant will activate the high-affinity state of β2-
integrins. Physiological shear stress for post-capillary endothelial cells will be 
established, and time-lapsed images of the flow of NB4* or THP-1 cells across the 
activated HUVECs will be reviewed to quantify rolling versus adherent cells, as shown 
previously in 89. Alternatively, GPSM3-deficient mice can be used for intravital 
microscopy to determine if there is an effect on adhesion in vivo. If there is not a 
significant effect of GPSM3 deficiency on leukocyte firm adhesion, this would be a novel 
finding that would be valuable to present alongside our existing data indicating the effect 
of GPSM3 deficiency on migration. A decrease in leukocyte cell line adhesion is 
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expected, because of the requirement of chemoattractant signaling in leukocyte firm 
adhesion44. 
 
Rationale – experiment 5 (phagocytosis of bacteria): Before proposing GPSM3 
as a therapeutic target for RA, potential advantages over current treatments should be 
considered. The most effective treatment is currently “combination therapy” with a 
disease-modifying antirheumatic drug (DMARD), like methotrexate90, and a biologic, the 
most popular being the TNFa inhibitors91 (e.g., etanercept, adalimumab). However, this 
therapeutic strategy is hindered by an increased risk of serious infections92,93, due in 
part to the systemic immunomodulatory role of TNFa94–96. Given this limitation, 
considering how GPSM3 functional deficiency (i.e., shRNA) affects responses to 
bacterial challenges is important. In mouse models Gpsm3-deficient mice exhibit 
abrogated joint inflammation following induction of either acute collagen antibody-
induced arthritis (Fig. 1) or chronic collagen-induced arthritis (Fig. 2); moreover, these 
mice show no overt signs of increased risk of infection during normal animal 
husbandry9,97. GPSM3 deficient NB4* cell lines are also capable of migrating toward 
formylated peptides, which are involved in leukocyte migration toward bacteria (Fig. 
3.2D). Thus, these data suggest that GPSM3 may represent a therapeutic target for 
pharmaceuticals that are both RA-specific and lack the risk of decreased bacteria-
induced immune responses associated with the currently used TNFa inhibitors98. 
Experiment 5: To address the effects of GPSM3 deficiency on phagocytosis of 
bacteria, bacterial particles labeled with a pH-sensitive fluorescent marker will be used. 
To model a physiologic tissue environment, cell models will represent the differentiated 
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state of neutrophils (NB4*) and tissue macrophages (differentiated THP-1*) within 
peripheral tissues when functioning in host defense99,100. The co-culture of labeled 
bacterial particles with NB4* or macrophage differentiated THP-1 cells (THP-1*) will 
allow the leukocyte cell models to phagocytize bacterial particles within phagosomes. 
These phagosomes will then acidify and activate pH-sensitive fluorophores on the 
bacterial particles. Measurement of fluorescence in real-time will allow quantification of 
the effect of GPSM3 deficiency on phagocytosis. Only minimal disruption of 
phagocytosis in GPSM3 deficient cells is expected, based on: (1) the dramatic 
downregulation of GPSM3 expression (to undetectable levels) seen during the 
differentiation pathway to mature macrophages,9 an important tissue phagocyte, (2) 
phagocytosis is driven primarily by Gαi-independent signaling processes (e.g., Toll-like 





5.3 – Figures 
	
Figure 5.1 –Manhattan plot of association statistics highlighting all autosomal loci 
associated with rheumatoid arthritis in this study. The P values of association to 
ACPA-positive rheumatoid arthritis from the meta-analysis of the Immunochip and 
GWAS data are shown. Known and newly identified rheumatoid arthritis risk loci are 
shown in red and black, respectively. The GPSM3 gene locus exists ~500 kb from the 
MHC region (P < 10-100), and may explain some of the inverse association with RA. 
Three associated loci (identified by asterisks) only reach P < 5 × 10−8 when both ACPA-
positive and ACPA-negative cases are included in the analysis. The dashed gray line 
indicates genome-wide significance (P = 5 × 10−8). Figure and legend adapted from 
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GPSM3 mRNA rs3134605 [A>G]
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Figure 5.2 – Predicted lack of mRNA structural consequences of GPSM3 SNP 
rs3134605 [A>G]. Bioinformatic prediction using RNAfold 16 of GPSM3 mRNA 
secondary structure reveals there are no predicted changes in transcript structure. The 







Figure 5.3 – Functional consequences of SNPs rs204989, rs204990, rs204991, and 
rs3096688 on GPSM3 promoter activity in THP-1 promyelocytic cells. Functional 
results upon subcloning a 3.5 kb-region immediately 5’ to the GPSM3 transcription start 
site from M/M and m/m genotype volunteers, leading to wild type (pGL3-M) and 
“minor”/polymorphic (pGL3-m) promoter-driven expression of firefly luciferase in THP-1 
cells. Luciferase activity is reported as a ratio of GPSM3 promoter-dependent firefly 
luciferase activity (FLuc) to control Renilla luciferase activity (pRL-TK control vector). 
 



































 THP-1 cells transfected with pRL-TK and
indicated plasmid (2.24x1011 copies/transfection). 
Data normalized to RLuc activity (Mean with SEM).
p = 0.0135






Figure 5.4 – Publically available HEK 293T and CD14+ monocyte H3K4me3 Chip-
Seq data, from Thurman, et al.21, for (A) HEK 293T and (B) CD14+ monocytes, 
retrieved from NCBI (NC_000006.12 GRCh38.2). Red boxes highlight the GPSM3 gene 
locus, light green boxes are GPSM3 untranslated regions (UTR), dark green boxes 
represent coding regions of the GPSM3 locus, and blue peaks represent the number of 
fragments per kilobase of transcript per million mapped reads (FPKM). The amplitude of 
the blue peaks represent the likelihood that genomic regions are associated with 
trimethylated H3K4. 
  
HEK 293 H3K4me3 








in RA SF 
(pg/ml) ± S.D. 
Concentration 
in OA SF 
(pg/ml) ± S.D. 
P value 
Eotaxin / CCL11 2.6 ± 0.9 1.5 ± 1.0 0.003 
Growth-related oncogene 
alpha (GROα) / CXCL1 101.4 ± 164.0 4.9 ± 6.6 0.033 
IL-8 / CXCL8 161.2 ± 187.4 8.2 ± 14.5 < 0.0001 
Monocyte chemotactic 
protein 1 (MCP-1) / CCL2 75.7 ± 147.1 30.3 ± 18.9 0.073 
Regulated on activation, 
normal T-cell expressed 
and secreted (RANTES) / 
CCL5 
7.0 ± 6.6 1.4 ± 37.9 0.021 






# = patients with non-inflammatory arthritis. 
Table 5.1 – Chemoattractant concentrations in synovial fluid samples of patients 
with rheumatoid arthritis (RA) and osteoarthritis (OA), adapted from Hampel, et 
al.103 and Klickstein, et al.104. For the first 5 chemoattractants 10-20 ml of synovial fluid 
(“SF”) were collected during total knee alloarthroplasy. Chemokine concentration was 
performed with 9-plex chemokine array (Quansys Biosciences; Logan, UT, USA). For 
LTB4, synovial fluid was collected by aspiration from knee joints, and HETE was 
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A1.1 – Abstract 
Inflammasomes are multi-protein complexes that regulate maturation of the 
interleukin 1β-related cytokines IL-1β and IL-18 through activation of the cysteine 
proteinase caspase-1. NOD-like receptor family, pyrin domain containing 3 
(NLRP3) protein is a key component of inflammasomes that assemble in 
response to a wide variety of endogenous and pathogen-derived danger signals.  
Activation of the NLRP3-inflammasome and subsequent secretion of IL-1β is 
highly regulated by at least three processes: transcriptional activation of both 
NLRP3 and pro-IL-1β genes, non-transcriptional priming of NLRP3, and final 
activation of NLRP3. NLRP3 is predominantly expressed in cells of the 
hematopoietic lineage. Using a yeast two-hybrid screen, we identified the 
hematopoietic-restricted protein ‘G protein signaling modulator-3’ (GPSM3) as an 
NLRP3-interacting protein and a negative regulator of IL-1β production triggered 
by NLRP3-dependent inflammasome activators. In monocytes, GPSM3 associates 
with the C-terminal leucine-rich repeat domain of NLRP3. Bone marrow-derived 
macrophages lacking GPSM3 expression exhibit an increase in NLRP3-dependent 
IL-1β, but not TNF-α, secretion. Furthermore, GPSM3-null mice have enhanced 
serum and peritoneal IL-1β production following Alum-induced peritonitis. Our 






A1.2 – Introduction  
 
Phagocytic mononuclear cells such as monocytes and macrophages respond to 
host and environmental cues through numerous signal transduction pathways to 
coordinate inflammatory responses.  The release of IL-1β and IL-18 from these cells 
plays a major role in inflammatory responses to challenge with infectious agents and in 
aseptic inflammatory conditions 1. These cytokines are produced as inactive 
cytoplasmic pro-cytokines and require specialized proteolytic processing and secretion 
mechanisms in order to be released as biologically active molecules. The proteolytic 
processing is carried out by a specific cysteine proteinase, caspase-1 2. Caspase-1 is 
synthesized as an inactive pro-enzyme and activation of procaspase-1 is tightly 
regulated 3.  Multiprotein complexes known as inflammasomes activate caspase-1 in 
response to numerous pro-inflammatory stimuli 4. While all inflammasomes activate 
caspase-1, inflammasomes are assembled from various core protein components, each 
of which has a defined range of triggers.  
 
 Inflammasome activation of procaspase-1 is ultimately responsible for proteolytic 
processing of the precursors of IL-1β and IL-18 into mature, active cytokines 4. In 
addition to procaspase-1, inflammasomes are known to contain other cellular proteins, 
including the adapter proteins ‘Apoptotic Speck protein containing a Card’ (or ASC) and 
Cardinal (also known as CARD8 or TUCAN), as well as a NOD-like receptor (NLR) 
protein family member 4. The mammalian genome encodes approximately 23 NLR gene 
family members, each defined by a conserved tripartite protein structure of a variable 
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number of leucine-rich repeat at the carboxyl terminus, a central nucleotide-binding 
oligomerization domain, and an amino-terminal effector domain. Most NLR effector 
domains are either caspase activation and recruitment domains (CARD), leading to the 
designation NLRC, or pyrin domains, leading to the designation NLRP 5. The 
immunologic signaling pathways within which many of these NLR proteins participate 
have been elucidated both through genetic disease associations and through cell 
biological and biochemical analyses of their function 6.  
 
 Of all inflammasome-forming proteins, NLRP3 is activated by the broadest range 
of stimuli and has been implicated in the pathogenesis of a wide array of 
autoinflammatory conditions, sterile inflammatory conditions, and infectious diseases. 
Monosodium urate and calcium pyrophosphate crystals, underlying causes of the sterile 
inflammatory arthritides gout and pseudogout, cause the activation of caspase-1 and 
secretion of IL-1β; macrophages from NLRP3-deficient mice fail to secrete IL-1β in 
response to either stimuli 7. Additionally, crystals linked to various other pathologic 
inflammatory processes are known to signal through NLRP3, including asbestos, silica, 
and β-amyloid fibrils 8-10. Aluminum hydroxide (Alum), a vaccine adjuvant used in 
humans, also stimulates the release of NLRP3-inflammasome-processed cytokines. 
NLRP3-deficient mice have blunted immunologic responses to vaccinations 
accompanied by aluminum hydroxide, suggesting that NLRP3 plays an important role in 
the adaptive immune response in this setting as well 10,11. In addition, several 
biochemical moieties produced by infectious disease agents or host inflammatory 
processes, named pathogen-associated molecular patterns (PAMPs) and damage-
	
	 217	
associated molecular patterns (DAMPs), are known to activate the NLRP3-dependent 
inflammasome; PAMPs and DAMPs include pore-forming toxins, pathogen-related RNA 
and DNA species, host cell-derived ATP and DNA, and hyaluronan generated from 
cellular damage 12.  Activation of the NLRP3 inflammasome in response to these 
diverse stimuli is controlled by a series of transcriptional and post-transcriptional 
mechanisms that include upregulation of NLRP3 and involvement of the chaperonin 
HSP90 and the deubiquitinase BRCC3 13-15. 
 
Some of us have recently described functional studies of G protein signaling 
modulator-3 (GPSM3), a newly identified signaling regulator with prominent expression 
in myeloid lineage cells, and at lower relative levels in a variety of lymphoid tissues 16. 
GPSM3 (a.k.a. AGS4 or G18; 17-18) possesses two functional “GoLoco motifs” 18 for 
binding inactive Gαi-GDP subunits and additionally binds to Gβ subunits during their 
synthetic pathway towards forming mature Gβγ dimers 19; these interactions with 
heterotrimeric G protein subunits are thought to underlie the effects of GPSM3 on 
chemokine receptor signaling that is critical to the development of inflammatory arthritis 
16. More recently, we have described GPSM3 as also interacting directly with the 
adaptor protein 14-3-3 20. To identify additional interacting partner(s) that might be 
involved in GPSM3-mediated signalling regulation, a yeast two-hybrid screen was 
performed using full-length GPSM3 as bait. This screen 19 identified one clone encoding 
a C-terminal fragment of NLRP3. Based on their co-expression in myeloid lineage cells 
and the discovery of their potential association by yeast two-hybrid screening, we 
investigated the role of GPSM3 in NLRP3-mediated IL-1β screening, we investigated 
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the role of GPSM3 in NLRP3-mediated IL-1β production and further characterized this 
association using biochemical approaches. Our data indicate a modulatory function of 
GPSM3 on NLRP3-dependent IL-1β generation. 
 
A1.3 – Results  
 
A1.3.1 – GPSM3 interacts with the C-terminal end of NLRP3 
 
Yeast two-hybrid screening for potential GPSM3-associated proteins within a 
commercial, 106 clone human leukocyte cDNA library identified NLRP3, a critical 
component of the monocyte inflammasome complex, as a potential GPSM3-interacting 
protein. Fig. 4.1A shows the growth under auxotrophic selection of yeast transfected 
with the cDNA encoding full-length GPSM3 fused to the Gal4 DNA binding domain (bait) 
and the NLRP3-transcriptional activation domain fusion encoding the partial NLRP3 
clone initially retrieved in the screen (prey). Sequence analysis of this prey clone 
revealed the last four leucine-rich repeats of NLRP3 (a.a. 831-979) in frame with the 
Gal4-transcriptional activation domain (Fig. 4.1B). To further characterize this 
interaction, cDNA encoding HA epitope-tagged NLRP3 and FLAG epitope-tagged 
GPSM3 were co-transfected in HEK293 cells which do not express either protein 
endogenously. Full-length NLRP3, as well as its C-terminal fragment (a.a. 831-979), 
were each efficiently co-immunoprecipitated with GPSM3 using anti-Flag antibodies 




Our group has previously described different point mutations to GPSM3 that 
abolish specific interactions with its known heterotrimeric G protein binding partners: 
Gαi·GDP and monomeric Gβ subunits. For example, mutation to phenylalanine of two 
arginines at positions 81 and 152, within the critical triad sequences of the first and third 
GoLoco motifs, completely abolishes direct interaction with Gαi·GDP subunits (herein 
described as the ‘RF mutant’) 22 (Fig. 4.1B). Moreover, the point mutations 58LSL60-to-
PLP, within a leucine-rich motif upstream of the first GoLoco motif, dramatically reduce 
the association of GPSM3 with monomeric Gβ subunits (herein described as the ‘LSL 
mutant’) 19 (Fig 4.1B). While the RF mutation did not perturb co-immunoprecipitation 
between GPSM3 and NLRP3, the LSL mutation decreased the ability of GPSM3 to 
interact with full-length and truncated NLRP3 (831-979) suggesting a common 
interacting protein or shared binding site (Fig. 4.1C and D, last lane), in a fashion similar 
to that observed for the GPSM3/Gβ interaction 19. To demonstrate that the 
GPSM3/NLRP3 association is not an artifact of protein overexpression, co-
immunoprecipitation of endogenous NLRP3 and GPSM3 was performed from the 
human monocytic cell line, THP-1. A sheep polyclonal anti-NLRP3 antibody was used to 
immunoprecipitate endogenous NLRP3 and associated proteins. The 
immunoprecipitated complexes were analyzed for the presence of GPSM3 using 
immunoblot with a mouse monoclonal anti-GPSM3 antibody 20,22. Immunoprecipitation 
with anti-NLRP3 antibodies led to capture of detectable endogenous GPSM3 as well as 





A1.3.2 – Mapping the GPSM3-interaction site(s) within NLRP3 
 
To further characterize the GPSM3/NLRP3 interaction, bioluminescence 
resonance energy transfer (BRET) was used to identify the minimal GPSM3-interaction 
domain within NLRP3. Full-length GPSM3, fused to the resonance donor Renilla 
Luciferase (RLuc-GPSM3) was co-expressed with fusion proteins comprising various 
domains of NLRP3 fused to the acceptor fluorescent protein GFP10 (GFP10-NLRP3, 
Fig. 4.2A). Any interaction between RLuc-GPSM3 and the NLRP3 domain-GFP10 
fusion proteins brings the luciferase donor and GFP acceptor proteins into close 
proximity, allowing energy transfer. Cellular co-transfection with a fixed quantity of 
RLuc-GPSM3 plasmid and a titration of increasing amounts of GFP10-NLRP3 (full-
length) plasmid generated a saturable signal (Fig. 4.2B) with a maximum net BRET ratio 
of 0.3. Furthermore, when the RLuc-GPSM3 fusion contained the LSL mutation, the 
BRET signal with GFP10-NLRP3 was lost (Fig. 4.2B).  Fig. 4.2C summarizes BRET 
experiment results between RLuc-GPSM3 and a variety of GFP10-NLRP3 truncation 
constructs (Fig. 4.2A). Expression of RLuc-GPSM3 with GFP10 fusion protein encoding 
solely the Pyrin domain of NLRP3 (Fig. 4.2C) gave no observable BRET signal. 
Truncation of individual leucine-rich repeat (LRR) domains, starting from the C-
terminus, revealed the importance of the last LRR (aa 911-932) to the GPSM3/NLRP3 
interaction, as ~50% of the signal was lost following its removal. However, a GFP10 
fusion protein encoding both the pyrin and NBD domains (GFP10-NLRP3 536 stop) also 




This BRET-based evidence of interaction with the N-terminal region of NLRP3 
was not expected, given that the cDNA clone retrieved from the yeast two-hybrid screen 
contained only the last 4 LRRs of NLRP3 and interaction between GPSM3 and this C-
terminal NLRP3 fragment was confirmed by reciprocal co-immunoprecipitation (Fig 4.1). 
One possible explanation for also detecting a GPSM3 interaction with the NLRP3 N-
terminal region is that the NBD domain is known to interact with the C-terminal LRR 
portion, forming an intramolecular hairpin-like structure 26. It is thus possible that, within 
this cellular context, the NBD domain of NLRP3 interacts with endogenous NLR 
proteins that might also interact with GPSM3. To determine whether GPSM3 could 
interact with the NLRP3 C-terminus without bridging by the NLRP3-NBD domain, we 
made a GFP10 fusion construct expressing only the C-terminal LRRs of NLRP3 
(GFP10-NLRP3-LRR). Additionally, a truncation of the GFP10-NLRP3-LRR fusion 
lacking the last LRR (a.a. 911-932) was generated. As expected, the construct 
containing all the C-terminal LRRs (i.e., NLRP3 without its pyrin and NBD domains) was 
sufficient to generate a robust BRET signal (Fig 4.2D). Removal of the final LRR 
abolished the BRET signal, confirming that the last LRR is required for interaction with 
GPSM3. Removal of the residual C-terminal extension beyond the final LRR domain 
(i.e., “NLRP3 934 stop”) had no effect on the GPSM3/NLRP3 interaction as measured 
by BRET (Fig. 4.2D). The interaction between GPSM3 and the GFP10-NLRP3-LRR 
fusion protein was also confirmed by co-immunoprecipitation. As also observed in the 
BRET assay, the coimmunoprecipitation of GPSM3 and the GFP10-NLRP3-LRR fusion 
protein was disrupted by deletion of the last LRR domain, but not the residual C-




A1.3.3 - Subcellular localization of the GPSM3/NLRP3 interaction  
 
We employed a third protein-protein interaction assay, bimolecular fluorescence 
complementation (BiFC), to confirm the interaction between GPSM3 and NLRP3 as well 
as to study the localization of their complex, using previously described methods 20,22. 
The N-terminal portion of the yellow fluorescent protein (YFP) was fused to full-length 
GPSM3 (“YN-GPSM3”) and the C-terminal part of YFP was fused to full-length NLRP3. 
When expressed alone or with the non-fused counterpart, no detectable fluorescence 
was measured. However, when both fusion proteins were expressed together (YN-
GPSM3 + NLRP3-YC), a fluorescent signal was detectable in transfected cells (Fig. 
4.4). As further confirmation of the co-immunoprecipitation and BRET results (Figs. 4.2 
and 4.3), the LSL mutation in GPSM3 greatly reduced the BiFC signal (Fig. 4.4A). The 
YN-GPSM3/NLRP3-YC complex was seen to form punctate structures throughout 
transfected cells as observed by fluorescence microscopy (Fig. 4.4B). Ectopic 
expression of the GFP10-NLRP3 fusion, which is fluorescent without binding the 
GPSM3 partner, was also observed to form similar punctate structures, suggesting that 
the GPSM3 interaction does not trigger this subcellular localization phenomenon nor 
perturb the localization of overexpressed NLRP3 (Fig. 4.4B). These large dots are likely 
oligomers of NLRP3 similar to those observed by others using immunofluorescence 
based studies of overexpressed NLRP3 or activation of native NLRP3 in NLRP3-




A1.3.5 – Functional effects of the GPSM3/NLRP3 interaction on NLRP3-dependent 
IL-1β secretion 
 
To test the hypothesis that the GPSM3 interaction regulates NLRP3 function and 
inflammasome activation, bone marrow-derived macrophages (BMDMs) were 
generated from GPSM3-deficient mice 16 and IL-1β secretion quantified following 
inflammasome activation. Inflammasome-dependent IL-1β secretion requires initial 
priming using lipopolysaccharide (LPS) to induce pro-ILβ synthesis 30,31. Following LPS 
stimulation, different inflammasome activators were added and mature IL-1β secreted in 
the medium was quantified. Activators of the NLRP3-dependent inflammasome 
including ATP, α-hemolysin (aHL), and Alum induced robust IL-1β secretion with a 
significant increase in IL-1β secretion in Gpsm3-/- mice after 4 hours of stimulation 
compared to littermate control mice (Fig 4.5A-C left panels). As expected, NLRP3-
deficient mice showed no observable IL-1β secretion (Fig. 4.5A-C left panels). 
Inflammasome activation is known to trigger release of IL-1β but not that of cytokines, 
like TNF-α, not dependent on Caspase-1 activation 25. TNF-α was also quantified in the 
culture supernatants from these stimulated macrophages and found to be secreted to 
the same extent by all three-mouse genotypes (Fig. 4.5A-C right panels); these results 
suggest that GPSM3 regulation of cytokine secretion is specific for those dependent on 
NLRP3-mediated Caspase-1 activation. 
 
The specificity of GPSM3 for the NLRP3 inflammasome signalling pathway was 
also tested using dsDNA stimulation, an AIM2-inflammasome activator 32, and a flagellin 
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derived peptide known to activate the NLRC4-inflammasome 33. BMDMs isolated from 
AIM2-, NLRC4- and NLRP3-deficient mice were used as controls. At 18 hours post-
treatment, dsDNA was found to induce a similar release of IL-1β secretion in BMDMs 
from WT mice as compared to Gpsm3-/- mice. As predicted, BMDMs from Aim2 -/- mice 
failed to secrete IL-1β upon dsDNA stimulation; notably, NLRP3-deficient BMDMs were 
found to have increased IL-1β release compared to BMDMs from WT control and 
Gpsm3-/- mice (Fig. 4.5C). Similarly, BMDMs from Nlrc4 -/- mice showed a significant 
decrease in IL-1β secretion in response to flagellin, as expected 33 (Fig. 4.5D). 
Importantly, GPSM3-deficient and WT BMDMs responded equally to dsDNA and 
flagellin as an inflammasome stimulator (Fig. 4.5D-E), suggesting that GPSM3 
regulation of inflammasomes is limited to the NLRP3-inflammasome.  
 
To explore the involvement of GPSM3 in NLRP3-dependent inflammasome 
activation in a more physiological context, we employed a model of Alum-induced 
peritonitis and quantified resultant IL-1β production from peritoneal lavage and blood 
serum. Gpsm3-/-, Nlrp3-/- and wild type littermate control mice were first pretreated 
intraperitoneally (i.p.) with LPS and subsequently injected two hours later with Alum, an 
NLRP3-dependent inflammasome activator 25. Peritoneal exudate and peripheral blood 
were both collected and cytokine content quantified. We observed that mature IL-1β 
secretion was higher in the lavage and serum of Alum-treated Gpsm3-/- mice compared 





To explore the mechanism by which GPSM3 regulated NLRP3-dependent IL-1β 
secretion, we undertook studies of NLRP3, IL-1β, and GPSM3 expression in 
macrophages and THP1 human monocytic cells. WT and Gpsm3-/- macrophages 
exhibited equivalent induction of NLRP3 and Pro-IL-1β mRNA after treatment with LPS 
and/or α-hemolysin (Fig. 4.6A and B), further indicating that GPSM3 alters IL-1β 
secretion through post-transcriptional regulation of NLRP3. In THP1 cells, priming with 
LPS led to increased Pro-IL-1β mRNA and decreased GPSM3 mRNA expression (Fig 
4.6C-E). GPSM3 protein levels were also found to be decrease after treatment with LPS 
(Fig. 4.6F), suggesting that priming by LPS relieves GPSM3 mediated inflammasome 
inhibition in part through down regulation of the protein. 
  
A1.3.5 – The GPSM3/NLRP3 complex includes HSPA8 and is independent of the 
GPSM3/14-3-3 interaction 
 
The chaperonin proteins HSP90, SGT1 34-36, and HSP70 37, 38 (reviewed in 39) are 
known to be essential in regulating NLRP3-inflammasome activation. Cellular heat 
shock diminishes NLRP3-inflammasome mediated Caspase-1 activation, suggesting 
that these chaperonins are part of an inactive, basal-state NLRP3-containing complex 
40. The scaffolding protein RACK1 (“receptor for activated C kinases 1”), is required for 
the functioning of a HSP90-, SGT1-, and HSP70-containing chaperonin complex in rice 
which regulates innate immune signalling through nucleotide binding leucine-rich repeat 
(NB-LRR)-type R proteins (the rice orthologs of mammalian NLR proteins) and other 
innate immune signalling systems 36,41,42. Our yeast two-hybrid screen identified the 
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heat shock protein HSPA8 (also known as HSC70 or HSP73) and RACK1 as additional 
GPSM3-interacting proteins, suggesting that GPSM3 may be involved in chaperonin-
mediated regulation of NLRP3 function.  We thus co-expressed Flag-tagged GPSM3 
and HA-tagged NLRP3 in the presence or absence of HA-HSPA8 and HA-RACK1 for 
co-immunoprecipitation analyses. Immuno-precipitation of GPSM3 revealed formation 
of a complex comprising GPSM3, NLRP3 and HSPA8 but excluding RACK1 (Fig. 4.7A). 
Co-expression of HSPA8 increased complex formation between GPSM3 and NLRP3; 
surprisingly, co-expression of RACK1 also increased GPSM3-NLRP3 complex 
formation, and co-expression of RACK1 and HSPA8 was found to act synergistically on 
complex formation. The LSL mutant of GPSM3, previously found to have a greatly 
reduced interaction with NLRP3 (Fig. 4.1), also failed to interact with HSPA8 (Fig. 4.7A 
and B, lane 7), suggesting a common binding site or partner. In addition, 
overexpression of RACK1 and HSPA8 was found to increase fluorescence signal 
between YN-GPSM3 and NLRP3-YC as observed using the BiFC assay (Fig. 4.7B). 
This result supports the idea of a synergistic effect of RACK1 and HSPA8 on GPSM3-
NLRP3 complex formation. 
 
We recently described GPSM3 as interacting directly with the adaptor protein 14-
3-3 20. Given that numerous heat shock proteins are known to interact or form a 
complex with 14-3-3 proteins, including HSPA8 43, we tested whether 14-3-3 proteins 
were involved in complex formation between GPSM3, HSPA8, and NLRP3. As 
previously described 20, mutation of a critical serine 35 within the 14-3-3-binding site of 
GPSM3 abolishes interaction with 14-3-3. However, the GPSM3 S35A mutant was seen 
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to associate with HSPA8 and NLRP3 identically as wild-type GPSM3 (Fig. 4.7C), while 
completely abolishing the 14-3-3 interaction, as previously reported 20.  
 
A1.4 – Discussion 
 
Activation of NLRP3 by various danger signals contributes to pathologic 
inflammatory responses that drive a number of disease states 12. Presumably the 
capacity to generate potent pathologic inflammatory responses has led to the evolution 
of a multistage activation process to rein in NLRP3 inflammasome activity in order to 
minimize inappropriate inflammation-driven pathologies. An unbiased screen for 
proteins that interact with GPSM3 identified a potential interaction with NLRP3. Our 
present results support an endogenous and physiologic interaction between NLRP3 and 
GPSM3, and the notion that GPSM3 exerts a negative regulatory effect on the function 
of NLRP3. GPSM3 has previously been found to contribute to the induction of acute 
inflammation in a collagen antibody-induced arthritis mouse model of acute 
inflammatory arthritis. This pro-inflammatory effect is likely mediated by the influence of 
GPSM3 on monocyte apoptosis and chemotaxis in response to several G protein 
coupled receptor-activating chemokines 16. This proinflammatory role of GPSM3 does 
not contradict the negative regulation of the NLRP3 inflammasome that we now 
describe because induction of collagen antibody-induced arthritis has previously been 
shown as independent of NLRP3 inflammasome activation 44,45, and additional GPSM3-
dependent impairment of leukocyte recruitment may offset the increase NLRP3 activity. 
Our current data suggests that GPSM3 has pleiotropic effects on immune signaling 
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pathways and that, in addition to modulation of G protein coupled receptor signaling, it 
is also able to regulate NLRP3 inflammasome activation.  
 
Using a combination of methodologies, we have shown that GPSM3 interacts 
with the distal C-terminal region of NLRP3 and absolutely requires the last leucine-rich 
repeat domain (LRR8). No structural information is yet available for either protein; 
therefore, we cannot exclude other determinants within NLRP3 that are also important 
for this association. The LRR domains of NLR proteins are generally believed to serve 
as ligand-binding domains for these innate immune sensors. Although the structure of 
the LRR domain of NLRP3 has not yet been elucidated, the LRR domains of NLR 
proteins are believed to associate with the NBD domain forming a horseshoe tertiary 
structure akin to other LRR-containing proteins. Crystal structures of the LRR portion of 
different TLR receptors have been elucidated in the presence of different molecular 
ligands including dsRNA 46, LPS 47, and lipoprotein 48, as well as the dsRNA-binding C-
terminus of the NLR protein NLRX1 49. It is possible that GPSM3 interferes with the 
ability of NLRP3 to interact with activating ligands through interaction with the final LRR 
domain of NLRP3.  A horseshoe tertiary structure for the LRR domains, if also present 
within NLRP3, might allow intramolecular interaction of the C-terminal LRR domains 
with the N-terminal NBD domain to facilitate the formation of a closed inactive state, 
similarly to that described by the NLRC4 crystal structure 50. The observed residual 
BRET signal between GPSM3 and NLRP3 constructs lacking the LRR domains raises 
the possibility of an endogenous NLR protein bridging truncated (LRR-lacking) NLRP3 
mutants and GPSM3 51. However, one could also speculate that, if GPSM3 is capable 
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of simultaneously interacting with both the amino-terminus and the LRR domain of 
NLRP3, such an interaction could inhibit release of the NLRP3 amino terminus and LRR 
domain, thereby locking the protein in an inactive form. Further experiments are clearly 
required to determine if either one of these mechanisms is involved in the inhibition of 
NLRP3 by GPSM3. 
 
A two-step regulatory circuit for cellular IL-1β secretion, in which pro-IL-1β is 
induced by TLR stimulation and NLRP3 inflammasome-mediated Caspase-1 activation 
is induced by a distinct second signaling event, has been a widely accepted model 52. 
The first step, or “signal 1,” of regulation of inflammasome-mediated IL-1β secretion is a 
cell surface receptor-induced NF-kappaB transcriptional activation event that can be 
initiated by various TLR-activating stimuli or by numerous cytokine receptors. TLR 
stimulation primes cells for IL-1β secretion by enhancing pro-IL-1β production and by 
increasing production of NLRP3, which is a very low abundance protein under basal 
conditions. Our data indicate that as mRNA transcript abundance of NLRP3 and pro-IL-
1β increase, the transcript of the negative regulator GPSM3 is decreased as well (Fig. 
4.6).  A heterogenous group of stimuli then provide “signal 2”, leading to post-
transcriptional activation of NLRP3 (reviewed in 52). The activation of NLRP3 by “signal 
2” is now known to further require a post-transcriptional deubiquitination event that is 
catalyzed by the DUB class of deubiquitinases 53. These data suggest that, in its basal 
state, NLRP3 is ubiquitinated. A complex containing HSP90 and the ubiquitin ligase 
subunit SGT1 is required for NLRP3 signaling in mammalian cells, and these proteins 
may be involved in the baseline ubiquitination of NLRP3 that has been previously 
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observed 39.  We have now presented data demonstrating that one other chaperonin 
protein, HSPA8, is also found in complex with NLRP3 and GPSM3. These data suggest 
the possibility of a third mechanism by which GPSM3 inhibits NLRP3 activation: namely, 
that GPSM3 exerts its negative regulatory effect on NLRP3 by helping to bring it to a 
basal Heat Shock protein ubiquitination/chaperonin complex. Based on our present 
study and recent advances in the field, we propose a refined model of basal NLRP3 
regulation (Fig. 4.8). The role of GPSM3 in promoting NLRP3 inactivation and whether 
this negative regulatory pathway can be exploited therapeutically in cases of pathologic 
NLRP3 activation remain areas for further study. 
 
A1.5 – Materials and Methods 
 
A1.5.1 – Commercial antibodies, constructs, and other reagents. Horseradish 
peroxidase (HRP)-conjugated anti-hemagglutinin (HA) monoclonal antibody (clone 
3F10) was obtained from Roche Diagnostics. Anti-Flag M2 antibody, and agarose-
conjugated anti-Flag M2 antibody were purchased from Sigma. HRP-conjugated goat 
anti-mouse and goat anti-rabbit antibodies were from GE Healthcare (Piscataway, NJ). 
Anti-GFP Abfinity antibody was from Invitrogen. Mouse monoclonal anti-NLRP3 clone 
cryo-2 was from Adipogen (San Diego, CA) and sheep polyclonal anti-NLRP3 from R&D 
systems (Minneapolis, MN). Monoclonal anti-GPSM3 antibody was produced by the 
UNC Antibody Core Facility and has been previously described 20. All cDNAs used in 
this manuscript were cloned in the pcDNA3.1 backbone vector (Invitrogen, Carlsbad, 
CA), with Flag- or HA- epitope tag sequences included in the forward PCR primer to 
	
	 231	
produce N-terminal tagged open-reading frames as described previously 20. 
Recombinant S. aureus α hemolysin was generated as previously described 21. 
Aluminum Hydroxide suspension (Imject Alum) was purchased from Thermo Scientific. 
 
A1.5.2 – Cell culture and transfection. Human embryonic kidney 293 (HEK293) and 
THP-1 cell lines were each obtained from the American Type Culture Collection (ATCC) 
and maintained in DMEM or RPMI-1640 media (Invitrogen, Carlsbad, CA), respectively, 
supplemented with 10% fetal bovine serum (Cellgro, Manassas, VA) at 37°C in a 
humidified atmosphere containing 5% CO2. Transient transfections of cell monolayers 
grown to 75–90% confluence were performed using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions.  
 
A.5.3 – Immunoprecipitation and immunoblotting. Cells were lysed with ice-cold lysis 
buffer (20 mM HEPES, pH 7.5, 1 mM EDTA, 150 mM NaCl, 1% NP-40, and Complete 
protease inhibitor cocktail tablets (Roche, Indianapolis, IN)) at 4°C on a rocker platform 
for 30 min. Lysates were clarified by centrifugation at 16,000 x g for 15 min at 4°C and 
quantified by the bicinchoninic acid (BCA) protein content assay (Pierce, Rockford, IL). 
For immunoprecipitation, lysates were incubated with specific antibody for 2 hours at 
4°C followed by overnight incubation with protein-A/G agarose (Santa Cruz, Santa Cruz, 
CA), or directly incubated with agarose-conjugated anti-Flag M2 antibody overnight. 
Pelleted antibody/bead complexes were then washed three times with lysis buffer and 
proteins eluted in Laemmli buffer. Eluted proteins or lysate samples were resolved on 4-
12% precast SDS-polyacrylamide gels (Novex/Invitrogen), transferred to nitrocellulose, 
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immunoblotted using primary and HRP-conjugated secondary antibodies, and 
visualized by chemi-luminescence (ECL, GE Healthcare). 
 
A1.5.4 – Bioluminescence resonance energy transfer (BRET). HEK293 cells were 
seeded in 12-well plates (3.5 x 105 cells/well) and transfected with fixed amount of 
RLuc-GPSM3 or RLuc-GPSM3 LSL mutant vector DNA (50 ng) and increasing amounts 
of GFP10-NLRP3 vector DNA (0-1500 ng) and corresponding (decreasing) amounts of 
pcDNA3 empty vector (1500 to 0 ng) to obtain a saturation curve. The others BRET 
assays were performed by transfecting cells with 50 ng of the RLuc fusion protein-
expressing vector with 750 ng of GFP10-fusion protein expressing vector as indicated. 
24h post transfection, cells were washed once, harvested and resuspended in BRET 
buffer (phosphate-buffered saline with 1 mM CaCl2, 0.5 mM MgCl2, 0.1% glucose) and 
distributed in white 96-wells microplates. BRET was initiated by adding coelenterazine-
400a at a final concentration of 5 m 0 Measurements of emitted light were collected on 
a Mithras LB-940 plate-reader (Berthold Technologies) using a BRET2 filter set. 
 
A1.5.5 – Bimolecular fluorescence complementation (BiFC). Fusion constructs were 
made similar to those previously described 22: namely, a fusion of the N-terminal 
fragment (a.a. 1-158) of yellow fluorescent protein (YN) to the N-terminus of full-length 
GPSM3 (“YN-GPSM3”) and the C-terminal fragment (a.a. 159-238) of YFP (YC) to the 
C-terminus of NLRP3 (“NLRP3-YC”). HEK293 cells were transfected with an equal 
amount of plasmids encoding the fusion proteins YN-GPSM3 and NLRP3-YC, and cells 
were incubated at 37°C for 24 h. Total DNA quantity was normalized using empty 
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pcDNA3.1 vector DNA. To measure fluorescence from formed complexes, transfected 
cells were washed, harvested and resuspended in PBS. BiFC signal was acquired using 
a Mithras LB-940 plate-reader using an excitation/emission filter set of 485 nm and 510 
nm. The level of expression of each fusion protein was quantified by western blotting 
using a polyclonal antibody directed against the GFP.  
 
4.5.6 – Immunofluorescence microscopy. HEK293 cells were seeded in a 12-well plate 
and transfected with 0.4 mEK293 cells were seeded in aNLRP3-YC. The following day, 
cells were transferred to a poly-D-lysine (PDL)-coated coverslip in a 6-well plate and 
grown overnight. Cells were then fixed with 4% paraformaldehyde plus PBS for 10 min 
at room temperature. Coverslips were mounted using Vectashield mounting medium 
containing DAPI (Vector Laboratories, Burlingame, CA) and examined by inverted 
epifluorescence microscopy (Olympus IX70) using a 40× objective. 
 
4.5.7 – Mice. Gpsm3 -/- mice were generated as previously described 16. Nlrp3 -/- mice 
were a kind gift from Dr. John Bertin (Millennium Pharmaceuticals) and were further 
backcrossed at UNC to achieve nine generations of backcrossing onto the C57BL/6 
background. Nlrc4 -/- mice were produced using C57BL/6 embryonic stem (ES) cells 
and were a kind gift from Dr. Vishva Dixit (Genentech) 23. Aim2 -/- mice were generated 
using C57BL/6 ES cells by inGenious Targeting Laboratory (Ronkonkoma, NY) 




A1.5.8 – Bone marrow-derived macrophages (BMDMs) isolation and culture. BMDMs 
were prepared from 9-12 weeks old mice. Briefly, femurs and tibiae were removed from 
CO2 euthanized mice. Both ends of the bones were cut and bone marrow cells were 
extracted by flushing with DMEM medium containing 10 % FBS using a syringe with a  
27-gauge needle. Cell suspension was filtered through a 75 ml cell strainer and then 
centrifuged and resuspended in RBC lysis buffer (150 mM NH4Cl, 10 mM KCO3, 0.1 
mM EDTA pH 7.4) for 10 minutes on ice. Cells were washed in complete medium and 
finally resuspended at a density of 4x106 cells/ml in macrophage-conditioned medium 
(DMEM containing 10 % FBS and 20 % L-929 culture supernatant as source of M-CSF). 
Cells were seeded in 10-cm tissue culture plate (4x106 cells/plate) in 10 ml final volume. 
Three days later, 10 ml of fresh macrophage conditioned medium was adde d and 
replaced with 10 ml fresh medium at day 6 and day 8. Cells were collected from culture 
dishes at day 8 by washing once with PBS and treated with 5 ml Accutase (Sigma) for 5 
minutes at 37°C.  
 
A1.5.9 – Ex-vivo inflammasome activation assay. BMDMs were resuspended in serum-
free RPMI 1640 and seeded in 24-wells plate at a density of 1x106 cells/ml/well. LPS 
(100 ng/ml) was added for 3 hours. Subsequently, cells were stimulated with NLRP3’s 
inflammasome activators as indicated: ATP (5 mM), α hemolysin (10 µg/ml) and 
Aluminum hydroxide (130 µg/ml Imject™, Pierce) for 1 hour. For AIM2 inflammasome 
activation, dsDNA (2 µg/ml, poly(dA:dT)/Lyovec™, Invivogen) was used and cells 
treated for 15 hours. For NLRC4 inflammasome activation, LPS treated macrophages 
were then transduced with 250 ng/ml flagellin (Invivogen) using Profect-P2 (1.25 µl/ml, 
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Targeting Systems) as described by Miao and colleagues 24 for 1 hour. Cultures 
supernatant were collected after centrifugation at 13,000 xg for 10 min and cytokines 
(IL-1β and TNFα) were measured by enzyme-linked immunosorbent assay (ELISA) as 
described by Craven et al. 21.  
 
A1.5.10 – Quantitative RT-PCR. THP-1 or bone marrow-derived macrophage (BMDM) 
cells were activated as previously described with LPS (100 ng/ml) and/or α hemolysin 
(10 µg/ml). Cells were harvested and lysed in buffer RLT (Qiagen) + 1% 2-
mercaptoethanol (Fisher Chemical) before immediately being placed on ice. RNA 
extraction was performed using the Qiagen RNeasy kit following manufacturer’s 
instructions, and isolated RNA was DNase I treated and used to synthesize cDNA 
immediately (Thermo Verso cDNA synthesis kit). Relative gene expression was 
quantified using Veriquest Fast Probe PCR master mix (Affymetrix) and Taqman probes 
(Life Technologies) for GPSM3, NLPR3, and pro-IL-1β normalized to multiplexed β2-
microglobin. Fold change in target gene expression was calculated using threshold 
values by the 2-ΔΔCt method, described by Livak & Schmittgen, and statistical 
significance was determined by one-way ANOVA with Bonferroni post-hoc (p<0.05). 
 
A1.5.11 – In vivo peritonitis experiments. Gpsm3-/-, Nlrp3-/- and wild type littermate 
control mice were first pretreated intraperitoneally (i.p.) with LPS (20 mg/kg) and 
subsequently injected two hours later with 350 µg Alum (Pierce), an NLRP3-dependent 
inflammasome activator 25. Peritoneal exudate and peripheral blood were both collected 
and peritoneal cavity rinses with 3 ml of PBS (i.p. lavage) and both samples mixed 
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together and cytokine content quantified as described previously for ex vivo assay. 
Cardiac puncture was used to bleed mice. Serum was collected from coagulated blood 
that has been centrifuged.  
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A1.8 – Figures 
 
Fig. A1.1. Identification of NLRP3 as a GPSM3-interacting protein. (A) 
Saccharomyces cerevisiae were co-transformed with indicated bait plasmids (either 
expressing the Gal4p DNA binding domain alone [pAS2-1] or as a fusion with full-length 
GPSM3 [pAS2-1/GPSM3]) and prey plasmids (either expressing the Gal4p activation 
domain alone [pGAD424] or as a fusion with the C-terminus of NLRP3 
[pACT2/NLRP3]). Transformed yeast were plated onto synthetic defined agar (Yc) 
lacking leucine (Leu-, to select for the prey plasmid) and tryptophan (Trp-, to select for 
the bait plasmid); growth on Yc Leu- Trp- medium demonstrates incorporation of both 
bait and prey plasmids (left panel). Growth on Yc Leu- Trp- medium also deficient in 
adenine (Ade-) and histidine (His-) indicates a positive protein-protein interaction (right 
panel). (B) Domain architecture of NLRP3 comprising the pyrin domain, nucleotide-
binding domain (NBD), and eight leucine-rich repeats (LRRs) in comparison to the 
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truncated domain structure for the NLRP3 fragment identified in the yeast two-hybrid 
screen. Additionally represented is the domain structure of GPSM3 comprising the three 
GoLoco motifs (GL1-GL3) and locations of point mutations used in this study. Amino 
acid numbering for each domain is based on data from UniProt identifier Q96P20 
(NLRP3) and Q9Y4H4 (GPSM3). (C-D) HEK293 cells were transiently co-transfected 
with plasmids expressing HA-tagged full-length NLRP3 (a.a. 1-979; panel C) or an 
NLRP3 C-terminal fragment (a.a. 831-979; panel D), along with Flag-tagged GPSM3, 
either of wildtype sequence (‘WT’), R81F + R152F double mutant (‘RF’; abrogates 
GPSM3/Gai·GDP interaction) or the LSL mutant in which the GPSM3 amino-acids 
L58SL were mutated to PLP to eliminate the GPSM3/Gb interaction as previously 
described. Immunoprecipitation (IP) of GPSM3 was performed using agarose-
conjugated anti-Flag M2 antibody and co-immunoprecipitating proteins were detected 
by immunoblotting (IB) with anti-HA epitope tag antibody. (E) Whole cell lysates from 
THP-1 cells were immunoprecipitated with anti-NLRP3 goat polyclonal antibody or with 
Protein-A/-G agarose beads alone. GPSM3 was subsequently detected using an anti-
GPSM3 mouse monoclonal antibody (clone 35.5.1) and NLRP3 was detected with anti-
NLRP3 mouse monoclonal antibody. Results shown are representative of two 
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Fig. A1.2. Characterization of the GPSM3/NLRP3 interaction using 
bioluminescence resonance energy transfer (BRET). (A) A constant amount of 
wildtype (or LSL mutant) RLuc-GPSM3 fusion expression vector was co-transfected into 
HEK293 cells with increasing amounts of GFP10-NLRP3 fusion expression vector; the 
resultant net BRET ratio was plotted as a function of the acceptor/donor ratio. (B) C-
terminal truncation mutants were used to identify the minimal determinants within 
NLRP3 required for the interaction with GPSM3.  A stop codon was inserted by 
mutagenesis after each domain of the GFP10-NLRP3 fusion construct (as indicated) 
and subsequently tested in the BRET assay upon co-expression with RLuc-GPSM3. (C) 
The leucine-rich repeat domains were fused to GFP10 (called “GFP10-NLRP3 LRR”) 






Figure A1.3. Co-immunoprecipitation of GFP10-NLRP3 protein constructs with 
GPSM3. Flag-tagged GPSM3 was co-transfected with the same GFP10-NLRP3 fusion 
proteins used to map the interaction by BRET (Figure 2) and immunoprecipitation was 
performed using anti-Flag M2 agarose-conjugated antibody; co-immunoprecipitated 
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Figure A1.4. Analysis of the GPSM3/NLRP3 interaction using bimolecular 
fluorescence complementation (BiFC). (A) HEK293 cells were transfected with 
plasmids expressing YN-GPSM3 (a.a. 1-158 of YFP fused to GPSM3) and NLRP3-YC 
(NLRP3 fused to a.a. 159-238 of YFP) and the fluorescence of reconstituted YFP 
fluorophore was measured at 24 hours post-transfection. Cells were harvested and 
fluorescence quantified on a plate reader. Total DNA used for transfection was 
normalized using empty pcDNA3.1 vector DNA. Data are expressed as relative 
fluorescence units (RFU) using the means ± S.E.M. of at least three different 
experiments; *p<0.05, **p<0.01 and ***p<0.001 by one-way ANOVA. (B) 
Epifluorescence microscopy images of HEK293 cells transfected with plasmids 
expressing the two YFP protein fusions YN-GPSM3 and NLRP3-YC (top panel) or the 
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Fig. A1.5.  GPSM3 deficiency leads to selective enhancement of the activation of 
the NLRP3-dependent inflammasome in macrophages and in a mouse NLRP3 
dependent peritonitis. Bone marrow derived macrophages (BMDMs) were generated 
from wild type (WT), Gpsm3-/- and Nlrp3-/- mice (panels A, B, and C), or with wild type 
(WT), Gpsm3-/-, Nlrp3-/-, Nlrc4-/- and Aim2-/- mice (panels C and D), and primed with 
LPS for indicated times at 50 ng/ml before treatment with specific NLR inducers. ATP at 
1 mM, Staphylococcus aureus a-hemolysin (HLA) at 10 ug/ml and aluminum hydroxide 
and potassium salts (Alum) at 130 ug/ml were used to activate the NLRP3-
inflammasome. Mouse macrophages were also separately transfected with dsDNA to 
activate AIM2 or flagellin peptide to activate NLRC4, as described in the Materials and 
Methods section. Cell culture supernatant was collected following treatment and 
secreted IL-1b and TNF-a quantified by ELISA as indicated. Twelve week old, wild type 
littermate (WT), Gpsm3-/- and Nlrp3-/- mice were each initially primed by an 
intraperitoneal injection of LPS (20 mg/kg) and subsequently injected 2 hours later with 
350 mg of Alum (or saline vehicle, as indicated).  Peritoneal exudate was collected and 
the peritoneal cavity rinsed with 3 ml of PBS (“i.p. lavage”) and IL-1β content quantified 
by ELISA (panel E). Blood was collected and serum IL-1β was quantified by ELISA 
(panel F). Data are expressed in pg/ml using the means ± S.E.M. of three different 






Fig. A1.6. Pro-IL-1β and GPSM3 are reciprocally regulated during LPS-induced 
inflammasome priming. Bone marrow derived macrophages (BMDMs) were 
generated from wild type (WT) or Gpsm3-/- mice and primed with LPS for 3 hours with 
100 ng/ml and/or subsequently treated with α -hemolysin (HLA) for 1 hour, as indicated. 
Pro-IL-1β and NLRP3 mRNA levels in each cell line were assessed using quantitative 
RT-PCR as described in the materials and methods (panels A and B). THP1 cells were 
treated with LPS (100ng/ml) or vehicle for 3 hours. GPSM3, Pro-IL-1β, and NLRP3 
mRNA levels were assessed by quantitative RT-PCR (panels C, D, and E).  Data are 
expressed in pg/ml using the means ± S.E.M. of three different experiments (n=8-10); 
*p<0.05, **p<0.01 and ***p<0.001 by one-way ANOVA.GPSM3, NLRP3, and actin 
(loading control) protein levels were also assessed using immunoblot analysis with the 
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Fig. A1.7. The heat shock protein HSPA8 is involved in the interaction between 
NLRP3 and GPSM3.  (A) To assess potential roles of HSPA8 and RACK1 in the 
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with plasmids encoding Flag-tagged GPSM3, HA-tagged NLRP3, HA-tagged HSPA8, 
and/or C-terminal HA-tagged RACK1. Immunoprecipitation (IP) of GPSM3 performed 
using agarose-conjugate anti-Flag M2 antibody revealed the presence of HSPA8 in the 
complex, but the absence of RACK1, when immunoblotted with anti-HA. (B) HEK293 
cells were transfected with plasmids expressing YN-GPSM3 and NLRP3-YC in the 
presence or absence of RACK1 and HSPA8 and the fluorescence of reconstituted YFP 
fluorophore was measured at 24 hours post-transfection. Cells were harvested and 
fluorescence quantified on a plate reader. Total DNA used for transfection was 
normalized using empty pcDNA3.1 vector DNA. Data are expressed as relative 
fluorescence units (RFU) using the means ± S.E.M. of at least three different 
experiments; *p<0.05, **p<0.01 and ***p<0.001 by one-way ANOVA. (C) To assess the 
role of the known GPSM3 interactor 14-3-3, HEK293 cells were similarly co-transfected 
with Flag-tagged wildtype GPSM3 or GPSM3 R35A mutant (a loss-of-function mutant 




























































































































































































































































































Fig. A1.8. Model of NLRP3 regulation by GPSM3. Formation of a network between 
GPSM3, chaperones, and NLRP3 maintains the steady-state level of NLRP3 by 
stabilizing it within the complex. Activation of the inflammasome requires two 
independent signals. Toll-like receptors (TLR) and tumor-necrosis factor receptors 
(TNFR) are known to trigger priming signals leading to up-regulation of NLRP3 and pro-
IL1b through a NFkB-dependent pathway as well as down regulation of GPSM3. Non-
transcriptional priming of NLRP3 allows inflammasome activation upon detection of the 
activation signal. The NLPR3 activation signal is triggered by endogenous (‘danger-
associated molecular patterns’; DAMPs) or exogenous (‘pathogen-associated molecular 
patterns’; PAMPs) danger signals. Activation of NLRP3 can also be mediated by 
bacterial pore-forming toxins such as the alpha-hemolysin (HLA) of S. aureus. 
Activation of NLRP3 leads to formation of a multiprotein complex containing 
oligomerized NLRP3, the adaptor ASC, and caspase-1. Once activated, caspase-1 
cleaves pro-IL1b (and pro-IL-18), releasing the biological active form of IL-1b (and IL-
18) and thereby triggering inflammation and antimicrobial activity. 
 
 
 
